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METABOLIC SYNDROME 
 
By DINESH BAGMANE 
Abstract  
Smoking is the major risk factor for COPD. Smoking also has systemic effects and is considered 
as one of the risk factors for metabolic syndrome (MeS). It is unclear whether it is smoking per 
se or the systemic effects of COPD that cause metabolic syndrome in smokers. 
Smokers with and without COPD and non-smoking controls were studied by pulmonary function 
testing, skin prick tests, body composition, fasting glucose, CRP, and lipids analysis to diagnose 
MeS. This showed a gradual increase in prevalence of MeS, but with only difference between non-
smokers on one hand and smokers with or without COPD on the other being significant. This 
suggested that smoking, rather than the systemic effect of COPD, was the cause of MeS. 
All smokers were then grouped and smokers and non-smokers compared in respect of 
lung function, inflammatory markers (CRP, a series of inflammatory cytokines), insulin 
resistance, and body composition. Smokers had increased central obesity and total body fat, 
which is in contrast to the common belief that smoking reduces weight. Male smokers 
demonstrated increased abdominal fat, while females showed an increase in total body fat. FEV
1 
was reduced when comparing all smokers with MeS and those without MeS, and there was a 
greater reduction in males who had a greater prevalence of MeS, but had better quality of life 
even though they smoked more. However, whilst smokers with MeS had higher levels of insulin 
resistance, as measured by Homeostasis Model Assessment (HOMA-R), none of the plasma 
inflammatory markers, except for IL-12, was raised, suggesting that these indices of 
inflammation were not the reason for MeS.  
Smoking is associated with a gradual decline in lung function in smokers with and without 
COPD. A previously recruited cohort of smokers with and without COPD and healthy non-
smoking subjects were followed up over a period of 5 years. Amongst a whole series of 
measurements, including HRCT, measures of lung density/emphysema, only sputum 
neutrophilia (both absolute and percentage counts) predicted the annual decline in FEV
1. 
In summary, this study suggests that there is an increased prevalence of MeS in smokers 
associated with insulin resistance caused by smoking but it fails to show an association between 
MeS and COPD. Smoking is also associated with central obesity and increased body fat, 
contributing to a reduction in FEV
1. Sputum neutrophilia, but not smoking pack years or lung 
HRCT measurements, predicts the annual FEV
1 decline in smokers.  
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WTCRF    Wellcome Trust Clinical Research Facilities 
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1.1. Introduction 
Chronic obstructive pulmonary disease (COPD) is a major health problem. The 
World Health Organisation (WHO) has predicted that it will become the fifth 
largest disease burden and the third greatest cause of death by 2020
1. The 
reason for this is that COPD is not usually detected until patients seek medical 
attention for shortness of breath or an exacerbation of the disease
2. It is an 
under diagnosed disease and thus the available data regarding the mortality 
and morbidity are likely to underestimate the total burden to patients and the 
healthcare providers. 
 
 
 
1.1.1.  Different COPD definitions 
COPD has been defined by many organisations and respiratory societies in 
different ways in an attempt to define the disease severity and thus help 
physicians in the classification and management of the disease. According to 
the Global Initiative on Obstructive Lung Disease (GOLD), COPD is a 
preventable and treatable disease with some significant extrapulmonary effects 
that may contribute to the severity in individual patients. Its pulmonary 
component is characterized by airflow limitation that is not fully reversible. The 
airflow limitation is usually progressive and associated with an abnormal 
inflammatory response of the lung to noxious particles or gases
3. It is now 
t e r m e d  ‘ S y n d r o m e ’  b y  m a n y ,  a s  i t  i s  composed of chronic bronchitis, small 
airway disease (Bronchiolitis) and emphysema that vary in proportions between 
affected individuals. 
The British Thoracic Society defines COPD as a chronic, slowly progressive 
disorder characterized by airflow obstruction (reduced FEV
1 and FEV
1/FVC ratio) 
that does not change markedly over several months. Most of the lung function 
impairment is fixed, although some reversibility can be produced by 
bronchodilator (or other) therapy
4. 
According to the American Thoracic Society, COPD is a disease state 
characterized by the presence of airflow obstruction due to chronic bronchitis 
or emphysema: the airflow obstruction is generally  progressive, may be 
accompanied by airway hyperreactivity and may be partially reversible
5. 
European Respiratory Society defines COPD as a disorder characterized by 
reduced maximum expiratory flow and slow forced emptying of the lungs: 
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features, which do not change markedly over several months. Most of the 
airflow limitation is slowly progressive and irreversible. This airflow limitation 
is due to varying combinations of airways disease and emphysema: the relative 
contribution of the two processes is difficult to define in vivo
6. These various 
definitions are meant to help in understanding the disease burden, the 
treatment costs, as well as the mortality and morbidity of COPD.  
 
 
 
1.1.2.  History and burden of the disease 
COPD is one of the leading causes of death in many countries and it has been 
on the rise because of smoking and an increasingly ageing population. In 
Europe there is a decreasing trend in many countries
7. In the United Kingdom 
over the last 30 years, mortality has decreased in men but increased in 
women
8. Surprisingly women who are exposed to solid  biomass fuels (animal 
dung, crop residue, and wood) and develop COPD have a similar picture of loss 
of quality of life and mortality as cigarette smokers
9, 10.  
COPD is thought to be the fourth most common cause of mortality in the 
world and WHO predicts that it will be third by 2020. This could be due to 
changing smoking habits in the developing world
11. In 2004, more than 27,000 
men and women died of COPD in the UK and most of the deaths were in the 
age group over 65years
12. There is a socio-economic trend in COPD mortality 
with men aged 20-64 employed in unskilled manual occupation being 14 times 
more likely to die of COPD than those in a professional occupation
12. It is 
difficult to assess the severity of the disease by symptoms alone or by the 
various definitions being used in the community. A systematic review of all 
population based studies of COPD across the world and published between 
1999-2004 estimated that the prevalence of COPD in adults over 40 years was 
9-10%
13. However, there was a variation in age specific rates and variation in 
current or past smoking history. In their study, de Marco et al measured the 
prevalence of COPD in adults under the age of 45 years living in Europe. They 
found a rate of 2.5% for GOLD stage 1 and approximately 15% for stages 2 and 
3
14. Women had more respiratory symptoms and less of airflow obstruction, 
however COPD was diagnosed  in older subjects. There was no measure of 
alpha-1 antitrypsin deficiency in that study. 
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COPD has increased the burden on the health services in the UK. It is estimated 
that there are 1.4 million consultations in primary care for COPD which is four 
times that of angina
15. The overall cost to the health services is around £800 
million
16, however, the National Institute of Clinical Excellence (NICE) estimates 
slightly lower costs
17. The disease remains underdiagnosed or misdiagnosed as 
something else, because of few or no symptoms. Early intervention in terms of 
mass screening for COPD diagnosis may give a better understanding of 
prevalence. This early diagnosis could also help the clinician in early treatment, 
prevention of morbidity and mortality as well as improvement in quality of life.  
COPD is a syndrome, which includes chronic bronchitis (previously 
classified as stage0), small airways disease, which is bronchiolitis and 
emphysema. There are clinical and pathological differences between chronic 
bronchitis and emphysema. 
 
 
 
1.1.3.  Chronic bronchitis and emphysema 
The  description of chronic bronchitis and emphysema was made in the early 
nineteenth century, but interest developed in the late 1950’s when many 
people died during the London smog
18. During this period, spirometry was 
becoming available, and this led to the observation that airflow obstruction 
was the key factor in determining disability and mortality. 
Chronic bronchitis is defined clinically, as the presence of cough with 
sputum production for most days for a minimum of three months per year for 
at least two successive years which cannot be attributed to other pulmonary or 
cardiac causes
19. The prevalence of chronic bronchitis in the United States is 
high, with approximately 12–15 million Americans suffering from this 
syndrome. 
The word emphysema is derived from Greek and means, "to blow into," 
hence "air containing" or "air inflated". The term emphysema was initially 
applied to air within the tissues (i.e. subcutaneous emphysema). In 1721, 
Ruysch described large air spaces in lung specimens of humans as 
emphysema. In 1799, Bailey subsequently provided the first clear illustration 
and description of emphysema as enlarged air spaces
20. Laennec contributed 
considerably to the understanding of emphysema and recognized that 
emphysema is associated with chronic bronchitis.
21. In 1939, Cournand 
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introduced the concept that emphysema causes airflow obstruction. In 1952 
Gough described the differences in the centrilobular and panacinar 
emphysema which opened up the understanding of the pathology of the 
airways 
22 
    The US Department of Health looked at the prevalence of COPD
23. 
Accordingly, the prevalence of chronic bronchitis was lowest in the 25-44 age 
groups. Across the age groups, females had a higher rate than males for both 
white and black races. Among the 25-44 year olds and the over 65s, 
prevalence was higher in whites than blacks for each group. The prevalence of 
emphysema was higher for the 65 and above age group and higher in males 
and in whites. Over the past two decades prevalence of emphysema has been 
consistently higher for the 65 and above age group
23. 
 
 
 
1.1.4.  The pathology of emphysema and bronchitis 
The lung appears first as an epithelial bud at the caudal end of the 
laryngotracheal groove on the 26th day after ovulation
24, 25. The bud derived 
from the endoderm will form the epithelium of the airways and the acini. The 
mesenchyme develops into the connective tissue, cartilage, smooth muscle, 
and vessels of the lung. By 33 days, the trachea is separated from the foregut 
and the pouches represent the five lobes. By 41 days the dichotomous division 
leads to the development of full adult segments and by 16 weeks terminal 
bronchioles and the bronchial tree develop
26. 
There are at least two genetic forms of chronic bronchitis, primary ciliary 
dyskinesia and cystic fibrosis (CF). In addition, the most common form of 
chronic bronchitis in North America is the acquired form, which typically 
reflects cigarette smoking and, to a lesser degree, air pollution
27. In the United 
Kingdom the prevalence of chronic bronchitis in smokers aged over 45 is 45 
for every 10000 people and around £120,000 would be saved for every 100 
hospital admissions avoided
28. Mucous gland enlargement is the histological 
hallmark of chronic bronchitis. The structural changes described in the airways 
include atrophy, focal squamous metaplasia, ciliary abnormalities, and variable 
amounts of airway smooth muscle hyperplasia, inflammation, and bronchial 
wall thickening.  
Emphysema on the other hand develops at later stages of the disease. 
Over 3.1 million Americans have been diagnosed with emphysema, of which 
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91% were 45 years of age or older. Emphysema rarely occurs in those under 45 
in smokers
29. Emphysema is most likely to develop in cigarette smokers, but 
cigar and pipe smokers also are susceptible, and the risk for all types of 
smokers increases with the number of years and amount of tobacco smoked. 
Men are affected more often than women are, but this statistic is changing, as 
there is raising trends in smoking in women. Other risk factors include age, 
second hand smoking, occupational exposure to chemical fumes, and 
exposure to indoor and outdoor pollution. Severe alpha 1-antitrypsin (AAT) 
deficiency is a proven genetic risk factor for chronic obstructive pulmonary 
disease (COPD), especially in individuals who smoke
30, 31. Unlike asthma, which 
occurs when the muscles in the airways tighten, emphysema causes a loss of 
elasticity in the walls of the small air sacs in the lungs. Eventually, the walls 
stretch and break, creating larger, less efficient air sacs that are not able to 
handle the normal exchange of oxygen and carbon dioxide. 
The three described morphological types of emphysema are centriacinar, 
panacinar, and paraseptal. The first type, centriacinar emphysema, begins in 
the respiratory bronchioles and spreads to the periphery and it is also called 
centrilobular emphysema, this form is associated with long-standing cigarette 
smoking and predominantly involves the upper lobes of the lungs. It occurs 
with loss of respiratory bronchioles in the proximal portion of the acinus 
sparing the distal alveoli. Second type is panacinar emphysema, which destroys 
the entire alveolus uniformly and is predominant in the base of the lungs. This 
type of emphysema is generally observed in patients with homozygous alpha1-
antitrypsin (AAT) deficiency, and is well established in pulmonary emphysema 
and infantile cirrhosis
32. Alpha 1-Antitrypsin deficiency is a hereditary condition 
where there is a high risk of developing emphysema at a young age
33. The third 
type, distal acinar emphysema (also known as paraseptal emphysema), 
preferentially involves the distal airway structures, alveolar ducts, and alveolar 
sacs. The process is localized around the septae of the lungs or pleura. 
Although airflow frequently is preserved, the apical bullae  may lead to 
spontaneous  pneumothorax. Giant bullae occasionally cause severe 
compression of adjacent lung tissue. 
The main symptoms of emphysema are shortness of breath and a 
reduced capacity for physical activity, both of which are likely to become worse 
as the disease progresses. In time, sufferers may have trouble breathing even 
when lying down, and it may be especially hard to breathe during and after 
 22  
respiratory infections, such as colds or the flu. Other symptoms include 
fatigue, loss of body fat and muscle mass and cough. Tissue remodelling 
associated with small airways inflammation is observed in patients with severe 
COPD
34. Many studies carried out using transgenic mice have reported that 
overproduction of inflammatory cytokines like TNF-α, IFNg, IL-1β and IL-13
35-38 
causes emphysema in these animal models.  This evidence suggests that these 
cytokines may be involved in the pathogenesis of COPD. There are few studies, 
which investigated the relationship between peripheral airways and 
inflammation. O’Donnell et al reported that peripheral airway dysfunction 
which was measured by HRCT was a determinant of COPD severity. Airway 
neutrophils are also associated with severity but are not related to overall 
emphysema
39. 
 
 
 
1.1.5.  Classification of COPD 
COPD is classified according the Global Initiative for Chronic Obstructive Lung 
Disease (GOLD). To understand the classification it is important to understand 
the pulmonary function testing used, as the classification is based on the 
forced expiratory volume in 1 second (FEV
1) and forced vital capacity (FVC) and 
their ratio (FEV
1/FVC). 
 
 
 
1.1.6.  Pulmonary function testing (PFT) 
Pulmonary function testing has three components, a) Spirometry, b) 
measurement of lung volumes and 3) diffusion capacity. Spirometry is the 
most common pulmonary function test which measures lung function, 
specifically the measurement of the amount (volume) and/or speed (flow) of air 
that can be exhaled (FEV
1 and FVC). Body plethysmography is used to measure 
resistance to flow and lung volumes.  
Pulmonary function testing will measure the different types of defect in health 
and disease. They are as, a) normal airways b) obstructive defect c) restrictive 
defect d) combined defect. 
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Figure 1.1 Flow volume loops in normal, obstructive, restrictive, upper airways 
obstruction and combined defects. 
 
 
This is seen in airways disease such as bronchial asthma and COPD. In asthma, 
there is no defect in the lung volumes but there is a decrease in FEV
1 and 
FEV
1/FVC ratio. In COPD patients FEV
1 may be normal or reduced and FEV
1/FVC 
ratio is <70%, along with obstruction in the small airways. There is also air 
trapping.  
 
 
 
1.1.7.  Obstructive defect 
1.1.8.  Restrictive defect 
The current gold standard tool to measure the restrictive pulmonary defect is 
by spirometry and by measuring the total lung capacity by helium dilution or 
by plethesmography
40. A restrictive ventilatory defect has a typical shape with a 
downward and rightward shift of the static expiratory pressure–volume curve. 
Lung recoil is increased over the range of the inspiratory capacity with a 
reduction of total lung capacity (TLC) and vital capacity (VC)
41-43. A low FVC 
could be seen in true restrictive lung disease or in the patients with obstructive 
defect with severe air trapping. In the absence of airflow obstruction, it has 
been recommended that restrictive defect can be measured by spirometry 
alone. So a low FVC by spirometry and  normal or high FEV
1/FVC ratio is 
traditionally classified as restrictive defect
44. Diseases of the parenchyma such 
as idiopathic lung fibrosis or sarcoidosis are examples of restrictive ventilatory 
defects. 
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1.1.9.  Combined or mixed defect 
Reduction in FEV
1/FVC ratio and a decrease in FVC are termed as combined 
ventilatory defect. In the majority of the cases this defect represents airway 
obstruction with lung hyperinflation
45. This needs to be verified by 
plethysmography to find the reason for these changes. 
 
  1.1.10.  GOLD classification of COPD 
   
     
Stage 0  Chronic 
bronchitis 
Normal lung function 
 
 
 
     
Stage I  Mild  FEV
1/FVC < 0.70 
FEV
1 > 80% predicted 
 
 
   
Stage II 
 
Moderate 
 
FEV
1/FVC < 0.70 
50% < FEV
1 < 80% predicted 
 
 
   
Stage III 
 
Severe 
 
FEV
1/FVC < 0.70 
30% < FEV
1 < 50% predicted 
 
 
Stage IV  Very severe  FEV
1/FVC < 0.70, FEV
1 < 30% predicted or  FEV1  < 50% 
predicted plus chronic respiratory failure 
 
 
 
Table 1.1 GOLD classification for chronic obstructive pulmonary disease 
illustrating different stages of COPD.
46  
 
Stage 0 has been omitted from the revised GOLD classification, which was used 
to describe chronic bronchitis without airway obstruction. As this study was 
started in 2004, I had recruited patients classified with stage 0 COPD. 
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1.1.11.  Mild COPD 
Patients with the milder form of disease have preserved FEV
1 i.e. they are able 
to expel all the air in the first second but the ratio between FEV
1/FVC is below 
70% predicted for their height, age and sex.  
 
 
1.1.12.  Moderate COPD 
Patients with moderate disease have FEV
1 <80% predicted and FEV
1/FVC <70%.  
 
 
 
1.1.13.  Severe and very severe COPD 
Severe disease is defined in patients who have more symptoms and their FEV
1 
is <50% predicted. These patients have restricted mobility and are often on 
o x y g e n  s u p p l e m e n t  a s  w e l l  a s  b o t h  s h o r t  a n d  l o n g  a c t i n g  i n h a l e d  
bronchodilators, steroids, and anti cholinergic inhalers. In the most severe 
disease there is a severe defect in the pulmonary function test with an FEV
1 
<30% predicted and in chronic respiratory failure. 
 
 
 
1.1.14.  COPD severity and symptoms 
COPD symptoms differ with the different stages of the disease. Patients with a 
mild form of disease or with mild airflow limitation may be asymptomatic. This 
limits the clinician for the early intervention. The main symptoms of the 
disease are variant degree of cough with or without sputum production, 
predictable shortness of breath mainly due to exertion and wheeze
47. These 
symptoms worsen as patients continue to smoke. Age in combination with 
smoking is a risk factor for COPD and any diagnosis for patients under 40 
years old should bring suspicion of genetic predisposition for COPD i.e. α-
1antitrypsin deficiency.  
Cough is one of the early symptoms in COPD. It can be productive and 
more frequent in the morning. Generally, the sputum would be colourless or 
clear i.e. not infected. However, during an exacerbation of COPD, the sputum 
produced could be green, yellow, brown, or blood tinged. This change in 
colour may be due to bacterial infection or due to the neutrophilia observed 
upon exacerbation. 
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Breathlessness worsens as the disease progresses. It is related to the degree of 
airflow limitation and the onset of emphysema. Breathlessness is measured by 
either asking the patients about their activity levels or by Medical Research 
Council (MRC) dyspnoea scale
48. This can also be determined by asking the 
patient to perform a six minute walk test
49. The percentage of emphysema is 
measured by High Resolution Computed Tomography scan (HRCT). Unlike 
asthma, there is no diurnal variation in breathlessness in COPD. The degree of 
breathlessness in COPD increases if exposed to infections, variation in climate, 
or smoky environments. 
Wheeze is also a common symptom in COPD patients. This varies with 
airflow limitations, but this is not a cardinal symptom as in asthma. Other 
features of COPD can include chest pain due to ischemia of intercostal muscles 
where other causes like ischemic heart disease or infection have been ruled 
out. 
The major complication of COPD is development of Cor Pulmonale. In this 
condition, there is right heart failure due to chronic hypoxia and tissue damage 
and pulmonary vasoconstriction. This is one of the complications of COPD and 
around 5-10% of patients develop severe pulmonary hypertension and right 
heart failure and deteriorate clinically
50. Patients may develop ankle swelling, 
shortness of breath and cyanosis and progress to right heart failure and death. 
There are different tests to classify and measure COPD severity for e.g. 
pulmonary function testing and HRCT. 
 
 
 
1.1.15.  Measurement of COPD severity 
Lung function decline is a common feature in patients with COPD. It is 
important to choose correct definition to diagnose a defect especially in 
obstructive ventilatory defect. This is because according to the American 
Thoracic Society and the European Respiratory Society, obstructive defect is 
defined as occurring when the ratio of FEV
1 to the slow expiratory vital capacity 
(VC) is below the lower limit of normal
51. However, according to GOLD and the 
British Thoracic Society, it is FEV
1/FVC<0.70 and FEV
1< 80  percentage 
predicted. Therefore, definitions are crucial when diagnosing the defect. 
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Table 1.2 CM Fletcher, R Peto, CM Tinker graph demonstrating FEV1 decline in 
health and disease 
52  
 
Historically, the rate of decline in respiratory disease was first developed by 
Fletcher and Peto three decades ago
53. More recently Anthonisen et al and 
Burrows  et al observed the prognostic factors in COPD including age, FEV
1, 
dyspnoea scale, poor bronchodilator response, functional reserve capacity, 
exercise tolerance, exercise heart rate, smoking and decline in FEV
1 
54, 55. 
Similarly there are other studies who have identified additional factors such as 
asthma, diet and other comorbid conditions which are associated with decline 
in lung function
56-58. David et al studied the lung function decline as a predictor 
of morbidity and mortality in a huge population with and without COPD. They 
found that rapid lung function decline was independently associated with a 
modestly increased risk of COPD hospitalization and death
59. Another 
interesting observation in this study was that, having a more rapid decline in 
lung function was a stronger predictor of death or COPD related 
hospitalizations among subjects who had GOLD stage 0 disease than with 
more severe disease. 
There are many studies in the literature showing a relationship between 
lung function decline and mortality, but it is not clear whether this is 
independent of smoking. There are other studies which have  examined the 
association between the rate of decline and total mortality during a long term 
follow up
60. The Honolulu Heart Program looked at 17-year mortality in a follow 
up study and found that the change in rate of decline in lung function is 
associated with mortality in subjects with debilitating illnesses and smokers. 
They suggested that smoking is a confounder; however, they found that FEV
1 
 28  
decline by itself might contribute to the causation of the illness, which 
ultimately causes death. 
 
1.1.16.  High resolution computed tomography (HRCT) in COPD 
The development of HRCT has brought new dimensions in understanding lung 
disease in recent times. The scanner acts as a densitometer and the 
reconstructed image enables the viewer to identify low attenuation areas 
consistent with the loss of lung tissue that accompanies emphysema. The 
contrast between the solid bronchial walls and the air within the lumen enables 
the bronchi to be visualised with a diameter as low as 1 mm. The pattern of 
low density areas enables a diagnosis of centrilobular and panacinar 
emphysema to be made with reasonable accuracy 
61.  
Peripheral airway dysfunction, assessed by expiratory HRCT 
measurements, is a determinant of COPD severity
39. There are many 
advantages of HRCT including diagnosis of bronchiectasis and interstitial lung 
disease. A further advantage of HRCT scanning is that densitometric analysis 
allows a quantitative measure of emphysema to be made, and this matches 
well with the macroscopic and microscopic assessment of pathological 
specimens
62. 
 
 
 
1.1.17.  Lung function decline in other major diseases 
Lung function decline is a very gradual process, which can be accelerated by 
various factors that affect the lungs including smoking. Some of the diseases 
where this could be seen are discussed below. 
 
 
1.1.18.  Diabetes Mellitus 
Pulmonary involvement in diabetes has been reported sporadically for many 
years. Chronic hyperglycaemia leads to wide spread non-enzymatic protein 
glycosylation and micro and macrovascular end organ dysfuction
63-65. Diabetic 
microangiopathy targets the lung as it does to other organs.
66 With the 
introduction of inhaled insulin, there is recognition that the lung can be 
involved in diabetes. Even though the respiratory dysfunction with diabetes is 
subclinical and rarely do the patients have any respiratory symptoms, there are 
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several reasons to recommend a pulmonary assessment in diabetics: (1) it is 
non-invasive, (2) there may be subclinical loss of pulmonary reserve in stress, 
aging, hypoxia, volume overload, cardiac and renal failure (3) it is largely 
independent of physical fitness, (4) it is simple to measure and could provide 
useful information about systemic microangiopathy, (5) it can provide 
information regarding the long term effects of inhaled insulin on the lungs
66. 
Up to one third of subjects with diabetes can be shown to have abnormal 
ventilator response to hypoxia, hypercapnia, or exercise. This is consistent 
with autonomic neuropathy which is depressed cholinergic bronchomotor tone 
and neuroadrenergic response
67. Patients with diabetes without a smoking 
history consistently demonstrate a modest restrictive defect with proportional 
8-20% reductions in lung volume, FVC, FEV
1, and vital capacity when compared 
with patients without diabetes
68-74. Elevated fasting blood glucose on its own is 
associated with reduced lung function
75. 
 
 
 
1.1.19.  Cardiovascular disease 
FEV
1 is associated with mortality in respiratory and cardiovascular diseases
76. In 
a study by Ebi-Kryston et al found that, FEV
1 <65% predicts higher mortality. 
The 15 year mortality for men in the Renfrew and Paisley study increases from 
15% among lifelong non-smokers to 28% among those smoking 20 cigarettes a 
day with a good FEV
1 of 48% for those smoking 20 cigarettes a day with a poor 
FEV
1 
77. 
There are many confounders to COPD severity. The important ones are 
age, smoking and gender. The affinity to cigarette smoke is different in men 
and women, which increases the morbidity and mortality in smokers. 
 
 
1.1.20.  Pathogenesis of COPD 
Cigarette smoke is the main cause for developing COPD. Inhalation will cause 
both local
34, 78, 79 and systemic inflammation
80-82. There are cellular and structural 
changes in both peripheral and central airways in COPD and the inflammatory 
process extends to the lung parenchyma and pulmonary arteries. There is 
evidence to show that the cigarette smoking can elicit an inflammatory 
reaction involving the entire tracheo-bronchial tree even in the absence of 
established airflow limitation
83 
84. 
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The central airways of smokers have shown that T lymphocytes and 
macrophages are the predominant cells infiltrating the airway wall, where as 
neutrophils, which are scarce in the airways wall are increased in the airway 
lumen
83, 85. Analysis of the cell profile in alveoli and small airways show an 
increase in all of the cell types implicated in COPD, including macrophages, T-
lymphocytes, B-lymphocytes and neutrophils
86. Early lesions in the peripheral 
airways are inflammatory cell infiltration into the wall, predominantly 
mononuclear cells and clusters  of macrophages in the respiratory 
bronchioles
84.  In established COPD patients the development of airflow 
limitation is associated with further increase of macrophages and T 
lymphocytes in the airway wall and neutrophils in the lumen
87-89.  
 
 
 
1.1.21.  Neutrophils in COPD 
Neutrophils are increased in the airways in patients with COPD, including the 
submucosal glands
90, indicating an important role in the development of 
mucus hypersecretion in COPD. Increased interleukin-4 gene expression by 
large numbers of inflammatory cells infiltrating the bronchial sub epithelium 
and sub mucosal mucous secreting glands of smokers with chronic bronchitis 
has also been observed 
91. In smokers there is a strong association between the 
accelerated decline in lung function and increased number of neutrophils in 
the airway lumen
92.  In subjects with a more rapid decline in FEV
1, neutrophils 
exhibited increased expression of CD11B/CD18, an important  activation 
marker of neutrophils which acts as an adhesion molecule whose ligand is 
intercellular adhesion molecule (ICAM)-1 
93. 
Neutrophils produce amongst other chemokines, the ligands for CXCR3, 
CXCL10, CXCL9, and the IFN-￿-inducible T cell chemoattractant CXCL11
94, 95. 
There is involvement of the CXC and other chemokines in the inflammatory 
processes associated with COPD. There is evidence to show that the CXC family 
plays a role in pathogenesis and remodelling in COPD. Cytokines of the CXC 
family not only have a role in the control of inflammation but also in 
angiogenesis as a result of shared expression of their specific receptors by 
leukocytes and endothelial cells 
96. 
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1.1.22.  Role of Cytokine and Chemokines in COPD 
Recent advances have shown insights into cytokine-regulated control of 
inflammatory processes. Most cytokines exert their function in a complex 
network where one cytokine can influence the production of and respond to 
another. Their important role is in inflammatory processes, in response to 
injury or infection. The disruption of their homeostasis can lead to local or 
systemic pathology as demonstrated in various chronic inflammatory 
conditions
97, 98 . 
          TNF-α plays an important role in chronic diseases and wasting disorders 
such as COPD emphysema, cachexia, cystic fibrosis, chronic heart failure 
82. 
Increased levels of TNF-α are seen in patients with severe COPD. Increased 
levels of IL-6 are found in exhaled breath condensate of patients with COPD
99, 
and stimulated primary cultures of human bronchial epithelial cells produced 
more IL-6 than unstimulated cells from patients with COPD
100. 
Inflammation is characterized not only by upregulation of 
proinflammatory cytokines but also of the antinflammatory cytokine inhibitor 
including their soluble receptors. These include IL-10, transforming growth 
factor (TGF)-β
101, IL-11 and IL-1 receptor antagonist, which are released to limit 
the duration and extent of inflammatory responses. Limited data is available 
on these anti-inflammatory proteins in COPD. One study reported significantly 
lower levels of IL-10 and IL-10-positive cells in sputum of patients with COPD 
102. 
The role of chemokines is important in the pathogenesis of COPD. 
Smokers with COPD have increased numbers of CXCR3+ cells in the peripheral 
airways and these cells are CD8+ and produce interferon (IFN), which suggests 
a predominant role for CD8+ cells in the pathogenesis of COPD. In addition, 
such findings indicate that the CXCR3/CXCL10 axis may be involved in the 
recruitment of Th1 T cells to the peripheral airways. Recent data have shown 
the involvement of airway smooth muscle in the inflammatory response of 
patients with COPD. Thus, the airway smooth muscle may also serve as a 
source of CXCL10 in inflamed airways. Human airway smooth muscle cells 
release a variety of pro-and anti-inflammatory mediators such as IL-8 and 
granulocyte colony-stimulating factor (GM-CSF), an important survival and 
activation factor for neutrophils 
103-105. 
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1.1.23.  Role of inhibitory cytokines 
Inhibitory cytokines are released to limit the duration and extent of 
inflammatory responses. They include IL-10, transforming growth factor TGF-β, 
IL-11, and IL-1 receptor antagonist. TGF-β is a multifunctional growth factor 
that modulates cellular proliferation and induces differentiation and synthesis 
of extracellular matrix proteins including collagens and fibronectin in many 
types of cells. It is also a potent chemotactic factor for  mononuclear 
phagocytes, mast cells and T lymphocytes
106-109. In the small airway epithelium 
from smokers and patients with COPD, it is reported that the levels of TGF-β1 
mRNA are significantly higher compared with non-smokers and showed 
positive correlation with the burden of cigarette smoking.  
The level of TFG-β, gene expression correlates with the degree of 
peripheral airway obstruction and cultured airway epithelial cells from smokers 
with or without COPD. There is an increased release of total TGF-β1 protein in 
COPD compared with non-smokers
110. It has been reported that in subjects with 
COPD there is higher expression of TGF-β1 mRNA and protein in airway and 
alveolar epithelial cells as compared with subjects without COPD. Higher 
expression of TGF-β receptors has also been observed in macrophages from 
COPD subjects
107-109, 111. The higher expression of TGF-β1 in bronchiolar 
epithelial cells correlated positively with both increased numbers of 
macrophages and mast cells present in the broncho alveolar epithelium in 
COPD current or ex-smokers. This suggests that TGF-β1 is implicated in the 
recruitment of macrophages and mast cells into the airway epithelium in 
COPD
111. 
 
 
1.1.24.  Inflammation in COPD 
Increasing evidence suggests that the clinical features of COPD and airflow 
limitations are poorly correlated and there is a need for a comprehensive 
approach which may include imaging
112, assessment of exercise tolerance and 
body mass index
113. There is evidence to show that COPD is not just a disease 
of the lung but also a systemic disease. Cigarette smoke causes not only 
inflammation in the lung but it also plays a major role in systemic cellular and 
humoral inflammation, oxidative stress, changes in vasomotor and endothelial 
function and increased circulating concentrations of procoagulant factors
114, 115. 
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COPD patients show changes in local and systemic inflammatory markers, 
which affect the disease progression. 
 
 
 
1.1.25.  Local inflammation 
Inflammation caused by smoking is thought to create an imbalance between 
oxidative and antioxidative factors, locally in the lungs. This imbalance leads 
to oxidative stress, which has been hypothesised as the most important pro-
inflammatory event in the pathogenesis of COPD
116. 
Markers of oxidative stress and inflammation include interleukin (IL)-8, 
tumour necrosis factor-alpha (TNF-α), nitrous oxide, hydrogen peroxide, and 
isoprostanes, which may be measured in induced sputum, blood, expired air or 
bronchoalveolar lavage fluids
117, 118. To date no epidemiological studies have so 
far included these specific measures. It is possible these could indicate early 
changes or even act as markers of susceptibility in subjects with normal lung 
function. 
The association of an abnormal inflammatory response of the lungs to 
noxious gases with airflow limitation in COPD indicates the important role of 
inflammatory process in the pathogenesis of COPD. Airway inflammation is the 
key feature in COPD and it is thought to have a role in the pathogenesis of the 
disease
119.  There is a marked increase in neutrophils and inflammatory 
mediators such as IL-8 and soluble tumour necrosis factor receptor P55 (s TNF 
R55) in bronchoalveolar lavage fluid and sputum from patients with COPD and 
these correlate with increasing disease severity
120.  Immunohistochemical 
staining of bronchial biopsies from patients with mild disease shows 
infiltration of macrophages and CD8+ T cells and this infiltration was 
associated with airflow limitation. In contrast, influx of neutrophils and 
macrophages into the lungs was reported to be associated with severity of 
obstruction in patients with severe disease 
121, 122. 
Enhanced levels of the extracellular matrix compound hyaluronan are 
found in the sputum of patients with mild to severe COPD
123. The presence of 
hyaluronan seems to be related to disease severity and to markers of local 
inflammation. Hyaluronan has also been shown to be a sensitive marker for 
C O P D  w i t h  i n c r e a s e d  l e v e l s  s e e n  i n  a  g r o u p  o f  p a t i e n t s  w i t h  m i l d  C O P D  i n  
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which IL-8, s TNFR55 and s TNFR75 are not enhanced. There was also an 
increase in sputum neutrophils in smokers suggesting local inflammation.  
 
 
 
1.1.26.  Systemic inflammation 
Many studies have shown convincingly that COPD is associated with increased 
levels of several proinflammatory cytokines including tumor necrosis factor 
alpha and its soluble receptors sTNF-R55 and sTNF-R75, interleukin-6 and 
interleukin-8, acute phase reactants such as C-reactive protein, oxidative stress 
and activation of several inflammatory cells specifically neutrophils, monocytes 
and lymphocytes
115, 124. 
   The origin of the systemic inflammation present in patients with COPD is 
still poorly understood, and several independent pathways may be involved. As 
smoking causes many extra pulmonary effects, cigarette smoke alone may 
contribute to systemic inflammation. Both systemic oxidative stress and 
peripheral vascular endothelial dysfunction have been  reported in passive 
smokers and smokers with few pack years 
125, 126. 
Vernooy et al studied a group of subjects with mild to moderate
127 COPD 
and found that patients with COPD showed significant increase in neutrophil 
count and levels of soluble (s) TNF-R55 and IL-8 in sputum as compared with 
control subjects, whereas sputum sTNF-R75 levels tend to be higher in COPD. 
Sputum TNF-α level was similar in both groups. When comparing sTNF 
receptors in sputum and plasma, no direct correlation was found despite 
elevation of circulating sTNF-R75 levels in patients with COPD. In addition, 
sputum sTNF receptors was inversely related to the FEV
1 in patients with COPD, 
whereas circulating sTNF receptors were not, suggesting different regulation of 
inflammation in the pulmonary and systemic compartment. When subjects 
were divided according to their current smoking status, levels of sTNF-R55, 
sTNF-R75, and IL-8 in sputum were significantly elevated in ex-smokers versus 
currently smoking patients with COPD, suggesting ongoing inflammation in 
airways and circulation of patients with COPD after smoking cessation.  
Recent study by Michel et al
128,  where they subjected healthy people to 
inhalation of the proinflammatory stimulus, bacterial lipopolysaccharide, 
showed differential changes in body temperature, airway reactivity and FEV
1.  
Subjects with elevated body temperature showed increases in the inflammatory 
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response whereas those with an airway hyperreactivity showed an increase in 
airway inflammation, but no systemic inflammation, suggesting that the 
responses are independent. The evidence so far suggests that these processes 
in the local and systemic compartment are regulated differently. 
Systemic inflammation is increasingly recognised as a risk factor for a 
number  of different diseases including atherosclerosis
129, cachexia
130, 
anorexia
131 and osteoporosis
132. All of the above changes are commonly 
observed in patients with COPD
133-138.  However, there is debate as to whether 
systemic inflammation is present in stable COPD and whether it is wholly or 
partially responsible for these associations. Studies, which addressed this 
issue, were all of very weak statistical power.  
A systematic review carried out by W Q Gan et al on the association 
b e t w e e n  C O P D  a n d  s y s t e m i c  i n f l a m m a t i o n  f o u n d  t h a t  w h e n  c o m p a r e d  w i t h  
healthy controls, patients with chronic airflow limitation had significantly 
raised levels of serum CRP, fibrinogen, leucocytes and TNF-α indicating that 
persistent systemic inflammation is present in COPD
139. Among ex smokers 
with chronic airflow limitation, there was still evidence of a low-grade systemic 
inflammation. This observation suggests that once patients develop COPD, 
smoking cessation may not fully halt the inflammatory process. 
T h e  p r e s e n c e  o f  s y s t e m i c  i n f l a m m a t i o n  i n  C O P D  i s  l i n k e d  w i t h  v a r i o u s  
types of complications including weight loss
140-142, cachexia
130, 131, osteoporosis
131, 
132 and cardiovascular diseases
133, 135, 143.  An interesting observation by Dahl et al 
suggests that individuals with increased inflammatory markers such as 
fibrinogen have an accelerated decline in lung function and have an increased 
risk of COPD exacerbations and hospitalization in the future 
144. 
 
 
1.1.27.  Markers of systemic inflammation 
The use of exhaled markers and markers measured systemically in blood could 
provide a means of measuring the extent of systemic involvement at different 
stages of the disease. In established COPD, a number of non-specific markers 
of ongoing inflammation are available. Neutrophils are increased in the airways 
of smokers
145 and patients with COPD
146. If compared with local inflammation 
there is data from a small study in smokers and ex smokers that indicates an 
increase in the number of neutrophils in the sputum is associated with an 
accelerated decline in lung function
147, and a similar observation has also been 
reported among smokers in an (aluminium smelter workers) occupational 
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cohort
148.  In most studies, neutrophils provide a crude marker of generalised 
inflammation, not least because of the large-individual variation in leukocyte 
count. 
 
 
 
1.1.28.  C-reactive protein (CRP) 
CRP is an acute phase reactant protein measured in plasma, which is 
synthesised by the liver in response to inflammatory stimuli. CRP is elevated in 
patients with stable COPD, regardless of severity
149-151. This is also a biomarker 
for low grade inflammation in stable COPD
152. In patients with acute 
exacerbation after treatment there is a decrease in CRP
149 levels. Schols et al 
demonstrated increased levels of CRP and lipopolysaccharide binding protein 
in patients with stable COPD, and this was more pronounced in a subset 
patients with COPD with an increasing resting energy expenditure and 
decreased fat-free mass
149, 150. 
 
 
 
1.1.29.  Fibrinogen 
Fibrinogen is synthesised by hepatocytes and is an acute phase reactant and a 
blood-clotting factor, released into the circulation in response to the cytokine 
IL-6, which is produced by macrophages and the airway epithelium. Elevated 
levels have been reported in patients with stable COPD and in exacerbation
149, 
153, 154. 
 
 
1.1.30.  Interleukin-6 
IL-6 is the primary regulating cytokine of the acute phase reactant α1-
antitrypsin, which is also considered the major inhibitor of neutrophil elastase 
in the lower respiratory system. IL-6 levels are reported to be high in acute 
exacerbation of COPD
155. It has a well-recognised role as a hereditary risk factor 
for emphysema; measures of α1-antitrypsin can also indicate ongoing 
inflammation in COPD. 
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1.1.31.  Tumour necrosis factor (TNF) – α 
TNF-α is a potent pro inflammatory cytokine which exerts its activities by 
interaction with two structurally related but functionally distinct 
transmembrane receptors TNF-R55 and TNF-R75
149, 156. TNF-α co ordinates the 
inflammatory process by stimulating increased expression of adhesion 
molecules on leukocytes and endothelial cells, with up regulation of other pro 
inflammatory cytokines such as IL-1 and IL-6, and inducing angiogenesis. 
Increased levels of TNF-α in induced sputum in patients with severe COPD 
have been reported 
157.  As well as increased levels of TNF, patients with COPD 
also have significantly higher levels of soluble TNF-R55 in sputum compared 
with control subjects and soluble TNF-R levels are related inversely to FEV
1 in 
patients with COPD
158. These soluble receptors are also considered pro-
inflammatory markers because they are shed from the cell membrane in 
response to endogenous TNF-α and other inflammatory mediators. Higher 
levels of TNF-￿ in spontaneously expectorated sputum has also been reported 
in patients colonized with Haemophilus influenza in comparison with non 
colonized patients
159. 
 
 
 
1.1.32.  Determinants of COPD severity 
 
1.1.33.  Gender differences in COPD 
The prevalence and mortality from COPD in females are on the rise compared 
to men
160. It is also seen that females are more likely to report with symptoms 
compared to men
161-163. Females also show greater baseline 
hyperresponsiveness to methacholine
164. A study from Copenhagen showed 
g r e a t e r  i m p a c t  o f  s m o k i n g  o n  l u n g  f u n c t i o n  a n d  h i g h e r  r i s k  o f  h o s p i t a l  
admission in women than in men
165, 166. One of the reasons for this rise could be 
due to heavy smoking by women for e.g.Danish women are among the heaviest 
smokers amongst females in Europe
167. 
Most of the studies are based on the lung function but there are concerns 
how lung function decline should be compared between genders. Some of the 
suggestions are that FEV
1 decline should not be taken as gold standard but 
studies are needed which are focused on other measures of morbidity. Prescott 
et al  believed that hospital admission is an appropriate measure of the impact 
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of the disease and it is a more sensitive measure of morbidity with less 
delay
166. 
Excess weight gain has been linked to reduction in lung function 
particularly FVC and this effect is greater in men
168 . This may be due to the 
central fat distribution in men compared to women
169. Raida et al showed that 
body fat distribution has independent effects on lung function that are more 
prominent in men than in women
169. 
There are studies which have investigated into the differences in small 
airways function in COPD emphysema. Martinez et al reported recently that in 
patients with severe COPD, women have an anatomically smaller airway lumen 
with disproportionately thicker airway walls relative to men
170. They also 
showed that emphysema is less extensive with smaller hole size and less 
peripheral involvement. 
 
 
 
1.1.34.  Gene expression in COPD 
The development of gene array technology in measuring hundreds of genes 
has changed the understanding of the many disease and the gene interactions. 
These methods can be used to screen for  differentially expressed genes in 
disease state
171. Epithelial cells play an important role in airway inflammation
172. 
Airway epithelium is the first source of contact for the cigarette smoke and 
smoke is a rich source of oxidants 
173, some of which are very reactive. Many 
studies have shown that there is an increase in oxidative stress in smokers 
including increased concentrations of H2O2 
174.  
Pierrou et al studied the mechanism of oxidant/antioxidant stimuli and 
gene expression in smokers with and without COPD
175. They hypothesised that 
the epithelial expression of genes in oxidant/antioxidant responses in smokers 
are different from non-smokers and also COPD patients may express different 
genes in addition to those expressed by smokers without COPD. Their 
observation was that cigarette smoke induces different oxidant responses but 
not in a linear pattern in patients with COPD. 
Schulz  et al showed that melanoma cell adhesion molecule (MCAM), a 
member of the immunoglobulin super family, is differentially expressed and 
induced in primary  bronchial epithelial cells derived from patients with 
COPD
176. MCAM is the single gene identified which is unregulated in primary 
bronchial epithelial cells. This was a comparison between ex smokers with 
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COPD and current smokers without COPD. It was thought that smoking might 
not be the reason for the expression; rather the results may indicate that 
MCAM expression may be related to pathophysiology of the disease. The 
important role of MCAM in different cell systems and its engagement in cell-
cell interactions show the possibility that it contributes to airway remodelling 
in subjects with COPD. Recent studies have shown increased epithelial gene 
expression levels of transforming growth factor-β1
177, monocytes 
chemoattractant protein-1and interleukin-8 in COPD patients
178. 
    Cell adhesion molecule expression under inflammatory conditions are 
well known such as ICAM-1 in psoriasis
179. In primary explant cultures, human 
bronchial epithelial cells from COPD patients seem to release high level of 
ICAM-1 compared to smokers without COPD when  exposed to cigarette 
smoke
180. ICAM-1 also serves as a receptor for activated T cells
180, 181. This up 
regulation may suggest the recruitment and  migration of these cells into the 
airway lumen
101. 
There are many uncertainties about gene expression in patients with 
COPD, like differences in expression between men and women, the different 
pathways involved the role of gene polymorphisms and expression in patients 
with COPD who have never smoked. 
1.2. Metabolic syndrome (MeS) 
 
 
1.2.1.  Definition 
The MeS has also been called by various names in the past like syndrome-X 
and sometimes insulin resistance syndrome. Central obesity, insulin resistance, 
dyslipidemia, and hypertension characterize this syndrome. These features 
increase the risk of cardio vascular morbidity and mortality. Many expert 
groups have attempted to develop a unifying definition for MeS. However, most 
widely accepted and used definitions are International Diabetic Federation 
(IDF), World Health Organisation (WHO), The European Group for the study of 
Insulin Resistance (EGIR) and the National Cholesterol Education Programme-
Third Adult Treatment Panel (NCEP-ATPIII). In my study, I have used the IDF and 
NCEP-ATP III definitions for diagnosis and for the analysis of the data.  
According to the IDF for a person to have MeS, individuals should 
primarily have increased central obesity, which is ethnic specific (for Europeans 
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and American (≥ 94cms for men and ≥ 80cms for women) plus any of the two 
of four additional factors. The four factors are (1) raised triglycerides ≥ 1.7 
mmol/l (150mg/dl) (2) reduced HDL-cholesterol ≤ 1.03 mmol/l (40mg/dl) in 
males and ≤ 1.29 mmol/l (50mg/dl) in females or specific treatment for these 
abnormalities,(3) raised blood pressure ≥130/85mmHg or on treatment for 
diagnosed hypertension and (4) raised fasting plasma glucose ≥ 5.6 mmol/l 
(100mg/dl) or previously diagnosed type-2 diabetes
182. 
NCEP-ATP III definition was a slightly differed in two major ways. Firstly it 
didn’t include a measure of insulin resistance as a component (Included in 
WHO and EGIR) and second treated glucose abnormalities as of equal 
important with other components in diagnosing MeS. It also includes waist 
measurement (≥ 102cms for men and ≥ 88cms for women)
182 slightly higher 
than that in IDF . 
 
 
1.2.2.  Epidemiology and prevalence 
MeS is highly prevalent in adults globally but particularly in affluent 
westernised countries. A quarter of the US population aged 25yrs and above fit 
into ATP-111 criteria for MeS. There is also an increasing trend in children and 
adolescents 
183. There is 3 fold higher rate of mortality from coronary artery 
disease in subjects aged 41-60yrs with MeS compared with those without MeS 
when studied for more than 10years
184. A very consistent finding is that MeS is 
age dependent, until recently with the increase rates of obesity in young 
people making clear that the disease can begin at any age group. According to 
the American Heart Association, three groups of people often have MeS, (1) 
people with diabetes who cannot maintain a proper level of glucose (glucose 
intolerance) (2) people without diabetes who have high blood pressure and 
secrete large amounts of insulin (hyperinsulinemia) to maintain blood glucose 
levels (3) heart attack survivors who have hyperinsulinemia without glucose 
intolerance.  
MeS has become increasingly common in the United States. The 
prevalence in U.S. adults ≥20years of age was recently estimated to be 23.7% 
185, and it is estimated that around  47 million U.S. adults suffer from this 
problem. The prevalence of MeS increases with age, reaching 43.5% and 42.1% 
for those 60-69 and ≥70 years of age respectively. MeS is closely associated 
with insulin resistance, where the body is unable to utilize insulin efficiently, 
hence MeS is also called the insulin resistance syndrome. Acquired factors such 
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as excess body fat and physical inactivity can elicit insulin resistance and MeS 
in these people. The biologic mechanisms at the molecular level between 
insulin resistance and metabolic risk factors are not fully understood, and 
appear to be complex. 
 
 
 
1.2.3.  Classification of MeS 
There are many definitions and clinical classification for this vastly researched 
syndrome. The important and accepted worldwide are the International 
Diabetic Federation (IDF) and the National Cholesterol Education Programme 
Adult Treatment Panel 111(NCEP ATP111) classification and are discussed in 
detail below 
 
 
 
1.2.4.  International Diabetic Federation definition (IDF) 
The IDF is an international body comprising 150 countries and its main 
objective is to guide physicians and other health care workers to prevent 
diagnose and treat diabetes in a way, which is uniform, and evidence based. 
The federation is committed to raise awareness globally for prevention and 
treatment of diabetes and working towards a cure for diabetes. According to 
IDF MeS is defined as having an abnormal waist (central obesity) circumference 
and two out of the other four variables, which are in the table 1.2. 
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Features of MeS 
 
I D F 
 
NCEP-ATP III 
 
Raised 
triglycerides 
 
 
 
≥150 mg/dl(1.7 mmol/L) or 
specific treatment for this 
abnormality 
 
 
≥ 1.7 mmol/l (150mg/dl) 
 
Raised blood 
pressure 
 
 
 
≥130/85mmHg) or  
specific treatment for this 
abnormality 
 
≥ 130/85 mmHg 
 
Reduced HDL 
 
 
≤ 40 mg/dL (1.03 mmol/L) in 
males 
≤ 50 mg/dl (1.29 mmol/L) in 
females 
or specific treatment for this 
lipid abnormality 
 
≤ 1.03 mmol/l (40mg/dl) 
Men 
≤ 1.29 mmol (50mg/dl) 
 
 
 
Raised fasting 
blood glucose 
 ≥ 100 mg/dl (5.6 mmol/L), 
or previously diagnosed type 
2 diabetes 
 
≥ 5.6 mmol/l (100mg/dl) 
 
Waist 
circumference 
 
 
 
≥ 94 cms –Men 
≥ 80 cms – Women 
 
≥102cms(>40inches)Men 
≥88cms(>35inches)Women 
 
Table 1.3 Classification of features of MeS according to IDF and NCEP-ATPIII 
criteria. 
1.2.5.  National Cholesterol Education Programme Adult Treatment 
Panel 111 (NCEP ATP111) 
There are many studies that show that there is an increase in coronary artery 
disease, which are not controlled, and a large proportion of patients whose 
lipids are not measured. The patients who are on lipid lowering medications 
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also did not attain the target. Therefore, NCEP produced recommendations for 
the global assessment for lowering cholesterol. The recommendations were 
that the high-density lipoprotein (HDL) should be secondary target in patients 
with increased triglyceride levels. Although low density lipoprotein (LDL) is 
generally considered as a primary target for treatment for the first time NCEP 
ATPIII classifies as a secondary target
186. The recommendations are described 
in the table 1.3 below, and any three of the five features will be considered 
indicative of MeS. 
 
 
Features 
 
Male 
 
Female 
 
Waist circumference 
 
>102cms (>40inches) 
 
>88cms (>35inches) 
 
Blood Glucose 
 
≥110 mg/dl(6.1mmol/l) 
 
≥110 mg/dl(6.1mmol/l) 
 
Triglyceride level 
 
≥150 mg/dl(≥1.69mmol/l) 
 
≥150mg/dl(≥1.69mmol/l) 
 
HDL level 
 
<40mg/dl(<1.03mmol/l) 
 
<50mg/dl(<1.29mmol/l) 
 
Blood pressure 
 
≥130/85mmHg 
 
≥130/85mmHg 
 
Table 1.4 NCEP ATP-III classifications of features of MeS in men and women 
 
 
 
1.2.6.  Clinical features 
It is unusual to diagnose MeS early in life. The features of MeS are central 
obesity (excessive fat tissue in and around the abdomen), atherogenic 
dyslipidemia with high triglycerides and low HDL cholesterol, raised blood 
pressure (130/85 mmHg or higher), insulin resistance or glucose intolerance, 
prothrombotic state (e.g., high fibrinogen or plasminogen activator inhibitor in 
the blood), and proinflammatory state (e.g., elevated high-sensitivity C-reactive 
protein in the blood).  
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1.2.7.  Pathogenesis of MeS 
The exact cause of MeS is not yet known, however, most researchers believe it 
is caused by a combination of genetic and lifestyle choices, including the types 
of diet and level of physical activity. 
MeS elicits a series of biochemical changes. Over time, these changes 
lead to the development of one or more associated medical conditions. The 
sequence begins when insulin, a hormone excreted from the pancreas, loses 
its ability to make the body’s cells absorb glucose from the blood. When this 
happens, glucose levels remain elevated after eating. The pancreas, sensing a 
high glucose level in blood, continues to secrete insulin. Loss of insulin 
production may be genetic or secondary to high fat levels with fatty deposits in 
the pancreas. Dyslipidemia may result from raised plasma triglycerides, 
decreased HDL cholesterol, raised remnant lipoprotein, increased 
apolipoprotein B, small particles of low-density lipoprotein and HDL.  
Hypercoagulability is another important aspect of MeS and is measured 
by raised plasma plasminogen activator inhibitor-1 and fibrinogen levels. MeS 
is also known to be a proinflammatory state (sub clinical Inflammation), 
however, clinically seen are elevated C reactive protein, elicited by 
inflammatory cytokines such as IL-6,TNF ￿ released from excess adipose 
tissues which are present in most subjects with MeS
187, 188. Clinically there are 
no immediate physical symptoms and the syndrome's associated medical 
problems develop over time.  
 
 
 
1.2.8.  Complications of MeS 
Consistently high levels of insulin and glucose are linked to many harmful 
changes including:   (1) damage to coronary and other arteries, a key step 
towards the development of heart disease or stroke, (2) changes in the 
kidney’s ability to remove salt, leading to high blood pressure, heart disease 
and stroke, (3) increase in triglyceride levels, resulting in an increased risk of 
developing cardiovascular disease,  (4) increased risk of blood clot formation, 
which can block arteries and cause heart attacks and strokes, (5) slowing of 
insulin production, which can signal the start of type 2 diabetes, a disease that 
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may increase the risk for a heart attack or stroke, and may damage the eyes, 
nerves or kidneys. 
 
 
 
1.2.9.  Obesity, insulin resistance and dyslipidemia 
Increased levels of free fatty acids, which are derived from adipose tissue in 
MeS, accelerate hepatic synthesis of very low-density lipo proteins (VLDL). 
Reduced triglyceride clearance may also contribute to dyslipidemia in diabetes 
via a relative decrease in lipoprotein activity
189. The reciprocal relationship 
between elevated VLDL triglycerides and low HDL levels is driven primarily by 
the action of cholesterol ester transfer protein, which mediates the transfer of 
excess triglycerides from VLDL to HDL compounds. Increased HDL turnover has 
been documented in type 2 diabetic patients
189. Increased triglycerides are also 
implicated as an underlying cause for the production of small particles of LDL 
cholesterol that are more easily oxidized, hence more atherogenic, and less 
readily cleared
189. In addition, excess triglyceride levels give rise to highly 
atherogenic, cholesterol-rich remnants of triglycerides-rich particles
190. 
 
 
 
1.2.10.  Proinflammatory and prothrombotic state   
It is now accepted that inflammation plays an important role in the 
pathogenesis of atherosclerosis
191. Excess adiposity is associated with the 
release of inflammatory adipokines or adipocytokines. These factors may 
c o n t r i b u t e  t o  a n  i n c r e a s e  i n  t h e  l e v e l  o f  C - r e a c t i v e  p r o t e i n ,  a  m a r k e r  o f  
inflammation and a recently recognised cardiovascular risk factor
192. Elevated 
C-reactive protein has been found in subjects who meet criteria for the MeS
193. 
Increased release of inflammatory adipokines may also mediate increases in 
fibrinogen and plasminogen activator inhibitor (PAI-1) levels. These findings 
are also reported in subjects with MeS. Elevated levels of PAI-1 may reflect 
impaired fibrinolysis and thus may be associated with the increased risk for 
arterial thrombosis which is a clinical association between increased PAI-1 
levels and insulin resistance is also well established
194. 
People with MeS are at increased risk of coronary heart disease, type 2 
diabetes and other diseases related to plaque build-ups in artery walls for e.g. 
stroke and peripheral vascular disease
195. Similar lipid changes in selective 
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hypothalamic neurons regulate insulin action and glucose homeostasis, in 
addition to food intake and body weight. This approach is integrated with the 
analysis of inflammatory reactions associated with end organ damage. 
Free fatty acids provoke insulin resistance. In striated muscle, the 
accumulation of intramyocellular lipid inhibits the uptake of glucose, the 
synthesis of glycogen through the activation of protein kinase C and oxidation 
of glucose. Free fatty acids also inhibit the insulin-mediated suppression of 
hepatic glycogenolysis
196. Leptin plays a protective role against obesity, at least 
in the early stages of weight accumulation by setting the plateau of body 
weight and by inducing compensatory oxidation of free fatty acids
197. 
 
1.3. Relationship of MeS with other diseases 
 
 
1.3.1.  Cardiovascular disease and mortality 
The clinical features of MeS are associated with an increased risk of 
cardiovascular disease
198, including the greater risk of coronary disease for a 
given level of low-density lipoprotein and cholesterol
199 and premature death
200. 
MeS consisting of a disorder of lipid storage, insulin resistance and 
hypertension is extremely significant in the pathogenesis of cardiovascular 
diseases
201-205. 
Although obesity is not a required element for the diagnosis of the MeS, 
there is considerable evidence that visceral intra abdominal fat, which 
increases with age 
206, is closely linked to insulin resistance. This 
pathophysiologic relationship is consistent with the emphasis on abdominal 
girth in the NCEP-ATPIII criteria and waist/hip ratio in the criteria of the WHO, 
rather than body mass index as an indicator of obesity-related cardiovascular 
risk
207. In fact, even in normal-weight subjects, increased waist circumference is 
associated with increased risk 
208.  
Several studies have attempted to quantify the positive association 
between the MeS and cardiac morbidity. For example Alexander et al reported 
that 19.2% of patients with MeS and type-2 diabetes had prevalent coronary 
artery disease based on the National Nutrition Examination Survey (NHANES III), 
compared to 13.9% with MeS but no diabetes and 7.5% with diabetes but no 
MeS
198. Similarly, Girman et al  found an approximately 50% greater risk of 
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major coronary events in patients with the MeS across two large clinical 
trials
209. In both, low levels of HDL cholesterol were found to be associated with 
an increased risk of developing MeS a finding also supported by analysis of 
data from NHANES. 
Several proinflammatory mechanise MeS contribute to atherosclerosis. 
These include monocyte recruitment and accumulation in vascular lesions as 
well as differentiation and activation of macrophages
191. It is clear that obesity 
drives a proinflammatory state, contributing to the development of insulin 
resistance, glucose intolerance, and atherogenesis. 
The pioneering work of Hotamisligil et al first established that TNF-￿  was 
expressed in adipocytes, that its expression was induced in obese states, and 
it could contribute to systemic insulin resistance
210. In addition the mechanism 
involving inhibition of proximal insulin signalling steps, and the attenuation of 
peroxisome proliferators activated receptor gamma activity have been 
implicated as the cause of TNF-￿ induction of insulin resistance
211. Several 
other proinflammatory molecules, including interlukin-6, serum amyloid A3, α1 
acid glycoprotein, and monocyte chemo attractant protein-1, are expressed in 
adipose tissue and are potentially induced in response to obesity and 
diabetes
192. 
Recent studies using gene microarray techniques found a broad 
proinflammatory gene expression program in adipose tissue from obese 
rodents
212. The fact that these effects appear to precede the development of 
insulin resistance during high-fat feeding further supports the notion that 
adipose-derived inflammatory factors have a causative role in the development 
of insulin-resistant type-2 diabetes, and MeS. 
 
 
 
1.3.2.  Hypertension 
Elevated blood pressure is a frequent component of MeS, and is more prevalent 
in subjects with either insulin resistance or obesity. Several studies have 
demonstrated that even modest weight gain can precipitate the onset of 
hypertension
213. Hypertension plays a vital role in cardiovascular mortality and 
morbidity. It is also one of the important risk factors for stroke. Good control 
of blood pressure would reduce risk and morbidity and this could be achieved 
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by primary care physicians via early diagnosis and life style modifications and 
appropriate pharmacological intervention
214. 
New epidemiological data has proved that there is a strong relationship 
between cardiovascular risk and blood pressure and also the importance of 
systolic blood pressure as a risk factor
215. Recent WHO report concluded the 
importance of blood pressure as a preventable cause of morbidity and 
mortality in the developing and developed countries
216. There is also growing 
evidence that people with borderline or high normal blood pressure will 
develop into patients with hypertension with age
217. This observation has 
prompted the US Joint National Committee to coin a new classification of blood 
pressure called ‘Pre hypertension’ referring to those with high normal blood 
pressure
218. According to the British Hypertension Society, there is 
underdiagnosis of hypertension in the UK, and treatment is suboptimal in the 
majority of the cases. The reason may be the use of monotherapy in 
treatment
219, which is in contrast to the recommended action. 
Proposed mechanisms which link insulin resistance and hyperinsulinemia 
to increased blood pressure include, (a). Insulin normally mediates 
vasodilatation; however resistance to this effect has been reported in obese 
and diabetic patients 
220. Cellular cation transport may also be altered in 
association with insulin resistance. This effect on either Na/K-ATPase or on 
Na/Li counter transport has been linked to insulin action, and could have a role 
in promoting vasoconstriction, (b)Insulin enhances renal sodium retention, and 
therefore hyperinsulinemia is envisaged as a cause of increased sodium 
retention
221, (c)Increased hyperinsulinemia driven by the sympathetic nervous 
system has been documented in association with obesity, although 
sympathetic activity itself could cause insulin resistance
222. It could also play a 
causative role in hyperinsulemia, (d) There is also a molecular link between 
obesity and the pathogenesis of hypertension, involving components of the 
renin-angiotensin system that are clearly present in adipose tissues 
222. 
 
 
 
1.3.3.  Non-alcoholic fatty liver disease 
Clinical, epidemiological and biochemical data strongly support the concept 
that non-alcoholic fatty liver disease is the hepatic manifestation of MeS. 
Insulin resistance is the common factor connecting obesity, diabetes, 
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hypertension, and dyslipidemia with fatty liver and the progression of hepatic 
disease to steatohepatitis, fibrosis, and cirrhosis and hepatocellular carcinoma. 
There may be, as in many other complex metabolic diseases, interactions 
between the genetics and the environment that determine phenotypic 
expression of the disease. The prevalence of MeS(22%) and the disease(20%) is 
similar in the US
223. This could be the hepatic complication of MeS. 
There is a close link between the components of MeS and non alcoholic 
liver disease
224. In a study in China they found fatty liver in 48% of patients who 
had MeS with 39% of them having a body mass index of 25kg/m
2 or greater. 
They also found that 41% were diabetic and 32% had dyslipedemia
225. 
Treatment aimed at reducing insulin resistance may help in preventing this 
complication of MeS. 
 
 
 
1.3.4.  Ischemic stroke and transient ischemic attack 
The combination of risk factors known to cause MeS has generated a great deal 
of interest, however prospective data on the syndrome’s association with 
ischemic cerebrovascular events is attracting less attention. 
In a study by N.Koren-Morag who looked at more than 14,000 patients, of 
which 26% fulfilled the criteria of MeS, patients without diabetes exhibited a 
1.49-fold increased risk for stroke or TIA, whereas there was a 2.29-fold 
increase in those who had diabetes
226. They concluded that the presence of the 
MeS without diabetes in patients with pre-existing atherosclerotic vascular 
disease identifies patients at increased risk for ischemic stroke or TIA. The 
suggestion of more pronounced risk MeS in women needs future 
investigation
226. 
 
1.3.5.  Metabolic consequences (Musculo skeletal effects and 
adipokines) of COPD 
COPD is a multicomponent disease and these components can act both locally 
(the lungs) and systemically. Furthermore, these effects can manifest in either 
a structural (including airway remodelling, emphysema, skeletal muscle 
wasting) or functional nature (Inflammation, apoptosis, senescence). 
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1.3.6.  Muscle wasting in COPD 
For many decades, weight loss was thought to be an irreversible component of 
terminal progression of the disease process. Wasting of body cell mass, the 
actively metabolising and contracting tissue is an important systemic 
manifestation. Loss of body mass can be clinically recognised by weight loss in 
general and loss of fat free mass in particular. In moderate to severe COPD 
patients who are clinically stable there is 20% depletion of fat free mass and 
35% patients who are eligible for pulmonary rehabilitation
227, 228. In patients with 
acute respiratory failure, nutritional depletion is reported in up to 70% of the 
cases
229. 
Weight loss particularly loss of fat mass, occurs if energy expenditure 
exceeds dietary intake. Muscle wasting is a consequence of an imbalance 
between synthesis and breakdown of protein. Several studies have shown the 
involvement of systemic inflammation in the pathogenesis of tissue depletion 
in patients with COPD 
230. It is clear that the body composition is an important 
indicator and hence may be used as routine screening test for COPD 
231. 
Wasting is a generally occurring manifestation in many chronic conditions 
and could be an important systemic manifestation of the disease. Tissue 
depletion is commonly seen in patients with COPD, its prevalence increases 
from 20% in clinically stable outpatients to 35% of those patients  eligible for 
pulmonary rehabilitation
232, 233. Several reports have provided evidence that 
weight loss negatively affects the prognosis of COPD. Schols et al 
demonstrated that low body mass index (BMI), age and low PaO2 are 
independent predictors of increased mortality rates 
234. A BMI below 25kg/m2 
has an increased mortality rate. Another from Copenhagen City Heart Study 
prospectively examined whether BMI was an independent predictor of mortality 
in subjects with COPD
235. Celli et al postulated that assessment of body mass 
index (B), obstruction (O), dyspnoea (D) and exercise capacity (E) (BODE index) 
is better predictors of  survival in COPD patients
113 
The presence of MeS was frequently observed in patients with COPD who 
participated in a cardiopulmonary program. Hence, this population should be 
considered for screening for MeS 
236. Progressive weight loss is characterized 
by disease-specific elevated energy requirements, unbalanced by dietary intake 
in many diseases including COPD. Weight gain can be achieved by caloric 
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supplementation while future studies should prove efficacy of amino acid 
modulation to stimulate protein synthesis and enhance muscle anabolism. 
Disproportionate muscle wasting resembles the cachexia syndrome as 
described in other chronic wasting diseases (cancer, chronic heart failure, and 
acquired immunodeficiency syndrome). At present, there is no adequate 
nutritional strategy available to treat cachexia in COPD. Muscle substrate 
metabolism has hardly been investigated, but the data available points toward 
a decreased fat oxidative capacity which may show similarities with the MeS as 
described in type II diabetes and obesity, and could theoretically benefit from 
polyunsaturated fatty acid modulation. 
To adequately target the different therapeutic options, more clinical 
(intervention) studies are needed in chronic obstructive pulmonary disease 
patients that are adequately characterized by local and systemic impairment 
and in which molecular and metabolic markers are linked to functional 
outcome 
237. 
 
 
 
1.3.7.  Role of adipokines in inflammation 
Leptin is a pleiotropic molecule which regulates food intake, and metabolic, 
endocrine function
238. Adipose tissue, gastric mucosa, intestinal epithelial cells, 
placenta, mammary epithelium, and importantly skeletal muscle secrete it. It is 
considered a hormone because it regulates the balance between food intake 
and energy expenditure signalling to the brain the changes in the stored 
energy. Leptin has an influence on hypothalamic-pituitary-adrenal axis, the 
reproductive system, hematopoiesis and angiogenesis
239. 
Leptin receptors are expressed in the kidneys, lung, adrenal gland, 
neutrophils, monocytes, and peripheral T-cells. It plays an important role in 
immunity, inflammation and haematopoiesis
238. Leptin is an adipokine 
produced in proportion to the total body fat mass. The other important role of 
leptin is to assess the total amount of body fat which indirectly reflects food 
availability, to stop food intake and to increase metabolism
240.  The relationship 
between leptin levels, body fat in COPD, and between systemic inflammation 
particularly in patients with emphysema is been reported
238, 241, 242. It acts 
independently and not with TNF-α which correlates with BMI suggesting its role 
in cachexia
243. Recent data demonstrates that colon epithelial cells are a source 
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of luminal leptin, which activates NF-kB implicating further that leptin is a 
proinflammatory cytokine
244. It has been shown recently by Poulain et al and 
colleagues that leptin levels are raised in obese patients with MeS and COPD
245.  
    Leptin has a similar structure to the type-1 family of cytokines which 
includes growth hormone, prolactin, erythropoietin, IL-3, IL-11, IL-2, oncostatin 
M and G-CSF. A long chain four helical bundle characterizes this family of 
cytokines structurally. Leptin levels are increased in acute infection and sepsis 
where it exerts direct effects on CD4+ T lymphocyte proliferation, macrophage 
phagocytosis and secretion of inflammatory mediators such as IL-1 and TNF-
α.
239, 246, 247. 
Increased levels of leptin have been observed in the peripheral circulation 
of COPD patients experiencing an acute exacerbation 
248. Leptin expression 
correlates well with different GOLD stages of the disease. It is expressed more 
on the epithelium in healthy people but its expression is more in the 
submucosa and is co localized mainly with activated T cells and CD8 positive 
cells and T lymphocytes
249. Leptin correlates negatively with FEV
1 and FEV
1/FVC 
ratio signifying the proinflammatory role associated with functional 
impairment
249. 
Adiponectin is an anti-inflammatory adipokine, which is secreted from the 
adrenal glands and adipose tissues. It is also said to have anti atherosclerotic 
effect
250, 250. Elevated circulating adiponectin is observed in underweight 
patients with COPD. It also correlates with the body weight loss, hyperinflation, 
and systemic inflammation. Increased adiponectin levels may reduce 
cardiovascular events in underweight patients with COPD
250. 
TNF-α i s  a s s o c i a t e d  w i t h  c a c h e x i a
82 and TNF-α along with leptin are 
elevated in stable and acute exacerbation of COPD. Administration  of 
endotoxin or cytokines like TNF-α or IL-6 produce a prompt dose dependent 
increase in serum leptin levels.
243. 
In the recent past, there has been a lot of interest in understanding the 
systemic effects of smoking and COPD. There has been increasing evidence to 
prove COPD is an inflammatory disease. Increased number of neutrophils is 
found in the sputum and bronchial biopsies of COPD patients, which prove the 
point. Systemic inflammatory marker like CRP and fibrinogen also shown to 
play a key role in this process. The main driver for the inflammatory process is 
smoking. The systemic effect of smoking causes insulin resistance and in turn 
central obesity.  
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There are no single studies that address the issue of systemic effects of 
smoking or COPD causing the development of features of MeS. It is not clear 
about the mechanism involved in development of MeS in COPD. Inflammation 
may be driving this process. However, there are other confounders like 
physical activity, insulin resistance. 
Gene environment interactions may be one important aspect, which will 
help to explore reason for development of both COPD and features of MeS. The 
answers will help the clinicians in the future to intervene early in the disease 
process to reduce mortality and morbidity and economic burden on the 
country.  
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1.4. Aims of the thesis 
 
The overall aim of my thesis was to elucidate the role of MeS and systemic 
inflammation in smokers with or without COPD. 
 
The specific aims were: 
To establish the prevalence of MeS in healthy non-smoking subjects and in 
smokers with or without COPD. 
 
To analyse mediators of inflammation in subjects with or without MeS in 
healthy non-smoking subjects, in smokers with or without COPD. 
 
To identify determinants of lung function decline in patients with COPD 
through follow up and analysis of their annual FEV
1 decline and correlate the 
latter with a series of clinical and radiological parameters. 
 
To explore the gender differences in smokers with features of MeS. 
 
My hypotheses were: 
Individuals who smoke have a higher prevalence of MeS than non-smokers. 
 
Smokers with COPD have an even higher prevalence of MeS.  
 
Smokers with COPD have more evidence of systemic inflammation as measured 
by a series of pro-inflammatory markers. 
 
Any association between MeS and COPD would suggest either that MeS 
contributes to the development of COPD or that COPD causes systemic 
inflammation and that, in turn, results in MeS. 
 
Neutrophilic airways inflammation is a determinant of lung function decline as 
measured by FEV
1 and TLco. 
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2.1. Subjects characterisation 
 
 
2.1.1.  Subjects in the MeS study 
The subjects for this study were recruited mainly from in and around 
Southampton city. Southampton is a major city in the South east of 
England with a population of around 230,000. According to the local 
council, it is the 91
st  most deprived city out 394 local authorities in UK (1 
being most deprived). According to the Health and Lifestyles survey of 
Southampton population, cigarette smoke is the leading cause of 
preventable death in Southampton. This is a cross sectional study wherein 
subjects were recruited from the community. The socioeconomic status of 
the subjects was not recorded. However, they represented a cross section 
of the general population in and around Southampton. The publicity for 
the study was by word of mouth.  
150 subjects were approached by providing an information sheet 
and 141 subjects were ultimately screened, out of which 131 were 
successfully recruited for the study. The rest of the subjects were 
excluded, as they did not fulfil the inclusion criteria: (criteria were non-
atopic, non-asthmatic and smokers with reversibility of less than 12-15% 
to 400mcg of inhaled salbutamol). Subjects were also excluded from the 
study if they had a cold or on inhaled corticosteroids /oral steroids or 
treated with antibiotics in the previous six weeks for any infection. The 
subjects were grouped as (a) healthy non-smoker control subjects (n=44), 
(b) healthy smokers without COPD (n=46) and (c) smokers with COPD 
(n=41). Subject characteristics are described in Table 3.1. Subjects with 
COPD as well as the healthy smokers group were current smokers at the 
time of recruitment with history of >10 pack years. All subjects were non-
atopic with minimal reversibility (<10%) in FEV
1 following inhalation of 
400 ug of the β
2-agonist salbutamol. All the subjects in the groups were 
matched for age, sex and BMI  
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2.1.2.  Subjects participating in a follow-up study with smokers and 
non-smoking control subjects 
I inherited a second cohort of subjects from a past research fellow in my 
supervisor’s group. These had been recruited into a study titled ‘Differential 
Gene Expression in the epithelium of smokers with and  without COPD and 
healthy non-smoking controls’
39. For this present study, these subjects 
followed up yearly from 2004 until 2007, but as some of them had been first 
studied in 1999, many more years of follow up data were available. In total 102 
were followed up once, of which 70 were also followed up once more after a 
further year. The analysis was done on 64 subjects comprised of 15 healthy 
controls, 21 healthy smokers and 24 COPD patients and 4 ex smokers. 
All participants underwent medical examination, skin prick testing for 
airborne allergens, pulmonary function testing and induced sputum. Blood 
samples were collected and stored for future analysis. 
 
2.2. Study design 
2.2.1.  Study 1: Prevalence of metabolic syndrome and body 
composition in smoking and non-smoking subjects. 
Subjects attended the department on 2-3 occasions, depending on convenience 
of the volunteer. The first visit included history taking and full medical 
examination and fasting blood sample collected for blood glucose, full blood 
count, lipids, electrolytes, urea, creatinine, liver function test, C-reactive 
protein, insulin levels, urine albumin. Blood was also stored for cytokine 
analysis. Subjects underwent full lung function testing, which included FEV
1, 
FVC, and transfer factor (TLco). On a separate visit, subjects underwent 
metabolic analyses. For this assessment, subjects’ height and weight was 
recorded and subjects completed quality of life (St George’s respiratory 
questionnaire), the Baecke’s physical activity questionnaire. Subjects had their 
body composition measured by air displacement plethysmography (BODPOD), 
bioelectrical impedance analysis (BIA), and skin-fold thickness measurements. 
Skin fold measurements were taken at four sites (sub scapular, biceps, triceps, 
and supra iliac). Furthermore, blood pressure in supine, sitting, and lying 
positions were measured. Oxygen saturation on room air was also measured in 
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all subjects. This  study was slightly underpowered (According to the power 
calculation each group should have 65 subjects to get a significant difference) 
 
2.2.2.  Study 2: Inflammatory markers in smoking and non-smoking 
subjects – the role in metabolic syndrome  
All subjects (131) were consented and bloods were taken. Blood was taken to 
separate serum and plasma. 10mls of clotted and 10 mls of EDTA blood were 
spun at 3000rpm for 10 minutes. Then plasma and serum was separately 
stored in 250μl of aliquots and stored at -80
oC. These bloods were later used 
to measure cytokines by multiplex ELISA by Luminex method. 
 
2.2.3.  Study 3 Insulin resistance, quality of life, and physical activity in 
smokers with MeS 
This study was designed to understand and explore the relationship between 
insulin resistance by HOMA-R
251 (The Homeostasis Model Assessment which 
estimates beta cell function and insulin sensitivity , as percentages of a normal 
reference population) and smoking in subjects with and without MeS. The 
study population was divided into three groups as mention in subject 
characterisation in study 1. All subjects were consented and fasting bloods 
taken for glucose, lipids, and insulin. Blood was also collected to measure 
cytokines and adipokines at a later stage. Their lung function and body 
composition was measured as stated in study 1. 
Subjects were asked to complete a quality of life questionnaire (SGRQ) in 
an environment with no prompting and with adequate time. This questionnaire 
ranged from 0-100% of possible distress and divided into symptoms, activity, 
impact scores (total of 76)
252. They also completed a validated physical activity 
questionnaire (Baecke’s) which measure work activity, sports activity and 
leisure activity. A total score was then generated, which was used for analysis.  
 
2.2.4.  Study 4: Gender influence on features of metabolic syndrome in 
smoking and non-smoking subjects  
Gender differences are common in any chronic disease. This study was 
designed to understand the various differences in male and female smokers 
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and their metabolic and inflammatory profile. A Total of 131 subjects were 
recruited for this study. They were subdivided into three groups, healthy non-
smoker controls, healthy smokers or smokers without COPD and smokers with 
COPD. In healthy controls there were 44 subjects 24 women, 20 men, second 
group consisted of 46 healthy smokers with 22 women and 24 men, and last 
group consisted of 41 COPD group with 19 women and 22 men (table 3.1 for 
details). Subjects were age matched. All subjects underwent similar visits as in 
study 1. In the second analysis all smokers were grouped (HS + COPD) and 
divided according to their gender (men=45 and women= 42). The groups were 
then subdivided into (a) with MeS (men=20, women=8) and (b) without MeS 
(men=25, women=34). 
 
2.2.5.  Study 5: Predictors of rate of decline in FEV
1 in follow up 
subjects with and without COPD  
I inherited a cohort who had participated from a previously done study in my 
supervisors group. The study was about differential gene expression in COPD 
and healthy smokers. These subjects had undergone HRCT and densitometric 
measurements and bronchoscopy to obtain bronchial biopsies. My predecessor 
did all the analysis of the brushings and biopsies. There was an optional yearly 
follow-up visit in the study wherein volunteers were invited to participate. 
Those subjects who agreed to return on an annual basis underwent pulmonary 
function testing, induced sputum, and an interview about symptoms and 
quality of life. All of them consented for the study, completed medical history 
with full physical examination, and skin prick testing. All subjects completed 
St. George’s quality of life questionnaire. 
  
2.3. Ethics approval 
The Southampton and South West Hampshire Research Ethics Committee 
approved all of the above study protocols and all subjects gave written 
informed consent. All research work was carried out at the Wellcome Trust 
Clinical Research Facility (WTCRF) at Southampton General Hospital. 
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2.4. Methodology 
 
 
2.4.1.  Medical examinations and questionnaires 
All subjects had a full history taken and underwent complete physical 
examination. Subjects were requested to fill in St George’s Quality of Life 
Questionnaire (SGRQ)
252, 253, a health-related quality of life questionnaire 
validated for COPD studies and subjects were also asked to complete the 
Baecke’s physical activity questionnaire. This is a validated questionnaire to 
assess the level of physical activity in many disease states. It is also designed  
to assess the different domain of the physical activity
254, which were sports 
activity, activity at work and leisure activity. 
 
 
 
2.4.2.  Skin prick tests 
Skin prick tests was performed to test allergies for different aeroallergens. This 
test was done on all subjects and smokers who were positive test was excluded 
from the study. Merck skin testing solutions by Allergo pharma Joachim Ganzer 
KG was used for the skin prick testing. The panel of aero-allergen tested were: 
aspergillus fumigatus, candida albicans, grass mix, tree mix (mid blossoming), 
dermatophagoides pteronyssinus, dermatophagoides farinae, dog dander, cat 
dander and feather mix (chicken, duck and goose). The criterion for a positive 
skin test was a wheal reaction (papule) 3 mm greater than positive (histamine) 
control. 
 
 
2.4.3.  Blood tests 
All the subjects visited the department in the morning fasting from midnight. 
Blood was taken to measure glucose levels, insulin, full blood count, ESR, lipid 
profile which included total cholesterol, triglycerides, HDL, LDL, 
cholesterol/HDL ratio, C reactive protein (CRP). Urine was collected to measure 
albumin/Creatinine ratio. Blood was collected and centrifuged at 3000rpm for 
10 minutes in Labofuge 400R (Heraeus instruments) and aliquoted into 5 
plasma and serum  samples of 250μl each and  stored at -80
0C for future 
cytokine/adipokine  measurements. 
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2.4.4.  Pulmonary function testing: Spirometry and transfer factor 
(TLco) 
Pulmonary function testing is a robust test used in research and clinical 
practice to diagnose airways disease like asthma and COPD. This test was 
carried out during visit 1 and diagnose of COPD was made accordingly. The 
test included spirometry with ￿-2 agonist reversibility (salbutamol), diffusion 
capacity of the lung and lung volumes. Spirometry was performed according to 
the American Thoracic Society guidelines(ATS)
255. Machines available for 
spirometry are the vitalograph and ‘COLLINS CPL’ system, which is a volume 
displacement pulmonary function system was used to perform spirometry, 
functional residual capacity (FRC) and single breath diffusion test (TLco).  
Procedure: The CPL machine was calibrated every morning prior to testing. 
Subjects were advised to avoid smoking for 24 hours and alcohol for 4 hours 
as per the protocol. Vigorous exercise was also avoided 30 minutes prior to 
the testing and importantly they were asked not to take short acting 
bronchodilators before the test for at least 4 hours. They were advised to relax 
as much as possible and seated for 5-10 minutes prior to the test. 
The subject was instructed to connect to the mouthpiece of the machine. 
Subjects were asked to in a breath to fully inflate their lungs and then blow out 
all the air into the mouth piece of the machine forcibly and quickly in one 
second (FEV
1) and continued blowing out until all the air in the lung had 
completely emptied (FVC) into the machine. Three such tests were done and 
the best was recorded. From the results, FEV
1/FVC ratio was then calculated. 
            Carbon Monoxide Transfer Factor (T
LCO) was measured as described in 
ATS recommendations
256,  via single-breath carbon monoxide test as follows 
Each volunteer was seated upright wearing a nose clip and exhaled the air 
from the lung completely via a disposable mouthpiece. The volunteer was then 
immediately asked to breathe from a reservoir bag containing gases, including 
carbon monoxide (CO) and Helium (He) at a known concentration 
(0.3%CO,14%He,18%O
2) from which was rapidly inhaled to total lung capacity. 
The volunteer held the breath for approximately 10 seconds at maximal 
inspiration before making a rapid and complete expiration. The first 750mls 
assumed to be contaminated with anatomic dead space gas was discarded and 
the next 500mls was collected for the analysis of CO and He. The TLco value 
was then determined by (a) calculating the rate of disappearance of inhaled CO 
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from the alveolar gas Kco (units: min
-1). This was done by dividing the 
difference between the alveolar concentration of CO at the beginning and at 
the end of breath holding time by the duration of breath holding time. (b) 
secondly to calculate the lung volume through which the CO diffused during 
breath holding, the alveolar volume Va (mlSTPD). Va was calculated by the 
helium dilution method. As helium does not cross the blood gas barrier, and 
the inspired concentration was known, the alveolar volume was calculated from 
the new dilution of helium in the expired air. (c) finally from these results the 
TLco was calculated and expressed as, 
TLco=kCOxVa per unit pressure= (kCOxVa)/Pb (mmpl
-1kPa
-1in SI units) where Pb 
is barometric pressure minus water vapour at 37 degrees. All tests were carried 
out either by me or by trained pulmonary technicians.  
 
 
 
2.4.5.  Bronchodilator reversibility test 
Repeat measurement of FEV
1 following treatment with 400mcg of salbutamol 
can help to differentiate COPD from other reversible airway disease for e.g. 
asthma. All subjects in this study underwent reversibility testing before their 
diagnosis. All subjects were given 400mcg of inhaled salbutamol through a 
spacer and FEV
1 was recorded at base line and after 15 minutes later. Subjects 
who demonstrated a reversibility of ≥ 12% FEV
1 were excluded from the study.  
 
 
 
2.4.6.  Histamine provocation challenge 
Histamine challenge is a standard technique used to determine the degree of 
non-specific bronchial reactivity of an individual. It is thought that the 
histamine may act in a direct way by causing contraction of the airway smooth 
muscle. The method used in the follow up study (section 2.2.5) is described by 
Chai et al
257. Histamine solution (0.03-16mg/ml in normal saline) was prepared 
as per the departmental protocol. A Spira Electro Dosimeter or a hand held 
nebuliser was used to nebulise for the challenge. The volunteer was  given 
adequate time to rest before the procedure and all the questions were 
answered. Volunteer’s height was measured and their age noted as this was 
required to calculate the predicted value for FEV
1 and FVC. 
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Procedure: Prior to commencing the challenge, spirometry was measured and 
the base line reading was recorded. The highest FEV
1 was used to determine 
that it was more than 70% of the predicted value. The volunteer was then 
nebulised via dosimeter driven by compressed air at 8L/minute. If the 
predicted value was more than 70% predicted then the test was continued. 
Subjects inhaled five breaths of nebulised saline. This involved forced 
inhalation from the functional residual capacity (FRC) to total lung capacity 
(TLC). Measurement of FEV
1 was made at 1 minute and 3 minutes after the 
inhalation. The lowest of the best FEV
1 readings at 1 minute and 3 minutes 
were used to calculate the percentage fall from the baseline.  
Calculation: Baseline FEV
1 x 100   = % Predicted 
                                      Predicted FEV
1 
 
Percentage change=Post saline baseline FEV
1- Post inhalation FEV
1x100                 
Post saline baseline FEV
1 
This reading was then used as the baseline for the future measurement to 
record the percentage (%) fall for the rest of the challenge. If there was a fall of 
greater than 10% after saline inhalation from the baseline value the challenge 
was aborted. If there was no fall in FEV
1 or if the fall was less than 10%, then 
the first dose of histamine was delivered starting with 0.03mg/ml solution and 
FEV
1 was recorded at 1 minute and 3 minutes and the lower of the best FEV
1 
readings
 taken and the % of fall in FEV
1 was calculated and compared to that of 
the baseline. If there was no fall or a fall of less than 10% then the histamine 
concentration was doubled and nebulised. This procedure was continued to a 
total of 16mg/ml of histamine solution. If there was fall of more than 20% FEV
1 
(PC
20 positive), which was calculated as: 
20% fall = Post saline FEV
1x 100    
                            100                                 
At this stage, 200mcg of inhaled salbutamol was given and FEV
1was measured 
after 15 minutes and when the FEV
1 was restored to 90% of the first baseline 
measurement and if there was no symptoms like cough, wheeze or chest 
tightness the volunteer was then discharged. 
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2.4.7.  Sputum induction and processing 
The ability to study and understand various inflammatory markers has changed 
with the development of techinics in induced sputum in research.  The first 
description of a standardised method was in 1921 by Pin et al
258. Since then 
researchers have published many papers about the advantages of induced 
sputum in the study various inflammatory cells in asthma and COPD. The first 
attempt to standarise and validate took place in a workshop in 1936 at 
Stockholm, Sweden. Subsequently ERS set up a task force in 1998 to validate 
the processing, read outs and its clinical implications 
259.  
Induced sputum is a technique used for research and diagnostic 
purposes. Trained doctors, nurses, or respiratory technicians who have been 
assessed and shown to be competent carried out this procedure. All the 
induction for my study took place at the WTCRF. The volunteer was given 
information about the procedure to read before hand with adequate time to 
ask questions.  
Procedure: The sputum induction was performed as previously reported 
260. To 
begin, baseline peak flow was recording and 200mcg of inhaled ß-2 agonist 
salbutamol was give through the volumatic spacer device according to the 
protocol. After 10 minutes, post bronchodilator peak flow reading was 
recorded. Ensuring the volunteer was comfortable wearing the nose clip, 4.5% 
of nebulised saline was nebulised. The subject was advised to maintain normal 
tidal breathing during each 5 minutes of procedure. After 5 minutes, the 
volunteer was asked to rinse the mouth with water and encourage 
expectorating into the petri dish, which was kept on the ice to preserve the 
cells until the processing. After every 5minutes period, peak flow measurement 
was performed and if there was no decrease in PEF or the decrease was less 
than 20%, nebulisation was continued for further 5 minutes. However, if the 
PEF dropped by more than 20% then the procedure was  discontinued and 
bronchodilator (salbutamol) was given. Where possible, the induction lasted for 
a total of 20 minutes.  
In subjects with COPD, the procedure was modified according to the 
standard operating procedure (SOP) and according to ERS guidelines
259. The 
procedure was started with 0.9% normal saline and as a safety precaution, PEF 
was measured at 30 seconds, 1min, and 5 minutes. If that failed to produce 
sputum, and provided there was no significant drop in peak flow values, the 
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concentration of saline was increased to 3 % and the procedure repeated at the 
same interval as above. If that fails to produce sputum then the concentration 
of saline was increased to 4.5%. Induction was stopped if the peak flow reading 
dropped by more than 20% or if the volunteer had excessive coughing/wheeze 
or was short of breath. Bronchodilator salbutamol 200mcg was given and peak 
flow reading was repeated after 15 minutes to ensure that it had returned to 
90% of the baseline measurement. 
Sputum processing was performed according to a standardised protocol. 
Sputum was placed on the petri dish on ice and processed within an hour. A 
portion of the sputum was sent to microbiology for analysis. Using forceps the 
more mucoid portion of the sample was selected and transferred into another 
petri dish. The sample was then thoroughly mixed with forceps and divided 
into two (A+B). Sample A was solubilised with DTE (Dithioerythritol), while 
sample B was solubilised with HEPES buffered saline (HBS). Using a cell scraper 
the sputum was removed from the petri dish into the falcon tube leaving the 
obvious saliva behind. The tube was weighed with the sample to get an 
accurate reading of the expectorate to be processed. The first portion (A) was 
treated with 4x the volume of DTE. The second portion (B) was treated with 4x 
the volume of HEPES. 22.5μl of protease inhibitor cocktail per gram of sputum 
was added to both A and B. The tubes were briefly vortexed, inverted several 
times to ensure thorough mixing, and placed on a bench roller for 30 minutes 
by inverting the samples once every 5 minutes. More viscous samples if 
needed was further mixed by aspirating with a Pasteur pipette (C), the contents 
were filtered through a 100μm filter into a pre weighed 50ml Falcon tubes to 
remove unsolubilsed mucus. Then it was reweighed to determine the weight of 
the filtrate recovered. g) Then the filtrate was centrifuged at 1500rpm (400g) 
for 10 minutes to pellet cells. (D). The supernatant was then carefully removed 
from the tube and put into labelled 1.5ml eppendorf tubes. (E) The supernatant 
was then aliquoted (250μl) into labelled eppendorfs (10 tubes depending on 
the sample) and any extra into a single tube and stored for future analysis at -
80
0C. (F) The cell pellet from the DTE treated sample (A) was resuspended in 
1ml PBS, k) 10μl of the cell suspension (A) was removed and mixed with 90μl 
of Trypan Blue in an eppendorf. The Total Cell Count was calculated per ml 
using the Trypan Blue exclusion method following the workings on the sputum 
processing work sheet. Cell viability was also calculated. It was diluted with PBS 
to obtain 1 x 10
6 cells/ml, (G) 8 cytospins were prepared using 75μl per slide at 
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450rpm for 6 minutes  the quality of the slides was assessed and repeated 
where necessary. Slides were air dried overnight, (H) One slide was stained with 
Rapi-Diff, and the remainder were wrapped in foil and stored at -20
0 C for 
future analysis. 
 
2.4.8.  High resolution computed tomography (HRCT) and densitometry 
measurements 
High resolution computed tomography (HRCT) is being used more frequently 
to assess the degree COPD and emphysema. It allows the early detection lung 
damage, and gives a quantitative measure of lung density, as well as small and 
large airways. Several studies has shown that HRCT is a safe and sensitive way 
of assessing pulmonary function, and that it often is a more sensitive test than 
PFT. However, most of these studies are concerned only with one sub-
phenotype (e.g. emphysema).  
HRCT is a radiographic test that supplies the details about the lung 
parenchyma. The lungs were divided into series of cross sectional radiographic 
images of 1mm thickness. This was measured in Hounsfield units (HU). The 
scan was performed on a General Electric Hi-speed CTi scanner, at 10mm 
intervals with a collimation (slice thickness) of 1mm. All scans were carried out 
in the supine, feet first position, on full inspiration and expiration, from the 
lung apices to the costrophrenic angles. Scanning voltage was 140kV and tube 
current was 250mA. Hard copy images were photographed at a window level of 
-650HU and the window width of 1500HU. The scans were evaluated both 
qualitatively by a blinded consultant radiologist and quantitatively by 
computerised density mask analysis. 
  High resolution CT images were acquired at both inspiration and 
expiration. A programme was written in IDL (Interactive Data Language, 
Research Systems Inc.,Boulder, CO, USA) to enable reasonably automated 
image processing of the CT images to be carried out. The images were 
converted into a suitable file format (interfile) and read by the program. The 
operator was then prompted to set an appropriate grey scale window width 
and level to enable structures in the lungs to be clearly visualised. The next 
stage of the process involved drawing one or two regions of interest on each 
slice, around each cross-section of the trachea and bronchi leading into the 
lung. These were set to a high pixel value of 5000HU. This was to effectively 
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block off the trachea and bronchi so that their volume would not be included in 
the automatically calculated lung volume. 
The lung volume was determined using a seed-growing algorithm. A seed 
growing start point was placed in a low-density area of each lung. An IDL sub-
routine was then initiated. This is detected in three dimensions, each 
connected voxel in the image volume within the range of HU values which had 
been established being lung tissue (-400 HU to -1000HU). 
  Once the lungs had been identified, several parameters could be 
calculated from their corresponding histogram of pixel values. The program 
automatically calculates the total volume of the lungs by multiplying the 
number of voxels identified as being lung tissue by the individual voxel 
volume. It also calculates the number of lung voxels below-950 HU (below 
which the tissue is thought to be emphysematous), the percentage that this 
was of the total lung volume, the CT number which 10% of voxels in the lung 
fell below, the mean and median CT number of the voxels in the lung and the 
ratio between the mean inspiration and expiration CT values.  
 
 
 
2.4.9.  Multiplex ELISA/Luminex 
Cytokines are small proteins that mediate immune response in health and 
disease. Many of these cytokines were first identified and characterised by 
biological assays
261. These assays are cumbersome and labor intensive and 
some of these tests are more expensive than others. Several multiples analysis 
technologies have been developed and used to measure cytokines in the recent 
years including flow Cytometry and the Luminex system. The advantages of 
multiplex cytokine assays over the standard ELISA assay include smaller 
sample volume, higher through put and low cost. Luminex is a well validated 
technique and a suitable alternative to the ELISA for most cytokines, provides a 
valid characterisation of cytokine expression profile and T helper bias and even 
may ve superior to ELISA which is commonly used in immunology
261 
Luminex assay (Bio-Rad, Hemel Hempstead, UK) was used to determine 
the concentrations of multiple cytokines (IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-
12p70, IL-13, TNF-α, IFNg) in patient plasma samples diluted 1:5 according to 
the manufacturer’s instructions. Briefly, recombinant cytokines for standard 
curve generation were purchased from RandD systems (Abingdon, UK). Capture 
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and detection antibodies were from RandD (TNFα), Pharmingen, UK (IL-2, IL-4, 
IL-13 capture anti body; IL-5, IL-10, IL-12p70, IL-13 detection antibody), 
Endogen, UK (IFNg, IL-6, IL-8, IL-10, IL-12p70 capture antibody; IFNg, IL-4, IL-6, 
IL-8, IL-12p70 detection antibody), and GlaxoSmithKline, Stevenage, UK (IL-5 
capture antibody).  
Briefly, 50 μl of standards or diluted samples were placed on a 96-well 
filter plate (Millipore, Watford, UK) pre-wet with 50 μl of assay buffer (PBS, 1% 
BSA, 0.025% Triton-X100). Fifty micro litres of appropriate antibody-conjugated 
xMAP carboxylated microspheres (Applied Cytometry Systems, Sheffield, UK) 
were added to each well (1x10
5 microspheres/ml for each conjugated 
microsphere set) and the plate covered and incubated at 4ºC overnight. After 
two washes with wash buffer (PBS, 0.05% Tween-20), 50 μl of a cocktail of 
appropriate detection antibodies (500 ng/ml for each antibody) was added to 
each well and incubated on a shaker at 700 rpm for 1 h at room temperature. 
After two further washes, 50 μl of streptavidin-PE (1 μg/ml in assay buffer - BD 
Biosciences, Oxford, UK) and incubated on a shaker for 30 min at room 
temperature at 700 rpm. The plate was then washed twice and 120 μl of 
sheath fluid was added to each well before reading on a Luminex xMAP100 
machine (Bio-Rad). Results were analysed using STarStation 2.0software 
(Applied Cytometry Systems). 
2.5. Body composition measurements 
Height was measured with the subject standing barefoot on the base of a 
vertical scale (SECA Model 220) to the nearest 0.1 cm. Weight was measured 
with the volunteers in their undergarments without any jewellery or eyeglasses, 
to the nearest 0.1 kg using the electronic weighing scale connected to the 
BODPOD. The weighing scale was calibrated to the nearest 0.001 kg prior to 
the test.  
Other body composition measurements were measured by three methods 
which included (a) measurement of lean mass and fat mass by air displacement 
plethysmography (BODPOD) (b) anthropometric  measurement by bioelectric 
impedance analysis (BODYSTAT) (c) measurement of lean and fat mass by skin 
folds (callipers). 
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2.5.1.  BODPOD 
Whole body plethysmography is a new body composition technique to measure 
total body fat and fat free mass. This systemic is been used for research 
purposes and been validated against some of the other available techniques 
like hydrodensitometry
262. The advantages of this system are,  
•  It is very accurate 
•  It uses a dedicated system with data management 
•  It has an option to either measure a subject’s Thoracic Gas Volume or 
use predicted equation 
•  Measures fat and fat free mass, resting metabolic rate and total energy 
expenditure
263 
•  Quick, the test may take less than 5 minutes 
•  Good reproducibility 
•  Importantly non invasive and suited for repeated test 
•  Simple and easy for both subjects and operator and no special training 
needed 
 
Procedure:Airdisplacement plethysmography was performed using the 
BODPOD® system according to the manufacturers’ instructions and 
recommendations. The proportion of body density contributed by muscle and 
bone (lean body density) was standardised according to the subjects’ age, 
height and sex
264. BODPOD® system was calibrated to a strict standard 
deviation value of below 75ml each day before use. The calibration outcome 
was unpredictable as many factors such as room temperature and room 
pressure could affect the process
265. 
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Figure 2.1 BODPOD and the chambers inside with a brief description. 
 
Subjects were in their undergarments and wearing a swim cap before entering 
the system. The volunteers sat in a test chamber and were asked to limit 
movement and breathe normally. Subject age, gender and height were entered 
into the system using the kiosk connected to the BODPOD®. Measurement of 
volume was taken using the BODPOD® S/T Body Composition Tracking System, 
which consisted of taking a mean value from three repeated tests, each lasting 
approximately 40 seconds. The results that were shown included fat and lean 
mass in percentage and kilograms to the nearest 0.1% and 0.1 kg respectively 
and total body weight in kilograms to the nearest 0.1 kg. 
The BODPOD® system utilises the principle of whole body densitometry to 
estimate amount of fat and lean tissue in the body. Body density was 
calculated using the formula: density = mass/volume. With the body density, 
percentage of fat was derived using the Siri Equation: 
 
% Fat = (495 / Body Density – 450) 
 
The percent lean mass was calculated as follows: 
 % Fat Free Mass = 100 - %Fat. 
The amount of fat and lean mass was calculated from these results: 
 
 Fat Mass (kg) = [(%Fat) (Body Mass)] / 100% 
Lean Mass (kg) = Body Mass – Fat Mass. 
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2.5.2.  Bioelectrical Impedance Analysis (BIA) 
The Bodystat® 1500 uses a BIA technique to measure body composition. The 
body’s lean (muscle, bone, and water) compartment conducts electricity better 
than the body’s fat compartment. These two compartments have very different 
resistance values to a high frequency electrical signal. The single impedance 
measurement reflects the degree of resistance to the flow of current in the 
body, water being a good conductor and fat a bad conductor, it calculates the 
percentage of these body components for an individual. 
A variety of body composition methods is available and majority of them 
are limited to the research or clinical laboratories that include determination of 
body water, tomography, and electrical conductivity. Some of these methods 
are less reliable and not friendly. BIA on the other hand is a non-invasive, 
cheap and easy method of measuring body composition. BIA is a safe 
procedure and requires no special skills on the part of the operator or the 
subjects, cooperation is minimal and importantly measurement are reliable and 
rapid
266, The instrument is portable and inexpensive. BIA has been validated in 
adults
267-269 Further more this method has also has high rate of reproducibility 
in adults
266.  
    The principle behind this is based upon the conduction of an applied 
electrical current in the organism. In living organisms the application of a 
constant low level alternating current results in an impedance to the spread of 
the current that is frequency dependent
266. This work was conducted by Nyboer 
of USA who studied arterial pulse wave forms and pulsatile blood flow to 
organs using electrical impedance  plthysmography
270 . Lukaski et al 
demonstrated a strong relationship between BIA measurements and fat free 
mass, total body water and total potassium
266 and suggested that this method 
may be very useful as a tool routine measurement. 
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Figure 2.2 Bodystat® displaying the four electrodes that is used to measure fat 
and lean mass. 
 
Procedure: Subject removed their shoes and socks from the right foot and lay 
down in supine position with no parts of the body touching one another. Two 
electrodes were used, one placed behind the second toe next to the big toe, 
and one on the ankle between the medial and lateral malleolus. A further two 
electrodes were used, one placed behind the knuckle of the middle finger, 
another one on the wrist next to the ulnar head. These electrodes were then 
connected to the Bodystat® 1500 by alligator clips. The volunteers’ age, 
gender, height, weight and activity level were entered into the system before 
starting the test. Activity levels were categorised in 5 levels; very low, 
low/medium, medium, medium/high and high. The whole test took 
approximately 5 minutes and the readings were displayed on the screen of the 
Bodystat 1500®. The readings included fat and lean mass in percentage and 
kilograms to the nearest 0.1% and 0.1 kg respectively, total body weight to the 
nearest 0.1 kg, water percentage to the nearest 0.1%, total body water to the 
nearest 0.1 litre, estimated metabolic rate and estimated average energy 
required to the nearest 1 kcal, body mass index (BMI) to the nearest 0.1 and 
impedance to the nearest 1.  
Although BIA does not require any complicated training to perform the 
test, minor difference in the distance between each electrode when placing the 
electrodes will produce significantly  different results
271. One  investigator for 
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one subject throughout the recording day policy was practiced; however, 
individual variations in placing the electrodes could not be avoided since each 
electrode is of single use only.  
 
 
 
2.5.3.  Skinfold measurement 
The skin fold measurements are the cheapest means to measure total body fat 
in adults. The measurements and validated and show a good correlation with 
Dexa scan 
272, however there is always interpersonal variation. To minimize this 
technical error of measurements, differences between repeat skinfold 
measures, measurement sites and measurement techniques have been defined 
273. It has been suggested that anthropometry measurements should possible 
show an error in land marking if done by different people. Hence it is advised 
that the measurement are done by one 
273 Few studies have investigated the 
magnitude of any error likely to derive from not measuring at exactly specified 
points. Ruiz et al reported that skinfold thickness varied by an average of 
2.5mm when the calliper was placed 2.5 cm from the correct site
274 
  Skinfold thickness is measured to the nearest mm, except for low values 
when it is taken to the nearest 0.5mm.The readings are made at four sites  
biceps, triceps, subscapular and supra iliac areas. These were done usually on 
the right side of the body with subject standing in a relaxed condition. , The 
circumference at the upper arm, upper thigh was obtained using a tape. Waist 
circumference, total leg length are also measured. Skinfolds and circumference 
are metered by the standard technique described by Weiner & Lourie (1969) 
except that the subscapular skinfold is taken at an angle of about 45
0 to the 
vertical and the position of the Suprailiac skinfold just above the iliac crest in 
the mid axillary line
275 
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Figure 2.3 Callipers used for skin-fold measurements. 
 
Procedure:    Measurements were all performed on the volunteer’s non-
dominant side by measuring tape and recorded to the nearest 0.1cm. Skin fold 
measurements were repeated three times to obtain average readings. 
Volunteers were standing without their top garments and with their back to the 
measurer, arms hanging by their sides.  
Firstly, the tips of the acromion at the point of the shoulders were 
palpated and marked with a cross. With the arm flexed at 90 degrees, the 
olecranon at the tip of the elbow were palpated and marked with a cross. The 
tape measure was placed on the mark on the acromion and dropped to the 
cross at the olecranon. Halfway between the acromion and the olecranon was 
marked. This indicated the half-upper arm length. 
Volunteers relaxed their arms by their side when the tape measure was 
placed around the upper arm with the upper border of the tape at the level of 
the mark to measure the mid upper arm circumference. With the tape in 
position, a line was drawn on the skin posteriorly and anteriorly at the level 
with the first mark. The posterior line was used for the triceps fold and the 
anterior line was used for the biceps fold. With the palm facing forward, the 
mid point of the part, which sticks out the furthest, was marked vertically to 
form a cross. The skin was picked out in a vertical tube with two hands, at 
least 1cm above and below the cross. The skin fold callipers were applied at 
the level of the cross, with the cross on the apex of the fold. The readings were 
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recorded after the callipers were applied for 5 seconds. Three readings were 
repeated and the same was done for triceps skin fold posteriorly. 
For the subscapular skin fold, volunteers stood topless with their back to 
the measurer with shoulders and arms relaxed. The lower most tip of the 
scapula were palpated and marked with a cross. The inferior angle of the 
scapula was palpated by following the medial border of the scapula 
downwards. The skin fold was then picked up obliquely and the callipers were 
applied at the level of the cross with the cross at the apex of the fold. 
The iliac crest was then palpated on the non-dominant side and a cross 
was marked. The lower rib margin was marked as well on the same side. The 
midway point between these two marks was measured and marked indicating 
the half rib/ iliac distance. Suprailiac skin fold was measured at this point. The 
midpoint on the half rib and iliac distance, where the skin sticks out furthest, 
were marked with a cross. Suprailiac skin fold measurements were then 
performed using the technique described above. The measuring tape was then 
placed around the volunteer on the same location.  
Body density was then calculated using the Durnin and Wormersley’s 
linear regression equations
276, which is shown below, 
 
BODY DENSITY = C-[M (LOG10 SUM OF ALL FOUR SKINFOLDS)]  
Where C and M are constant depending on sex and age.  
 
Male 
 
17-19 yrs 
 
20-29 yrs 
 
30-39 yrs 
 
40-49 yrs 
 
50+ yrs 
 
C 
 
1.1620 
 
1.1631 
 
1.1422 
 
1.1620 
 
1.1715 
 
M 
 
0.0630 
 
0.0632 
 
0.0544 
 
0.0700 
 
0.0779 
 
 
Female 
 
16-19 yrs 
 
20-29 yrs 
 
30-39 yrs 
 
40-49 yrs 
 
50+ yrs 
 
C 
 
1.1549 
 
1.1599 
 
1.1423 
 
1.1333 
 
1.1339 
 
M 
 
0.0678 
 
0.0717 
 
0.0632 
 
0.0612 
 
0.0645 
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2.5.4.  Waist circumference measurement
 
Volunteers relaxed and the reading of the waist circumference was measured 
to the nearest 0.1cm
277. Circumference was measured with the volunteers 
removing objects bulging out in the trousers. The measuring tape was placed 
around the hip and few measurements were performed to get the largest 
measurement. Total leg length was measured with the volunteer standing 
straight and barefoot. The distance from the head of femur to the sole of the 
foot was measured. With the head of the measurement tape still in place on the 
head of femur, the kneecap was palpated. The distance from the head of femur 
to the kneecap was measured and the midpoint was recorded and marked with 
a tailor pen on the volunteer’s pants. The mid thigh circumference was then 
measured by placing the tape around the mark on the volunteer’s pants. 
 
 
 
2.5.5.  Blood pressure recording 
Blood pressure was usually measured in the brachial artery using a manual or 
electronic sphygmomanometer. Blood pressure is the force of blood against 
the walls of the arteries. It is recorded as systolic over diastolic pressure. In my 
study the blood pressure was measured by DOSCH monitor. The blood 
pressure was measured in standing, sitting and lying positions at an interval of 
2-3 minutes between each measurement. The mean of the three readings was 
then calculated and recorded for analysis. 
 
         
 
2.5.6.  Measurement of insulin resistance by HOMA 
Homeostasis Model Assessment measures insulin resistance and beta cell 
function which was designed by Matthews et al 
278 to understand and calculate 
insulin resistance from fasting glucose and fasting insulin levels. This is a 
computer-solved model used to predict the homeostatic concentrations which 
arise from varying degrees of beta-cell deficiency and insulin resistance. This 
model compares subjects fasting values with the models predictions, which 
allows a quantitative assessment of the contributions of insulin resistance and 
deficient beta-cell function to the hyperglycemia. The accuracy of this model 
has been compared with independent measures of insulin resistance and beta-
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cell function using hyperglycaemic and euglycaemic clamps and an intravenous 
glucose tolerance test.  
  
The formula for calculating insulin resistance (IR):  
           IR= (fasting insulin in μU/ml x fasting glucose in mmol/l)/ 22. 
This assessment model is well validated and been used in many diabetic 
studies, however this less accurate than the clamp method. 
2.6. Statistical methods 
Results are presented as mean ± standard deviation (SD) for normally 
distributed variables and median and interquartile range otherwise. Initial 
statistical comparison was performed by ANOVA for normally distributed and 
Kruskal-Wallis for non normally distributed data. P values for differences 
between groups and linear trends across groups were analysed, taking p<0.05 
as significant. Student’s t-test and the Mann-Whitney U test were used to 
compare normally and non-normally distributed data between two groups 
respectively. The Chi-square test was used to compare proportions of features 
of MeS between the three groups. Pearson and Spearman correlation analyses 
were undertaken to examine associations between normally and non-normally 
distributed variables, respectively. Linear regression models were developed 
with FEV
1 to investigate the effect of variables on the outcome measure. All the 
analyses were undertaken using the SPSS 14.0 package, SPSS Inc., Chicago, IL, 
USA. 
  The statistical hypothesis were based on Austin Bradford Hill’s criteria 
from ‘The environment and disease association or causation’  published in the, 
‘Proceedings of the the Royal Society of Medicine’ in 1965
279. Hills criteria of 
Causation outlines the minimal conditions needed to establish a causal 
relationship between two variables. The criteria have been applied in my study 
and in much epidemiological research to illustrate how this would be applied 
to research in the social and behavioural sciences. The criteria included 
temporal relationship, strength, Dose-response relationship, consistency, 
plausibility, consideration of alternative explanations, experiment, specificity, 
and coherence. 
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3.0 Chapter- Features of metabolic syndrome and 
body composition in smokers 
 79  
3.1. Introduction 
The clinical importance of diagnosing features of metabolic syndrome (MeS) in 
smokers with and without Chronic Obstructive Pulmonary Disease (COPD) has 
not been studied extensively. The systemic effects of smoking not only has an 
impact on exercise intolerance which is associated with COPD
115, 280, 281 but also 
lead to other co morbidities
115, 282-284, including cachexia 
284, skeletal muscle 
abnormalities
281, 285, 286  hypertension
287, 288 and diabetes 
289. 
COPD is characterised by poorly reversible airflow limitation that is 
usually progressive and associated with an abnormal inflammatory response of 
the lungs to noxious particles or gases, particularly cigarette smoke
290. There is 
an increasing evidence that the airflow limitation including imaging and clinical 
features are poorly correlated
291. Smoking is the most important risk factor for 
people to develop COPD and also for many chronic diseases and some 
cancers
292. According to WHO it is estimated to kill 250 every hour
293. COPD is 
also the leading cause of mortality and morbidity globally and it estimated to 
be the third leading cause of death by 2020
294, 295, 295, 296.  
MeS is a global phenomenon and it is estimated to be on the rise, with 
one in four individuals in the US having features of metabolic syndrome. MeS is 
a cluster of cardio-metabolic risk factors consisting of hyperlipidemia, 
dysglycaemia, central obesity and hypertension that predisposes individuals to 
increased risk of developing cardiovascular and type-2 diabetes 
297. Various 
definitions have been proposed and commonly used ones are the International 
Diabetic Federation (IDF) and National Cholesterol Education Programme-Adult 
Treatment Panel III (ATP III). The definitions and classification have been 
discussed in the chapter I (section 1.7.3). Early recognition of metabolic 
syndrome would not only help patients with early diagnosis and treatment but 
also lessens the long-term health care costs and resources. 
Body composition measurement in COPD plays a pivotal role in the 
disease progression. Low body weight and low body mass index (BMI) is found 
to be a major risk factor for mortality in COPD. Several studies have 
investigated factors affecting mortality
235, 298-301. Marquis et al 
301 in their study 
found that body composition measured as midthigh muscle cross sectional 
area obtained by computed tomography (CT) scan is a  better predictor of 
mortality than BMI. It is also been reported that there is a relationship between 
total body water and electrical impedance based on the principal that fat mass 
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(FM) and fat free mass (FFM) which have different conductive and dielectrical 
properties
302. This is due to the fact that FFM contains water and therefore has 
a lower resistance than FM
303. 
What is less understood is the relationship between effects of COPD on 
the metabolic features and the relationship between body composition and 
COPD. My hypothesis was that COPD causes systemic inflammation and is 
driven by smoking. These systemic effects of COPD contribute to the 
development of features of metabolic syndrome and hence the prevalence of 
m e t a b o l i c  s y n d r o m e  i s  h i g h  i n  C O P D  s u b j e c t s  w h e n  c o m p a r e d  t o  s m o k e r s  
without COPD.  
The aim of my study was to understand the prevalence of metabolic 
syndrome and the role of body composition in my cohort of smokers with and 
without COPD. 
 
3.2. Methods  
A total of 131 subjects including 44 healthy controls (HC), 46 smokers without 
COPD (HS) and 41 with COPD were recruited for this study and were matched 
for age and sex. Subjects were than categorised according to the GOLD criteria 
for diagnosing COPD.   
All subjects had clinical history taken, underwent medical examination as 
outlined in Chapter 2 (section 2.2.1 study 1). Blood was taken for fasting 
glucose, fasting insulin, lipids, and for inflammatory marker CRP. Height and 
weight were measured as explained in chapter 2. Subjects underwent 
pulmonary function testing, measurement for body composition was measured 
by BODPOD, bioelectrical impedance analysis (BIA), and skin-fold 
measurements. All subjects had their blood pressure checked in sitting, 
standing and lying positions. 
Metabolic syndrome was defined according to the IDF criteria which are 
discussed in detail in chapter 1 (section 1.16.4). 
 
 
3.2.1.  Statistical analysis 
Descriptive data are expressed as means and standard deviation for the 
normally distributed data and median and quartiles for others. Independent t-
test or Mann-Whitney-U test was used for the comparative analysis. Qualitative 
variables were compared by chi-square test. Linear regression analysis was 
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done to compare the characteristics of smokers and non-smokers. For the 
correlation analysis, Spearman’s rank correlation was used, as the data was not 
normally distributed. Statistical Package for the Social Sciences 14 (SPSS Inc, 
Chicago IL, USA) software was used for the analysis. GraphPad prism 5 was 
used for the scientific graphing in this study.  
 
3.3. Results 
 
Subjects were characterised as described in Chapter 2 (study I). A total of 131 
subjects were recruited for the study. The subjects were subdivided into 
healthy non-smoker controls (HC=44), smokers without COPD (HS=46) and 
smokers with COPD (COPD=41). Subject characteristics are in table 3.1. 
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Subject characterisation 
  
Non-smoker 
control 
 
Healthy smoker 
 
COPD 
No of subjects 
 
         
44 
        
46 
      
41 
Sex M/F 
 
      
20/24 
 
24/22 
 
22/19 
Age (yrs) 
 
  
*53 ± 8.5 
 
*54.7 ± 8.1 
 
*55.6 ± 8.4 
Pack years 
 
      
N/A 
 
**31(21 to 40) 
 
 
**45(39 to 57.5) 
 
FEV
1 (%predicted)   
**112 (102 to 
121.7) 
 
 
**106(98 to 114) 
 
 
**73(60 to 90.5) 
 
BMI 
 
 
*25.8 ± 4.2 
 
 
*26.5 ± 4.7 
 
 
*26.8 ± 5.7 
 
β
2 agonists use 
(long and short 
acting) 
 
N/A 
 
None 
 
None 
Inhaled/oral 
corticosteroids 
use 
 
N/A 
 
None 
 
None 
  
 Table 3.1 Subject characteristics.  
* mean and standard deviation, ** median and quartiles. 
FEV1:Forced expiratory volume in 1 second, BMI:Body mass index, N/A:not 
applicable. 
 
 83  
3.3.1.  Prevalence of metabolic syndrome in smokers with and without 
COPD 
When using the criteria of IDF to define the presence of MeS, the prevalence of 
MeS was 11.4% in healthy non-smoking individuals, 28.3% in healthy smokers 
and 36.6% in smokers with COPD (Figure 3.1)  
B). Using the ATPIII criteria, the prevalence was 4.5%, 19.6%, 29.3%, in the three 
groups of subjects, respectively (Fig 3.1 A).  
     A      B 
ATP III
p<0.03
n.s
p<0.002
HC HS COPD
0
10
20
30
40
%
p<0.006
HC HS COPD
0
10
20
30
40
%
p<0.04
n.s
IDF
Figure 3.1 Prevalence of MeS in healthy non-smokers (HC), healthy smokers (HS) 
and smokers with COPD. 
Data are represented as percentage of prevalence of metabolic syndrome. Chi 
square test was used to test the difference in prevalence between the groups. 
ATP: Adult treatment programme 111, IDF: International Diabetic Federation, 
n.s.: Non-significant, %: percentage. 
 
3.3.2.  Measurement of features of MeS 
3.3.3.  Fasting triglycerides  
Hypertriglyceridemia is more common in coronary disease than high total 
cholesterol. The normal range of triglycerides is 0-2.0 mmol/L. In my study it 
was high in smokers with and without COPD (p<0.004 and p<0.002, 
respectively) when compared to non-smoker controls. However, I found no 
difference between smokers with and without COPD. It was noted from 
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correlation analysis that there was a weak inverse relationship between 
triglycerides and FEV
1 (r
s= -0.202, p<0.02). 
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Figure 3.2 Triglyceride levels in healthy non-smokers (HC), healthy smokers (HS) 
and smokers with COPD 
The data are expressed as median and quartiles. Mann-Whitney U test was 
used for analysis. n.s.: not significant, mmol: millimoles per litre. 
 
 
 
3.3.4.  Fasting high-density lipoprotein (HDL) 
Reduced HDL cholesterol is accepted as a major risk factor for coronary 
disease. The normal range in our laboratory for HDL was 0.91-2.21mmol/L. 
The HDL levels in COPD subjects was lower than that in healthy non-smoker 
controls (p<0.01). There was a positive correlation (r
s= 0.201, p<0.02) between 
HDL and FEV
1 which was suggesting that HDL could be contributing directly or 
through a different mechanism in preserving the lung function in smokers. 
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Figure 3.3 High-density lipoprotein levels in (HDL) healthy non-smokers (HC), 
healthy smokers (HS), and smokers with COPD. 
The data are expressed as median and quartiles. Mann-Whitney U test was 
used for analysis. n.s.: not significant, mmol/L: millimoles per liter. 
 
 
 
3.3.5.  Fasting glucose 
Increase fasting glucose or glucose intolerance is one of the main features of 
MeS (Normal range 4-6 mmol/L). It is  well know that there is interrelationship 
between visceral abdominal fat and insulin resistance
185 which is a major risk 
factor for atherosclerotic cardiovascular disease. In my study I found that there 
was a difference between non- smoker controls and COPD (p<0.01), however, 
there was no difference between smokers with and without COPD. There was a 
strong negative correlation (r
s= -0.251 and p<0.004) between fasting glucose 
and FEV
1. 
 
 
3.3.6.  Waist circumference 
There is a pathophysiological relationship between abdominal girth or central 
obesity and waist/hip ratio rather than the body mass index as obesity related 
cardiovascular risk
304, 305. This is even true in normal weight subjects where 
central obesity is associated with increased cardiovascular risks
305, 306. In my 
study COPD smokers had more central obesity than non-smoker controls 
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(p<0.03). There was a strong negative correlation between waist circumference 
and FEV
1 (r
s= -0.225, p<0.01). 
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Figure 3.4 Waist circumference in healthy non-smokers (HC), healthy smokers (HS) 
and smokers with COPD. 
The data are expressed as median and quartiles. Mann-Whitney U test was 
used for analysis. n.s.: significant, cms: centimetres. 
 
 
3.3.7.  Waist-hip ratio 
The wait/hip (w/h) ratio is a well-standardized and simple measure of central 
obesity. A trend has been shown for smokers to have a lower BMI but higher 
W/H ratio
307. In my study, COPD subjects had a higher w/h ratio than non-
smokers (p<0.001). However, there was no difference between smokers with 
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and without COPD. 
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Figure 3.5 Waist/hip ratio in healthy non-smokers (HC), healthy smokers (HS), and 
smokers with COPD. 
The data are expressed as median and quartiles. Mann-Whitney U test was 
used for analysis. n.s.:non significant, W/H:waist hip ratio. 
 
 
 
3.3.8.  Systolic blood pressure 
 
Elevated blood pressure is a frequent component of MeS and hypertension is 
more frequent in subjects with either insulin resistance or obesity
185, 220, 308. In 
my study, there was no difference in mean systolic blood pressure (mean of 
lying, sitting, and standing blood pressure) between non-smoker controls and 
smokers with or without COPD. 
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Figure 3.6 Systolic blood pressure in healthy non-smokers (HC), healthy smokers 
(HS), and smokers with COPD 
 
The data are expressed in median and quartiles. Mann-Whitney U test was used 
for analysis n.s.:not significant, mmHg:millimetres of mercury.  
 
 
 
3.3.9.  Diastolic blood pressure 
Diastolic blood pressure was measured in three positions: lying, sitting and 
standing. The means of those three measurements were recorded for the 
analysis. Blood pressure ≤85mmHg was accepted as normal. Any reading 
above 85mmHg or systolic blood pressure >130mmHg was considered as 
indicating presence of one of the features of MeS. There was no difference in 
diastolic blood pressure between the groups. 
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Figure 3.7 Diastolic blood pressure in healthy non-smokers (HC), healthy smokers 
(HS), and smokers with COPD. 
The data are expressed as median and quartiles. Mann-Whitney U test was 
used for analysis. n.s.:not significant, mmHg:millimeters of mercury. 
 
 
 
3.3.10.  Body composition by bioelectrical impedance (BIA) 
Body composition measuring fat free mass, lean mass, total body water and 
impedance (resistance) in the body were analysed. The measurements were 
done by three methods: BIA, BODPOD and by skin fold measurements in all 
subjects. 
 
 
 
3.3.11.  Percentage and total body fat (kg) 
The Percentage of fat was no different in all three groups. However, there was 
a trend towards an increase in percentage fat in smokers with COPD. 
Correlation analysis with FEV
1 showed no significant correlation between 
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percentage body fat with FEV
1. There was no significant difference between 
non-smokers and smokers in fat weight and there was no correlation with FEV
1. 
 
HC HS COPD
0
20
40
60
Diagnosis
F
a
t
 
%
n.s.
Fat % 
 
Figure 3.8 Percentage fat in healthy non-smokers (HC), healthy smokers (HS), and 
smokers with COPD 
The data are expressed as median and quartiles. Mann-Whitney U test was 
used for analysis. n.s.:non significant. 
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Figure 3.9 Total body fat (kg) in healthy non-smokers (HC), healthy smokers (HS), 
and smokers with COPD 
The data are expressed as median and quartiles. Mann-Whitney U test was 
used for analysis.n.s. not significant, kgs: kilograms. 
 
 
 
3.3.12.  Measurement of percentage of lean mass 
Muscle wasting is an important phenomenon in severe COPD and contributes 
significantly to the mortality and morbidity of the disease. It is, therefore, 
important to measure lean mass or fat free mass of the body. This was 
measured as both percentage of total lean mass and absolute weight 
expressed in kilograms. There was no difference in lean mass (absolute or 
percentage) between the groups. 
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Figure 3.10 Percentage of lean mass in healthy non-smokers (HC), healthy 
smokers (HS), and smokers with COPD 
The data are expressed as median and quartiles. Mann-Whitney U test was 
used for analysis. 
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Figure 3.11 Lean (kg) mass in healthy non-smokers (HC), healthy smokers (HS), 
and smokers with COPD 
n.s. not significant. 
 
3.3.13.  Comparison of non-smoker controls  and smokers with and 
without metabolic syndrome 
There was no significant difference in prevalence of MeS between healthy 
smokers and COPD as I hypothesized. The increase in prevalence of MeS in 
these two groups may be due to the effect of smoking rather than the disease, 
in COPD group. To understand the effect of smoking better, I therefore 
grouped all smokers and compared with non-smoker controls. There was a 
significant difference (p<0.01) between non-smokers and smokers (Fig 3.13). 
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  3.3.14.  Prevalence of metabolic syndrome 
 
Non-smoker Smoker
0
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%
p<0.01  
 
 
 
 
 
 
 
Figure 3.12 Prevalence of metabolic syndrome (using IDF criteria) in healthy non-
smokers (n= 44) and smokers (n=87). 
The data are expressed as percentage and chi-square test was used to analyse 
the data and to derive the p value (0.01). %: percentage. 
 
 
3.3.15.  Waist circumference 
After finding that there was an increase in prevalence of MeS in smokers, I 
went on to analyse the individual features of MeS in smokers. The subjects 
were divided into four groups, non-smokers without MeS (NS-N, n=39), non-
smokers with MeS (NS-Y, n=5) and smokers without MeS (Sm-N, n=59), 
smokers with MeS (Sm-Y, n=28) Measurement of waist predicted to be as good 
as abdominal fat. It is suggested to a simple clinical alternative to BMI
309. In my 
study there was a significant difference in both groups (p<0.01, p<0.0003), 
however, the significance was more pronounced in smokers group. 
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Figure 3.13 Waist circumference measurement in non-smoker controls and 
smokers with and without MeS. 
The data are represented as median and quartiles. Non parametric Mann-
Whitney U test was used for the analysis.  
NS-N: non-smoker controls with no metabolic syndrome, NS-Y: non-smoker 
control with metabolic syndrome, Sm-N: Smokers with metabolic syndrome, 
Sm-Y: smokers with metabolic syndrome, cm: centimetre. 
 
 
 
3.3.16.  Waist Hip ratio 
Smoking associated difference in w/h ratio contributes to the development of 
early diabetes particularly in smokers who has a smoking history of >10 pack 
years
310. Hence, I analysed the w/h ratio in my group of subjects, and ratio of 
more than one was clinically significant and contributes to the morbidity and 
mortality of COPD. I found that there was difference in non-smokers (p<0.002) 
and in smokers (p<0.0004). In the correlation analysis w/h ratio was negatively 
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correlated with FEV
1  (r
s=-0.301, p<0.0004). W/h ratio was also positively 
correlated with insulin resistance (r
s=0.536, p<0.0006).  
 
 
 
3.3.17.  Measurement of fat 
There is evidence that stopping smoking increases body weight, however, it is 
less understood the relationship of smoking and increase body fat. In my 
study, the total body fat in kilograms in smokers with and without MeS was 
measured. There was an increase in total body fat in smokers with MeS 
(p<0.003), however, there was no difference in non-smokers (Fig 3.15).  
 
 
Fat (kg)
NS-N NS-Y Sm-N Sm-Y
0
20
40
60
80
k
g
n.s.
p<0.003
n.s.
n.s.
 
Figure 3.14 Total body fat (kg) measured by the bioelectrical impedance method 
in non-smoker controls and smokers with and without MeS. 
NS-N: non-smoker controls with no metabolic syndrome, NS-Y: non-smoker 
control with metabolic syndrome, Sm-N: Smokers with metabolic syndrome, 
Sm-Y: smokers with metabolic syndrome, n.s: not significant, kg: kilogram. 
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3.3.18.  Measurement of lean mass 
The lean mass in my subjects was increased in smokers and non-smokers with 
MeS as compared to subjects without MeS (p<0.04 and p<0.0004, 
respectively).  
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Figure 3.15 Total lean mass (kg) by bioelectrical impedance method in non-
smoker controls and smokers with and without MeS. 
The data are represented as median and quartiles. 
NS-N: non-smoker controls with no metabolic syndrome, NS-Y: non-smoker 
control with metabolic syndrome, Sm-N: Smokers with metabolic syndrome, 
Sm-Y: smokers with metabolic syndrome, kg: kilogram, n.s.: not significant. 
 
 
3.3.19.  Measurement of systolic blood pressure 
Increased systolic blood pressure in smokers contributes to cardiovascular 
disease and also to haemorrhagic stroke
311. I found that systolic blood pressure 
was high in both groups (p<0.005 and p<0.002). There was a strong negative 
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correlation between systolic blood pressure and FEV
1 percentage (r
s= -0.273, 
p<0.002) which explains the effect of the blood pressure on the lung function. 
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Figure 3.16 Systolic blood pressure (mmHg) in non-smoker controls and smokers 
with and without MeS. 
The data are represented as median and quartiles. 
NS-N: non-smoker controls with no metabolic syndrome, NS-Y: non-smoker 
control with metabolic syndrome, Sm-N: Smokers with metabolic syndrome, 
Sm-Y: smokers with metabolic syndrome, n.s: not significant, mmHg: 
millimetre of mercury. 
 
 
 
3.3.20.  Measurement of diastolic blood pressure 
Diastolic blood pressure is as important as the systolic blood pressure. This is 
strongly associated with MeS. There is evidence to say that this could be due to 
a insulin receptor gene polymorphism
312. In my study the diastolic blood 
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pressure was high in both groups (p<0.005 and p<0.05 respectively) but more 
so in non-smokers. With Spearman’s rank correlation, there was no correlation 
between diastolic blood pressure and FEV
1 percentage. 
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Figure 3.17 Diastolic blood pressure (mmHg) in non-smoker controls and smokers 
with and without MeS. 
The data are represented as median and quartiles. 
NS-N: non-smoker controls with no metabolic syndrome, NS-Y: non-smoker 
control with metabolic syndrome, Sm-N: Smokers with metabolic syndrome, 
Sm-Y: smokers with metabolic syndrome, n.s.: not significant, mmHg: 
millimetre of mercury. 
 
 
 
3.3.21.  FEV
1 and TLco in smokers with MeS 
FEV
1 percentage and TLco percentage was measured in all smokers and non-
smokers with and without MeS. Smokers with MeS had reduced FEV
1 
percentage (p<0.04), however, there was no difference in non-smokers group. 
There was no difference in TLco percentage in smokers or non-smokers, 
however there was a difference in TLco percentage between non-smokers and 
smokers with and without MeS (Fig 3.19, p<0.05 and p<0.0001 respectively). 
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The data are represented as median and quartiles. 
NS-N: non-smoker controls with no metabolic syndrome, NS-Y: non-smoker 
control with metabolic syndrome, Sm-N: Smokers with metabolic syndrome, 
Sm-Y: smokers with metabolic syndrome. FEV
1: Forced expiratory volume in 1 
second, TLco: transfer factor for carbon monoxide, n.s.: not significant. 
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Figure 3.18 FEV1 percentage and TLco percentage in non-smoker controls and 
smokers with and without MeS. 
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3.4. Discussion  
To date there have been no studies of the prevalence of features of MeS in 
smokers with COPD although limited research has shown an increased 
prevalence of MeS in smokers but has not taken into account the presence or 
absence of airways disease. The main aim of my study was to understand the 
prevalence of features of metabolic syndrome in smokers and COPD and to 
confirm whether it is smoking or systemic effects of COPD, which is, 
associated with the prevalence of features of MeS. In this well characterised 
cohort, there was an increase in prevalence of MeS in smokers regardless of 
the diagnosis of COPD when compared with non-smoker control subjects, 
suggesting that it is current smoking that is associated with MeS regardless of 
airways disease. The strong association between smoking and features of 
metabolic syndrome confirms the findings of Oh et al that smoking is 
associated with features of metabolic syndrome. Furthermore, that study went 
on to show that there was  a dose-dependent association between pack years 
and the presence of MeS
245, 313.  
There is good evidence to suggest that smoking has systemic effects
314. 
Life-long smokers have an increased prevalence of  cardiovascular disease 
314. 
Large population-based studies in smokers have confirmed an increase in 
serum CRP that reflects low-grade inflammation but the driver for this increase 
remains unknown. Metabolic Syndrome and the association with   
cardiovascular and type-2 diabetes 
297 is well studied. It is also known that 
smokers with abdominal obesity are at high risk of developing coronary artery 
disease
315. Smoking has been associated with increased abdominal fat, which 
has been shown to be associated with glucose intolerance and dyslipidemia. It 
has been established that central obesity measured by waist circumference 
predicts obesity-related health risk
316-319. Whether smoking is at the origin of the 
abdominal obesity
320 has been debated. There was an increase in central 
obesity in smokers when compared to non-smokers in my cohort. This was 
also shown to the case when they were assessed for waist circumference and 
waist hip ratio. This confirms that smokers gain weight around the waist 
compared to healthy.  
There is an important public message about the relationship between 
smoking and weight gain. This may be used as a tool in smoking cessation 
clinics, which may increase the success rate in future. However, it is unclear 
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from the results in my study whether smokers with central obesity would loose 
this feature of MeS if they stopped smoking. The other important feature of 
MeS is increased triglycerides and high-density lipoprotein (HDL). My study 
contrasts the data in the literature, Stefania Basili et al found that there was no 
difference in triglyceride and HDL levels in smokers and COPD compared with 
healthy subjects
321 but in my study I found that triglycerides were raised in 
both smokers with and without COPD when compared to healthy non-smokers. 
It was also noted that there was no difference between smokers with and 
without COPD suggesting the effect of smoking, rather than disease, on 
triglyceride levels.  
There was a decrease in HDL level in COPD compared to healthy subjects. 
However, there was no difference in smokers without COPD and healthy or 
between smokers with and without COPD. This is again contrasts the study 
done by Tisi et al 
322  where in they described an increase in HDL levels in COPD 
subjects. Others have reported an association between smoking and 
hypertension
323 however in my study there was a difference in systolic and 
diastolic blood pressure in healthy smokers with MeS but not in COPD group. 
This is again an indication of the effect of smoking and its role on endothelial 
damage. 
There is a coexistence of type-2 diabetes and COPD and an increase trend 
of diabetes in elderly patients
324. Abnormal glucose concentration and fasting 
insulin are important contributors for the development of feature in MeS. This 
opens a new treatment approach, which could be developed in such patients 
where both diseases co exist. The question why smokers have an increase in 
blood glucose remains open. One possible explanation is that smoking and 
indulgence in food go hand in hand. The other is that smoking induces insulin 
resistance. Indeed, in my study I found that COPD subjects had elevated fasting 
glucose compared to healthy and a borderline difference with smokers without 
COPD. There was an association between smoking and insulin resistance, 
which is discussed in chapter 5. 
I found that fat mass was increased in both smokers with and without 
COPD (fig 4.2.5 and fig 4.2.8). This important finding suggests that smoking 
can increase fat-mass and also contradicts the widely held view amongst the 
public and doctors that smoking keeps people slim. It was also confirmed by 
increase in waist/hip ratio which showed increase with smoking (Fig 4.2.7 and 
4.3.1).  
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After these analysis I realised that more of the changes seen are due to the 
effect of smoking rather than COPD. I therefore grouped both HS and COPD. 
The combined smoking group, as expected had high prevalence of MeS. The 
percentage of smokers having MeS was 32.18% and 11.36% in non-smoker 
controls. There was no difference in blood glucose, smokers had high 
triglycerides, and HDL was same when comparing smokers with and without 
MeS. This suggests that these features are not key in differentiating smokers 
with and without MeS. However, smokers with MeS had more fat mass and had 
increased waist, raised fasting insulin, and insulin resistance. It was also seen 
that both systolic and diastolic blood pressure were high in smokers with MeS. 
Other important finding was that the subject with MeS had decreased FEV
1 
percentage and TLco was decreased compared to non-smokers with MeS. The 
reason could be that the features of MeS are probably driven by decrease in 
FEV
1. The possible hypothesis is that smoking causes decline in lung function, 
which in turn drives oxidative stress, and insulin resistance, which ultimately 
effects in early developlement of MeS in smokers. Alternatively, MeS could 
contribute to the progression of airways damage and development of COPD, 
i.e. decline in FEV
1. 
Much remains to be understood about the association between smoking 
and metabolic features. It is unclear why some smokers develop features of 
MeS and what might be the protective mechanism in others. We also need 
evidence of reversal of these features if patients stop smoking and it remains 
unclear what is the role of early intervention such as diet and physical activity. 
There are no studies on gene environment relationship in COPD and metabolic 
syndrome which could shed some light on the contributing factors. 
The limitation of this study was that the subjects all had mild-moderate 
disease and normal to overweight subjects with relatively small number. Future 
study should focus on severe COPD subjects and focus separately on obese 
and cachextic patients where the interaction between lung disease and the 
metabolism may be different.  
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4.0 Chapter- Systemic inflammatory markers in 
COPD and metabolic syndrome 
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4.1. Introduction  
Inflammation is important in the pathogenesis of COPD
79. Cigarette smoke 
known to cause local inflammatory changes in the airways and also systemic 
cellular and humoral inflammation, systemic oxidative stress and endothelial 
dysfunction and  increased procoagulant factors
314, 325. Inflammatory markers 
play an important role in the pathogenesis of COPD and there is a suggestion  
that inflammation is an important pathway between lung disease and vascular 
disease
326, 327. Studies have explored the role of specific inflammatory cells in 
COPD and suggested the importance of neutrophils
328-330, CD8+ T 
lymphocytes
331-333, macrophages
334-336. In chronic smokers neutrophils are 
increased in blood and bronchoalveolar lavage fluid
337. IL-6 is considered to 
play a role in innate and adaptive immunity and studies have showed that IL-6 
activity was decreased after smoke exposure. IL-8 measurement is used to help 
to discriminate between smokers with and without COPD and COPD patients 
reported to have a raised IL-8 levels
338. 
There is an increasing evidence suggesting that clinical features of COPD 
and airflow limitation are poorly correlated and there is consensus about a 
comprehensive approach, including radiological evidence
112 , inflammatory 
markers, assessment of body composition, exercise tolerance
113 for the 
diagnosis and to classify the severity of the disease.  
MeS is a cluster of specific risk factors for cardiovascular disease with 
common underlying abnormality in insulin production. The aetiology of 
metabolic syndrome is uncertain but it is accepted that MeS is associated with 
inflammation and it has been suggested that subclinical inflammation is a 
contributory factor in the development of MeS
339. The inflammatory markers 
which are raised in MeS are CRP
340, TNF-α, fibrinogen and IL-6 and leptin among 
others
341. The association between inflammation and MeS is complex. One of 
the accepted reasons is that the proinflammatory cytokines are released by 
adipocytes into the systemic circulation which in turn triggers hepatic CRP 
production, thereby increasing inflammation. A second view is that there is an 
increase in the prothrombotic molecule plasminogen activator inhibitor-1 (PAI-
1) in individuals with MeS
342, which correlates with visceral adiposity
343. 
  Loss of body weight and fat free mass is associated with increased 
mortality, poor functional status and quality of life of patients with COPD
298, 301, 
344. However, there is an inverse relationship between mortality and BMI in 
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these patients and putting on weight in cachextic patients improves 
prognosis
113, 231, 298. The association of features MeS like dyslipidemia, 
inflammation, insulin resistance, type 2 diabetes is associated with increased 
visceral fat seen in obese subjects
308, 345, 346. There is a debate whether the 
presence of metabolic syndrome alone can predict global cardiovascular 
disease risk or is it abdominal obesity, the most prevalent manifestation of 
metabolic syndrome and a marker of dysfunctional adipose tissue, that is of 
central importance
346. 
There is a view that COPD is a chronic systemic inflammatory syndrome 
which, apart from age and smoking, contributes to develop chronic heart 
failure, features of MeS and increased CRP. It is well known that inflammation 
plays an important role in COPD and there is evidence that inflammation may 
be associated with MeS but what is less understood is that which inflammatory 
cells, markers and inflammatory mediators play a crucial role in smokers and 
COPD who develop features of MeS. My hypothesis is that there is a strongh 
relationship between inflammatory mediators and smoking and that systemic 
effect of smoking contributes to the development of features of MeS in 
smokers and COPD.  
The aim of this study was to understand the role of common 
inflammatory cells and markers, mediators released in smokers who develop 
COPD and to compare the same with non-smoker controls who also develop 
features of metabolic syndrome.  
 
4.2. Methods 
 A total of 131 subjects were recruited for the study. They were sub divided 
into non-smoker controls (HC), smokers without COPD (HS) and smokers with 
COPD. Subjects underwent medical examination, body composition 
measurements. Bloods were taken for full blood count, CRP. Cytokine 
measurement was done on 98 subjects by multiplex ELISA (Luminex). The 
study design is explained in detail in chapter 2.0 (section 2.4.9). 
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4.2.1.  Systemic inflammatory marker and inflammatory cells in 
smokers with and without COPD 
4.2.2.  C-Reactive protein (CRP) 
Smoking increases the levels of CRP by causing tissue damage, however, there 
are inconsistencies with the results from many studies. In clinical practice CRP 
is routinely used as a marker of systemic inflammation. In my study CRP was 
measured from the peripheral blood and, the normal range was between 0-
7.5mg/L. When CRP was analysed in all subjects there was a significant 
difference between HC and HS (p<0.04), HC and COPD (p<0.0001) and HS and 
COPD (p<0.0003). Smokers with COPD had high levels of CRP compared to 
smokers without COPD. This suggests that there is an increased inflammation 
in COPD subjects and confirms that CRP is raised in smokers in general. 
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Figure 4.1 C-Reative Protein (CRP) levels in peripheral blood in healthy non-
smokers (HC), smokers (HS) with and without COPD. 
Data are represented as median and quartiles.  
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4.2.3.  Blood neutrophils 
Neutrophils are important mediator of inflammation in smokers and COPD. 
Neutrophils are short lived and transient cells in the body and they are 
recruited into the lung during inflammation and infection. In COPD patients, 
they play pivotal role in host defence. Neutrophil count was measured in 
peripheral blood in all subjects in the study. Bloods was taken after making 
sure that subjects had not exercised nor smoked for 12 hours. The normal 
peripheral blood neutrophil level is between 2.0-7.5*10^9/L in our laboratory 
and there was a difference between non-smoker controls (HC) and smokers 
with and without COPD (p<0.0002 and p<0.0004 respectively), however, there 
was no statistical difference between smokers with and without COPD. 
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Figure 4.2 Peripheral blood neutrophils in non-smoker controls (HC), smokers (HS) 
and COPD subjects (COPD). 
Data are shown as median and quartile and Mann.n.s: not significant. 
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4.2.4.  Blood monocytes 
The role of monocytes is to participate and help in host defence in COPD 
patients. Peripheral blood monocytes are the circulating precursors of alveolar 
macrophages
347.  Monocytes was measured in the peripheral blood in all 
subjects in the study. The data suggests that there was difference between HC 
and HS (p<0.0001), HC and COPD (p<0.0001), however, there was no 
difference between HS and COPD. 
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Figure 4.3 Peripheral blood monocytes in non-smoker controls (HC), smokers (HS) 
and COPD subjects. 
Data are shown as median and quartiles and Mann Whitney U test used to 
analyse the difference between the groups. n.s: not significant. 
 
 
 
4.2.5.  Blood lymphocytes 
Total lymphocyte was measured in the peripheral blood in all subjects in the 
study. There was difference between HC and HS (p<0.0002) and HC and COPD 
(p<0.0001), however, there was no difference found between HS and COPD. 
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Figure 4.4 Peripheral blood lymphocytes in non-smoker controls (HC), smokers 
(HS) and COPD subjects (COPD). 
Data are presented as median and quartiles.  
 
4.2.6.  Systemic inflammatory marker (CRP) and inflammatory cells in 
smokers combined 
The inflammatory marker CRP levels and inflammatory cells neutrophils, 
monocytes and lymphocytes were higher in smokers and subjects with COPD. 
However, there was no difference between smokers with and without COPD 
except for CRP. This suggests that the inflammatory changes are due to 
smoking rather than COPD as a disease. All the smokers were then grouped to 
analyse the differences in inflammatory marker and inflammatory cells in 
smokers and non-smokers with and without MeS.  
CRP was strongly associated with inflammation and there are numerous 
studies, which demonstrate this in smokers. In my study  there was a steep 
increase in levels when compared with non-smokers (Fig 4.5 p<0.0004). In the 
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bivariate analysis CRP showed a strong negative correlation to FEV
1 percentage 
(r
s change=-0.514, p<0.0006), TLco (r
s change=-0.507, p<0.0006).  
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Figure 4.5 C-Reactive Protein (CRP) levels in healthy non-smokers and smokers. 
The data are represented as median and quartiles. mg/l: milligram per litre. 
 
4.2.7.  Blood inflammatory cells, neutrophils, monocytes,  and 
lymphocytes 
The results were analysed and found that there was difference (Fig 4.5A, 
p<0.0001) between smokers and non-smokers. Subsequently multivariate 
analysis was done with other inflammatory markers and FEV
1 as dependent 
variable. I found that neutrophil counts were not associated with FEV
1. 
However, there was a strong association between transfer factor (TLco) and 
neutrophils (r
2 change=0.311, p<0.002).  
Blood monocytes were also measured in the study. The effect of smoking 
on monocytes is   important to understand as blood monocytes are the 
precursors of tissue macrophages and the defective microbicidal function may 
represent an additional pathogenic factor in the diminished host defence 
observed in  smokers. In my study I found that the monocyte counts were 
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raised in smokers when compared with non-smoker controls   (Fig 4.5 B, 
p<0.0005). In the multivariate analysis there was no association of monocytes 
with FEV
1 percentage or transfer factor.  
Many studies have shown that lymphocytes play an important role in the 
pathogenesis of asthma but there are few studies which have looked at their 
role in COPD. Lymphocyte counts in blood were raised in smokers when 
compared with non-smokers (Fig 4.5 C p<0.0006). In the multiple variant 
analysis there was a positive correlation between lymphocytes and transfer 
factor (r
2 change 0.311, p<0.02). 
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Figure 4.6 Blood neutrophils, monocytes, and lymphocytes between healthy non-
smokers and smokers. 
The data are represented as median and quartiles. Mann Whitney U test was 
used for the analysis. 
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4.2.8.  Systemic inflammatory markers in smokers with and without 
MeS 
4.2.9.  C-Reactive protein  
CRP is a strong marker of systemic inflammation. It has been shown to be 
r a i s e d  i n  s m o k e r s  a n d  i n  C O P D  a n d  i s  known to be raised in MeS. In this 
present study when analysed in smokers with and without features of MeS 
there was no difference between the groups and even in non-smoker controls 
(Fig 4.7). However there was a correlation with individual features of MeS: 
triglycerides (r
2= 0.255, p<0.003), HDL (r
2= -0.302, p<0.0004), waist 
circumference (r
2= 0.306, p<0.0003), glucose (r
2=0.202, p<0.02) and with 
systolic blood pressure (r
2= 0.271, p<0.002). 
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Figure 4.7 CRP levels in non-smoker controls and smokers with and without 
MeS 
 
 
The data are represented as median and quartiles and p<0.05 was considered 
significant. NS-N: non-smoker controls with no metabolic syndrome, NS-Y: non-
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smoker control with metabolic syndrome, Sm-N: Smokers with metabolic 
syndrome, Sm-Y: smokers with metabolic syndrome, n.s.: not significant, 
mg/L: milligram per litre. 
 
 
4.2.10.  Blood neutrophils, monocytes and lymphocytes 
Neutrophils play an important role in smokers with COPD but its role in 
features of MeS is less studied. It has been found to be elevated in men with 
MeS
348. Neutrophils, monocytes and lymphocytes were measured from the 
peripheral blood in my study. They were analysed using Mann Whitney-U non-
parametric test. There was no difference in neutrophils (Fig 4.8), monocytes 
(Fig 4.8) and lymphocytes (Fig 4.9) between subjects with and without features 
of MeS.   
 
 
 
 
 
 
 
 
 
  115  
Neutrophils
NS -N NS- Y Sm-N Sm-Y
0
5
10
15
*
1
0
^
9
/
L
n=39 n=5 n=59 n=28
n.s.
n.s.
p<0.0006
n.s.
Blood Monocytes
NS -N NS- Y Sm-N Sm-Y
0.0
0.2
0.4
0.6
0.8
1.0
*
1
0
∧
9
/
L
n.s.
n.s.
p<0.0001
n.s.
Lymphocytes
NS -N NS- Y Sm-N Sm-Y
0
1
2
3
4
5
*
1
0
∧
9
/
L
n.s.
n.s.
p<0.0001
n.s.
Neutrophils
NS -N NS- Y Sm-N Sm-Y
0
5
10
15
*
1
0
^
9
/
L
n=39 n=5 n=59 n=28
n.s.
n.s.
p<0.0006
n.s.
NS -N NS- Y Sm-N Sm-Y
0
5
10
15
*
1
0
^
9
/
L
NS -N NS- Y Sm-N Sm-Y
0
5
10
15
*
1
0
^
9
/
L
n=39 n=5 n=59 n=28
n.s.
n.s.
p<0.0006
n.s.
Blood Monocytes
NS -N NS- Y Sm-N Sm-Y
0.0
0.2
0.4
0.6
0.8
1.0
*
1
0
∧
9
/
L
n.s.
n.s.
p<0.0001
n.s.
Lymphocytes
NS -N NS- Y Sm-N Sm-Y
0
1
2
3
4
5
*
1
0
∧
9
/
L
n.s.
n.s.
p<0.0001
n.s.
Figure 4.8 Inflammatory cells neutrophils, monocytes, lymphocytes in non-smoker controls and 
smokers with and without MeS 
 
The data are expressed as median and quartiles and p<0.05 was considered 
significant.   
NS-N: non-smoker controls with no metabolic syndrome, NS-Y: non-smoker 
control with metabolic syndrome, Sm-N: Smokers with metabolic syndrome, 
Sm-Y: smokers with metabolic syndrome, n.s.: not significant. 
 
4.2.11.  Inflammatory cytokines smokers with and without MeS 
Plasma cytokines were measured by multiples ELISA (Luminex method). The 
total number of subjects sampled were 97: of these, 27 were healthy non-
smokers without MeS, 3 were healthy non-smokers with MeS, 46 were smokers 
without MeS and 21 were smokers with MeS. The cytokines measured were IL-
13, IL-8, IL-6, IL-10, IL-4, IL-12p70, IL-2, IL-5, TNF-α, IFNg and Apolipoprotein 1 
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(apo 1) which is a protein component of HDL cholesterol, which plays a role in 
autoimmunity. 
 
 
4.2.12.   Plasma IL-13 
Pro inflammatory cytokine IL-13 is associated with MeS and type 1, 2 diabetes. 
In my study, I measured IL-13 in plasma of 97 subjects with and without MeS. 
The measurement was done by Luminex method. There was a difference in 
non-smokers group with and without MeS (p<0.002), however, there was no 
significant difference in smokers group (n.s.). 
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Figure 4.9 Plasma IL-13 levels in non-smoker controls and smokers with and 
without MeS. 
The data are expressed as mean and standard error of mean. 
NS-N:non-smoker controls with no metabolic syndrome, NS-Y:non-smoker 
control with metabolic syndrome, Sm-N:Smokers with metabolic syndrome, Sm-
Y:smokers with metabolic syndrome, n.s.: not significant, pg/L:picogram per 
liter. 
 
 
4.2.13.  Plasma IL-12 
IL-12 is a heterodimeric 70kDa glycoprotein (IL-12p70) consisting of 40kDa 
subunit. It is secreted by peripheral lymphocytes and is produced mainly by B-
cells and to a lesser extent by T-cells. Plasma IL-12 with polypeptide subunit 
p70 was measured by multiplex Luminex method. There was significant 
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difference in smokers with and without metabolic syndrome (p<0.04). This was 
also raised in non-smokers with MeS (p<0.009). 
IL-12p70
NS-N NS-Y Sm-N Sm-Y
0
100
200
300
400
500
p
g
/
m
l
p<0.04
p<0.009
p<0.04
n.s.
 
Figure 4.10 Plasma IL-12p70 levels in non-smoker controls and smokers with and 
without MeS. 
The data are expressed as mean and standard error of mean.  
NS-N:non-smoker controls with no metabolic syndrome, NS-Y:non-smoker 
control with metabolic syndrome, Sm-N:Smokers with metabolic syndrome, Sm-
Y:smokers with metabolic syndrome, n.s.:not significant, pg/L:picogram per 
liter. 
 
 
4.2.14.  Plasma IL-8 
IL-8 is chemotactic factor for neutrophils. They are secreted by macrophages 
and epithelial cells to attract neutrophils so that they could adhere to the 
vascular endothelium to migrate into the tissue. It is also produced by 
endothelial cells which store them in their vesicles
349, 350. In the study IL-8 was 
measured by Luminex and there was no difference in smokers group, however 
it was found to be raised in non-smokers with MeS (p<0.02). 
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Figure 4.11 Plasma IL-8 levels in non-smoker controls and smokers with and 
without MeS. 
The data are shown as means and standard error of mean. 
NS-N: non-smoker controls with no metabolic syndrome, NS-Y: non-smoker 
control with metabolic syndrome, Sm-N:smokers with metabolic syndrome, Sm-
Y:smokers with metabolic syndrome,IL:Interlukin, n.s.: not significant, pg/l: 
pictogram/litre. 
 
 
 
4.2.15.  Other inflammatory cytokines measured in plasma 
Measurement of IL-2 and IL-4 showed differences in non-smokers (Fig 4.12 A 
and B, p<0.02 and p<0.04) and IL-5 (Fig 4.13 E, p<0.03), however, there was 
no difference in smokers with and without MeS. 
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Figure 4.12 Inflammatory cytokines measured in plasma in non-smoker controls 
and smokers with and without MeS, (A) TNF-α, (B) IFNg, (C) IL-2, (D) IL-4). 
The data are represented as median and quartiles. 
NS-N:non-smoker controls with no metabolic syndrome, NS-Y:non-smoker 
control with metabolic syndrome, Sm-N:Smokers with metabolic syndrome, Sm-
Y:smokers with metabolic syndrome.TNF-α:Tumor necrosis factor alpha, 
IFNg:Interferone gamma, IL:interlukin, n.s.: not significant, pg/L:picogram per 
liter. 
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Figure 4.13 Inflammatory cytokines measured in non-smoker controls and 
smokers with and without MeS, 
 (E) IL-5, (F) IL-6, (G) IL-10. The data are represented as median and quartiles. 
NS-N:non-smoker controls with no metabolic syndrome, NS-Y:non-smoker 
control with metabolic syndrome, Sm-N:Smokers with metabolic syndrome, Sm-
Y:smokers with metabolic syndrome. 
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4.3. Discussion  
The aim of this study was to improve the understanding of the role of 
inflammation in COPD but more importantly, to better understand the effects 
of metabolic syndrome. The important findings in this study are, a) CRP levels 
have been shown to rise with increasing severity of COPD
327, 351. I have shown in 
this study that CRP levels increased in a linear fashion in the three groups and 
that COPD subjects had the highest CRP levels, b) Result alos demonstrates an 
inverse relationship of CRP with FEV
1 which was consistent with the previous 
study that showed in general population there is an inverse relationship 
between CRP and FEV
1 predicted
352 c) Inflammatory cells are not raised in stable 
COPD compared to healthy smokers.  
IL-6 and CRP have related roles in the inflammatory response:
 IL-6 induces 
CRP production in the liver by activating Janus
 kinases, signal transducers and 
activators of transcription
  subsequently switch on the CRP gene expression, 
leading to the
 production of CRP
353. There is also a relationship between IL-6 
and CRP in driving inflammation
354. However, when CRP was measured in the 
my study, suggested no association between blood CRP and MeS and there was 
no correlation between IL-6 and CRP in MeS. This is in contrast to the available 
evidence about CRP levels
193. One of the limitation here was CRP was not high 
sensitive and the number of subjects with MeS were small. There are 
inconsistent reports on the relationship between CRP level and lung function. 
CRP was also correlated with smoking. It is difficult to understand whether it is 
secondary to smoking or due to the  systemic inflammation in COPD
355. It is 
also seen that CRP reduces after treatment with inhaled corticosteroids
355. In 
the regression analysis in my study, the CRP was independently associated with 
smoking and COPD. It is certain that CRP is playing a significant role in driving 
inflammation in COPD. 
Inflammation plays an important role in the pathogenesis of features of 
metabolic syndrome. It is suggested that there is an ongoing subclinical 
inflammation in these people and there are very few studies that have looked 
at these markers in MeS in smokers. It has been suggested that the production 
of cytokines such as TNF-α
356, IL-6
357 and leptin
358 by adipose tissue may be 
involved with acute phase response in obesity related co morbidities. In this 
study, I found that inflammatory cells play a major role in smokers regardless 
of presence of COPD. Neutrophils. monocytes and lymphocytes were all raised 
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in smokers. There was not enough evidence in this study to confirm that 
inflammation in smokers play a role in the development of features of MeS. Of 
note, IL-4, IL-5, and IFNg were elevated in non-smokers without MeS. 
  Airway remodelling and destruction of the parenchyma is associated with 
inflammation in COPD
359. Different cells and mediators of inflammation are 
involved in the pathogenesis of COPD
338. Activation of monocytes/macrophages 
and oxidative changes in low density lipoprotein are important in 
atherogenesis
360. In my study neutrophils, monocytes and lymphocytes were all 
elevated in healthy smokers. What was less understood was that these cells did 
not show any increase in COPD group in my study. One of the possible reasons 
may be that,  the COPD subjects were mild-moderate and clinically stable at the 
time of recruitment. 
The other interesting observation in my study is the raised eosinophils in 
healthy smokers and COPD. Even though the levels were within the laboratory 
accepted normal range, eosinophil counts were raised in COPD. Eosinophils are 
the inflammatory cells, which are commonly seen in asthmatic airways. 
However there is little evidence of eosinophilia in stable COPD subjects
361. One 
of the other reasons is  that raised eosinophils are seen in subjects with 
chronic bronchitis
362 and there were smokers with chronic bronchitis in my 
study  group of healthy smokers. 
In addition, other inflammatory cells have been shown to be raised in 
smokers compared to non-smokers (neutrophils, monocytes, and 
lymphocytes). However, inflammatory cells were not raised in COPD when 
compared to healthy smokers in my study. To examine the relationship 
between cellular immune status and features of MeS I measured total 
lymphocytes count in my subjects. There was no difference in the total count 
in subjects with and without MeS. In the Spearman’ rank correlation I found 
that lymphocytes were stongly correlated with triglycerides (r
s= 0.424, 
p<0.0007) and weakly with waist circumference (r
s= 0.173, p<0.048) 
suggesting the role of inflammation in driving these two specific features of 
MeS. 
In summary my study has shown that there was no association between 
inflammatory markers and features of MeS in either smokers or non-smokers. 
However, this study confirms the role of inflammation in smokers with and 
without COPD. I believe that there is more than one pathway involved and 
contributing to the development of MeS in smokers. Therefore, it is important 
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to understand other possible causes, which are contributing to the features for 
e.g. central obesity, insulin resistance, or physical activity, which are discussed 
in chapter 5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  124  
 
 
 
 
 
 
 
 
 
 
 
 
 
5.0 Chapter- Role of insulin resistance, physical 
activity, and quality of life in smokers and COPD 
with metabolic syndrome 
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5.1. Introduction 
Insulin resistance is a condition that increases the chances of developing 
diabetes and heart disease. This salient features is also thought to be the key 
in the development of metabolic syndrome (MeS), however, the relationship 
between smoking habits, insulin resistance, and related
  risk factors is less 
understood. It is also less known how insulin resistance has any role in the 
development of COPD.  
MeS is a cluster of cardiovascular risk factors consisting of dyslipidemia, 
glucose intolerance, central obesity, and hypertension
363. There are several 
additional possible risk factors that have been included recently, for example, 
increased total body fat including non-alcoholic fatty liver. The mechanisms 
behind this complicated syndrome are debated even today. Some believe that 
this syndrome is caused by insulin resistance and others think it is a 
combination of insulin resistance, subclinical inflammation and physical 
activity. One of the arguments about insulin resistance is that obesity mainly 
visceral adiposity contributes to insulin resistance
364. As the prevalence of 
obesity is increasing globally, this new clinical disorder, which is associated 
with central obesity and insulin resistance, emerged and identified as the 
major risk factor for cardiovascular disease
364. It is also been suggested that 
hyperinsulemia per se as a driver for muscle insulin resistance and anabolic 
effects, which could lead to hepatic steatosis and insulin resistance
365. Reaven 
coined this cluster of features as’ Syndrome X’ and was named ‘insulin 
resistance syndrome’ later by others
185. 
Smoking on the other hand is the main cause for development of COPD in 
the over 50-age group and it is an airway disease which is partially reversible in 
the early stages of the disease. There is a strong association between smoking 
and features of MeS (chapter 3). However, there is a large disparity in smokers 
who develop this condition. Smoking also contributes to elevated blood 
pressure, which is more frequent in insulin resistance and obese patients
185, 220. 
One of the mechanisms of developing insulin resistance in smokers is that the 
acute affects of smoking increases the sympathetic activity and circulating 
levels of catacholamines
366, and these catacholamines are antagonist to insulin 
action
367 and hence smoking may have a link to insulin resistance. Smoking has 
local and systemic effects and the local effect of smoking is the cause for the 
development of COPD, which is accepted as  an inflammatory disease. 
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Inflammation is considered to be one of the main reasons for development of 
MeS, however there was no evidence of that in my study (chapter 4). The other 
possible causes like insulin resistance, physical activity and diet is less 
explored. 
Physical activity plays a major role in development of obesity and type-2 
diabetes. Ekelund et al. examined a large population with no MeS at the 
baseline and found that physical activity energy expenditure independently 
contributes towards development of MeS
368. This finding is important in 
context of my study because smokers tend to do less exercise. 
The physical activity is reduced in COPD. This is seen more in GOLD stage 
III and stage IV diasease
369 . Hence there are reports of early referral to 
pulmonary rehabilitation to strengthen the respiratory muscle tone and to raise 
the quality of life in patients with COPD. 
Quality of life (QOL) is an important part in any chronic disease 
management. It is more so in COPD patients who suffer from symptoms mainly 
shortness of breath. It has been shown previously that COPD patients have 
decreased quality of life
370. The reasons for this reduced QOL apart from the 
symptoms are physiological, psychosocial, and sometimes functional. QOL is 
less understood in various stages of the disease process in COPD. In this study 
I hypothesise that QOL may be worse in smokers with features of metabolic 
syndrome. 
  I tested the hypothesis by studying the relationship between insulin 
resistance, physical activity, and QOL in smokers with and without features of 
MeS.  
5.2.  Methods 
A total of 131 subjects were recruited for this study. The subjects were 
stratified into two groups: non-smoking control subjects, and smokers. The 
subjects underwent pulmonary testing, body composition mesaurements and 
bloods for fasting glucose and insulin (n=128). By HOMA-R insulin resistance 
was calculated. Subjects completed quality of life (SGRQ) and physical activity 
(n=120) questionnaires (Baecke). The details of the questionnaire are discussed 
in chapter 2 (section 2.2.3). 
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5.3. Results 
5.3.1.  Fasting insulin and HOMA-R measurement 
5.3.2.  Fasting insulin levels 
Blood was taken from subjects (n=128) who were fasting overnight for the 
measurement of insulin. Mann-Whitney-U non-parametric tests were 
undertaken as the data was normally distributed. The results showed that there 
was no difference in insulin levels between non-smoker controls and smokers. 
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Figure 5.1 Fasting insulin levels (mU/L) in non-smokers and smokers. 
The data are represented as median and quartiles. n.s.:not significant. 
 
5.3.3.  Insulin resistance measurement in non-smoker controls  and 
smokers 
Insulin resistance was calculated by Homeostasis Model Assessment (HOMA-R). 
This was calculated taking into account fasting insulin and fasting glucose 
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levels. In the analysis it showed no difference in insulin resistance between 
non- smokers and smokers (Fig 5.1.2). 
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Figure 5.2 Insulin resistance measured by HOMA-R. 
The data are represented as median and quartiles. 
IR:Insulin resistance, n.s.:not significant.  
 
5.3.4.  Relationship between fasting insulin and insulin resistance in 
non-smokers and smokers with and without MeS 
The subjects were divided into non-smokers with and without MeS (NS-N and 
NS-Y) and similarly in smokers group (Sm-N and Sm-Y). The analyses were done 
by non parametric Mann-Whitney U test. Firstly there was a significant 
difference in fasting insulin levels both in non-smoker controls and smokers 
with MeS (Fig 5.3 A, p<0.009 and p<0.0003 respectively). Secondly there was a 
difference in insulin resistance in non-smokers and smokers with MeS (Fig 5.3 
B, p<0.007 and p<0.0006). 
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A  B 
Figure 5.3 Fasting insulin (A) and insulin resistance (HOMA-IR) (B) measured in 
non-smoker controls and smokers with and without MeS. 
The data are represented as median and quartiles and p<0.05 was considered 
significant. NS-N:non-smoker controls with no metabolic syndrome, NS-Y:non-
smoker control with metabolic syndrome, Sm-N:Smokers with metabolic 
syndrome, Sm-Y:smokers with metabolic syndrome, n.s.:not significant, 
IR:Insulin resistance 
 
5.3.5.  Quality of life measured in non-smokers and smokers with MeS 
Quality of life was measured by St George’s Respiratory Questionnaire (SGRQ), 
which is a validated and reproducible questionnaire. This questionnaire has a 
range from 0-100 and with total of 76 points to be scored from their 
symptoms, impact, and activity scores. The analysis showed that in the 
smokers group the quality of life was significantly reduced compared to non-
smokers (p<0.0001). When this was compared in smokers with and without 
MeS, there was no difference; however, there was trend towards reduced 
quality of life in smokers. When analysed between non-smokers with MeS and 
smokers with MeS there was reduced score in smokers (p<0.009). In the linear 
regression analysis model quality of life and physical activity were 
independently associated with FEV
1  (Adjusted r
2 = 0.48). However, insulin 
resistance was not independently associated with FEV
1 in a regression model 
when controlled for smoking, age, and gender. 
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Figure 5.4 (A) Quality of life measured by SGRQ in non-smoker controls and smokers and (B)         
Quality of life in non-smoker controls and smokers with and without MeS. 
 
The data are represented as medians and quartiles. 
NS-N:non-smoker controls with no metabolic syndrome, NS-Y:non-smoker 
control with metabolic syndrome, Sm-N:Smokers with metabolic syndrome, Sm-
Y:smokers with metabolic syndrome, n.s.:not significant. 
5.3.6.  Physical activity scores in smokers with and without MeS 
A total of 120 subjects (44 non-smokers and 76 smokers) completed the 
Baecke habitual physical activity questionnaire. The questionnaire included 
scores from sports activity, activity at work and leisure activity. Then a total 
score was generated according to the calculation given in the guidance 
notes
371. When the analysis was done in this study, there was a difference in the 
total score in non-smokers and smokers. Smokers were less physically active 
(Fig 5.5 A, p<0.01) compared to their counterpart, however, when the analysis 
was done in smokers with MeS there was no difference between the non-
smokers and smokers (Fig 5.5 B). In the linear regression analysis the physical 
activity was independently associated with FEV
1  (Adjusted r
2 = 0.49 and 
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p<0.0001) when controlled for smoking, age, and gender and inflammatory 
markers. 
 
 
 
 
 
Figure 5.5 Total score measured from Baecke’s physical activity questionnaire and 
scatter plot of correlation of physical activity with FEV1 percentage 
 (Adjusted  r
2=0.49, p<0.0001). NS-N:non-smoker controls with no metabolic 
syndrome, NS-Y:non-smoker control with metabolic syndrome, Sm-N:Smokers 
with metabolic syndrome, Sm-Y:smokers with metabolic syndrome, FEV
1:Forced 
expiratory volume in 1 second, n.s.:not significant. 
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5.4. Discussion 
This study was aimed to investigate the relationship between the measure of 
insulin resistance, features of MeS and respiratory related outcomes such as 
FEV
1 in smokers with MeS. The important findings in this study are, a) there 
was non increase in fasting insulin in smokers, b) there was no increase in 
insulin resistance in smokers, c) Physical activity measured by Baeck’s 
questionnaire was and quality of life measured by SGRQ was independently 
associated with impaired FEV
1 in smokers, 
   Insulin resistance is a state in which supra-physiological concentrations of 
insulin are required for glucose homeostasis. Key insulin sensitive tissues that 
are normally affected by this state are adipose tissue, liver and skeletal muscle 
resulting in impaired insulin-mediated suppression of hepatic glucose 
production and impaired insulin-mediated peripheral glucose utilization in 
skeletal muscle and adipose tissue. In affected individuals, there is continual 
demand for insulin hypersecretion to compensate for insulin resistance and to 
maintain glucose homeostasis leading to eventual islet cell exhaustion and the 
development of glucose intolerance and type 2 diabetes mellitus
372. 
There are many reasons for developing insulin resistance in normal 
individual and in smokers, e.g. excess visceral or hepatic fat insulin resistance 
tends to run in families and has a strong genetic predisposition
372, 372. There are 
other possible mechanisms whereby smoking can elicit insulin resistance 
mediated via cardiovascular, neurohormonal and endocrine effects 
373, 374. 
Smoking could also have an effect on central obesity that is driven by insulin 
resistance and contributes to the development one of the early clinical signs of 
MeS.  
A common clinical feature in the development of MeS is central obesity or 
abdominal fat and this is highly indicative of increased insulin resistance 
375. 
Central obesity is common in smokers and this has been discussed in chapter 
The results were surprising, central obesity measured by waist circumference 
or waist/hip ratio was raised in smokers with or without COPD. It is known that 
there is a strong correlation between systemic effects, COPD and insulin 
resistance
376. One of the common reasons for individuals developing central 
obesity and insulin resistance is physical inactivity. Smoking can acutely impair 
insulin action
377 and causes insulin resistance. The amount of nicotine smoked 
per day is shown to be directly related to degree of insulin resistance
378. In 
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contrast to the finding, in my study there was no increase in fasting insulin or 
insulin resistance amongst smokers or non-smoking control subjects. However, 
in my study there was a difference in fasting insulin levels and insulin 
resistance between smokers with and without MeS and the results were similar 
in non-smoker controls. Regardless of smoking effect, insulin resistance is a 
common mechanism by which individuals develop features of MeS. In smokers, 
this could be one of the many pathways by which smoking contributes to the 
development of MeS.  
Insulin resistance and physical activity obviously play a major role in 
quality of life (QOL) in chronic disease subjects. Improved QOL is one of the 
indicators for the improvement in management of the disease. The 
questionnaire which was used (SGRQ) was subjective and not only depends on 
the physiological parameters but also on the psychological frame of mind. 
SGRQ questionnaire is a reproducible tool to measure quality of life in subjects 
with airway disease mainly COPD. The main observation in this study was that 
the quality of life was reduced in smokers and in COPD subjects. There was 
similar results seen when compared smokers with or without MeS. However, 
the difference in QOL was only found to be significant when smokers with or 
without MeS was compared with non-smoker controls. This explains that all 
smokers have reduced quality of life, which may be due to increased body fat 
and central obesity.  
  Pulmonary function abnormalities are seen in both insulin dependent and 
non-insulin dependent diabetes mellitus
74, 379. In non diabetic individuals there 
is an inverse relationship between forced vital capacity (FVC) and forced 
expiratory volume in 1 second (FEV
1)
380, 381 in men.  In my study the linear 
regression analysis showed that insulin resistance was not independently 
associated with FEV
1 when controlled for age, gender, smoking. This could only 
be due to excessive fat accumulation in the abdomen which is known to 
influence both insulin resistance and ventilatory function
382. 
Physical inactivity is a global public health problem and there is 
compelling evidence to suggest its contribution to many chronic diseases
383, 384. 
The change in lifestyle contributes to an epidemic of obesity globally not only 
in health but also in chronic disease such as COPD. There are many reasons for 
this epidemic for example increased portions of unhealthy food intake
383, lack 
of physical activity and also increasing levels of stress in everyday activities. 
However, there is not enough evidence to support this argument. There are 
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many recommendations as to the amount and duration of physical activity to 
be undertaken to stay healthy and one of the recommendations is to undertake 
physical activity for 60minutes/day to prevent unhealthy weight gain or 
30minutes moderate-intense activity, which provides substantial health 
benefit
385. The main benefit of undertaking physical activity is to keep the 
balance between energy expenditure to energy stored. This principle is 
essential in chronic diseases like COPD. Henceforth there is new 
recommendation for early referral to pulmonary rehabilitation for smokers with 
mild to moderate COPD who develop exercise-induced symptoms. This 
programme has shown to be beneficial in COPD with MRC dyspnoea score 2 
and above.  
In this current study, Baecke’s physical activity questionnaire was used to 
assess the daily physical activity in all the subjects. When the smokers in this 
study were analysed for physical activity scores it was found that they were 
less active when compared to non-smoker controls. However, when physical 
activity scores were assessed in smokers with and without features of MeS 
there was no measurable difference between the two. The inference from this 
data is that in this particular cohort the physical activity was not influencing 
the development of insulin resistance and features of MeS. When physical 
activity scores were analysed by linear regression analysis, there was a strongh 
independent relationship between physical activity and FEV
1 percentage when 
controlled for smoking, age, and gender. However, one of the limitations with 
this questionnaire was, it was a subjective assessment, and there are less 
comparable studies with physical activity devices that quantitatively assess 
physical activities in smokers and COPD. Historically features of MeS are 
related to physical activity, however, this was not found in my data in smokers.  
In conclusion, the data in my study show evidence of insulin resistance in 
people with MeS. There was no evidence of increased insulin resistance in 
smokers versus non-smokers. There was no evidence of an association 
between a measure of insulin resistance (HOMA-R) and respiratory outcomes 
such as FEV
1 percentage. In univariate, analyses there were associations 
between Baecke physical activity score and FEV
1. I have also shown that 
physical activity and quality of life were independently associated with reduced 
lung function.  
Future work should be guided towards more precise assessment of 
insulin sensitivity and physical activity energy expenditure in people who 
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smoke to understand the relationship between smoking and insulin resistance 
in subjects with MeS.  
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6.0 Chapter-Gender differences in healthy smokers 
and COPD in relation to MeS 
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6.1. Introduction  
Interest has grown over the last few years regarding the long-term effect of 
smoking in men and women. Data suggests that women are more susceptible 
to develop airway obstruction compared to men for the same number of 
cigarettes smoked
386. Smoking is the single largest preventable cause of death 
in the world. There are many adverse health effects for which smoking is the 
main cause which includes cardio-respiratory, vascular, reproductive system, 
and cancers
387. These diseases affect differently both in men and women 
smokers across the globe. There has been an impact on clinicians’ interest to 
understand the gender differences in smokers and COPD. Smoking was rare in 
women in the early 20
th century and became more prevalent in recent times. In 
2006 it was reported that 17.6% of women smoked in the US
388.  European 
women are historically heavy smokers and Danish women in particular are 
heaviest amongst all
389.  
The effects of gender difference depends on the exposure and 
susceptibility to tobacco smoke and also to other environmental pollutants 
which causes harmful effects  to the airways
390-395. The adverse effects of 
smoking are not uniformly distributed between both sexes. In one of the 
studies, they found that smoking affects pulmonary vasculation in women and 
airways in men
396.  
COPD is one of the local complications of smoking and there are recent 
evidence to show more women with COPD than men
160. It is also observed that 
mortality from COPD is increasing in women in Europe and North America
397. 
One of the views is that female smokers more than male smokers tend to 
inhale deeper and breath hold for a long time which may predispose them to 
more airway damage
398. 
Metabolic syndrome on the other hand is more prevalent in men than in 
women
399, however, it is noted that the first isolated component of MeS occurs 
earlier in women than in men
399, however there is no data on which of these 
features appear first in women. MeS has been observed in many ethnic groups 
and the influence of gender varies between population and on the definition 
used
400. The development of MeS is slower in subjects who have normal BMI 
and follow good exercise habits
399. Age, genetic inheritance, race, and gender 
specific hormones influence fat distribution in the body. It is observed that in 
women due to estrogens, fat is deposited on the hips, thighs and abdomen 
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and in men fat is deposited around abdomen and upper body because of the 
hormone testosterone. 
In the Lung Health study the gender differences were produced a result of 
differential abdominal deposition of fat in men compared with women and this 
had a greater impact on FEV
1 and FVC than peripheral obesity, which is seen in 
women
401. However, there is also an association between abdominal fat and 
visceral fat. The increase in abdominal fat deposition is associated with an 
increase in visceral fat in the abdomen which could reduce vital capacity
402. 
There are other important features between gender, which could affect, for e.g. 
quality of life, and physical activity. How quality of life and physical activity 
influence the development of MeS in men and women smokers is not yet 
known. 
The relationship between gender and MeS in smokers is less well 
understood. There is also less evidence to confirm the pathways, which drive 
MeS differently in men and women smokers. For the first time in this study I 
aim to find out how different smoking habits in men and women could affect 
lung function, inflammation, metabolic features and body composition, quality 
of life and physical activity and to understand the role played by the 
combination of smoking and gender in worsening the features of MeS and 
COPD. 
 
6.2. Methods 
A total of 131 subjects were recruited for the study. They were sub-divided into 
three groups according to their smoking habits, non-smoker controls (HC, 
M=20, F=24), healthy smokers (HS, M=24, F=22) and smokers with COPD 
(M=22, F=19). The subject characterisation is discussed in chapter 2 (section 
2.1.1). Non-smokers and healthy smokers had normal predicted values for FEV
1 
and TLco. 
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6.3. Results 
6.3.1.  Smoking habits (pack years), FEV
1, and TLco% in smokers and 
COPD 
There was no difference between men and women. In the COPD group, there 
was a trend in reduction in FEV
1 and TLco in men compared to women. Men 
smoked more in COPD (p<0.0002) group than women.  
 B 
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Figure 6.1 FEV1 percentage (A), pack years (B) and transfer factor (C) in non-
smoker controls (HC) (A and C) Healthy smokers(HS) and COPD (A, Band C). 
The data are represented as median and quartiles.FEV
1:Forced expiratory 
volume in 1 second, TLco:Transfer factor for carbon monoxide, n.s.:not 
significant. 
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6.3.2.  Measurement of blood inflammatory cells 
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Figure 6.4 Inflammatory cells.The data are represented as median and 
quartiles. 
HC: Healthy non smoker controls, HS:Healthy smokers, COPD:Chronic 
obstructive pulmonary disease, n.s.:not significant. 
 
Blood inflammatory cells play an important role in smokers and COPD. 
Inflammatory cells like neutrophils, lymphocytes, monocytes, and eosinophils 
were measured in blood. There was no difference in neutrophils, lymphocytes, 
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monocytes, and eosinophils between men and women in non-smokers, healthy 
smokers or in COPD subjects. 
 
6.3.3.  Measurement of inflammatory marker C - reactive protein (CRP) 
CRP is a clinical marker of inflammation and is widely used in clinical practice, 
which helps in diagnosis or in follow up after treatment. CRP was measured in 
the hosipital laboratory. The data was compared between men and women by 
Mann-Whitney U test. There was no difference in CRP levels between men and 
women in any of the group. 
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Figure 6.5 C-Reactive Protein (CRP) levels in non-smoker controls (HC), healthy 
smokers (HS) and COPD men and women. 
The data are represented as median and quartiles. 
 
 
 
6.3.4.  Measurement of features of MeS in men and women 
Metabolic syndrome features are central obesity measured by waist 
circumference or waist/hip ratio, fasting glucose, triglycerides, HDL and blood 
pressure. IDF criteria was used in this study to diagnose MeS. 
 
 
  
  142  
6.3.5.  Measurement of waist circumference and waist/hip ratio in non-
smokers, healthy smokers and COPD men, and women 
Central obesity is one of the key features of MeS. Waist circumference is the 
measure for central obesity. Waist/hip ratio is a more accurate measure for 
central obesity. According to the International Diabetic Federation waist 
circumference over 80cms in women and 94cms in men and  waist/hip ratio >1 
is considered to be abnormal.  
In my study the analysis showed significant difference in waist 
circumference in non-smokers (Fig 6.4 A) (p<0.002) and in healthy smokers 
(p<0.006). Men tend to have more central obesity than women in my study, 
however, there was no difference in waist circumference in COPD men and 
women. There was a difference throughout groups in waist/hip ratio (Fig 6.4 
B). Men again tend to have increased central obesity in non-smokers 
(p<0.0001), healthy smokers (p<0.0002) and in COPD subjects (p<0.007).   
 
6.3.6.  Measurement of triglycerides, HDL and blood glucose 
The normal range for fasting triglyceride was 0-2.0mmol/L and HDL was 1.2-
1.8mmol/L. There was a difference in HDL levels between men and women in 
non-smokers (p<0.01) and healthy smokers group (p<0.02), however COPD 
subjects showed no difference. 
There was a borderline difference in triglyceride levels in non-smokers 
(p<0.057). Blood glucose was high in non-smokers male (p<0.05) and healthy 
smokers male (p<0.02, Fig 6.5).Triglyceride were no different except for a 
borderline significance in the non-smoker group (p<0.057). Fasting blood 
glucose was high in non-smoker males (p<0.05) and in healthy smoker males 
(p<0.02). 
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Figure 6.6 (A) waist circumference (cms), (B) waist/hip ratio in healthy smoker controls (HC), 
healthy smokers (HS) and COPD men and women. 
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The data are represented as median and quartiles. 
HC:Healthy non smoker controls, HS:Healthy smokers, COPD:Chronic 
obstructive pulmonary disease, n.s.:not significant, w/h:waist/ hip 
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Figure 6.7 Fasting HDL, triglyceride, and blood glucose in non-smoker controls 
(HC), healthy smokers (HS) and COPD men and women. 
Data are represented as median and quartiles <0.05 was considered 
significant. HDL:High density lipoprotein, HC:Healthy non smoker controls, 
HS:Healthy smokers, COPD:Chronic obstructive pulmonary disease, 
mmol/L:Millimoles per liter, n.s.:not significant. 
 
 
 
6.3.7.  Body composition measurements 
Body composition measurement includes fat in percentage and kilogram, lean 
mass or fat free mass, total body water and BMI. The important measure is fat 
and fat free mass. More accurate is the fat free mass index (FFMI) which takes 
into account the person’s muscle mass and relates to their height. This is a 
better measure than BMI. In this study, body fat and FFMI was compared in 
  145  
non-smokers, healthy smokers and COPD men and women. Women in the non-
smokers group (p<0.0007), healthy smokers group (p<0.0001) and COPD 
group (p<0.0001) were all fatter (fat %) than their counterparts and there was a 
difference in fat in kgs in COPD women. The FFMI was significantly different in 
all three groups, more so in non-smokers (p<0.0001) and healthy smokers 
group (p<0.0007). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 6.6 (A) total body fat (%), (B) total body fat (kilograms) and (C) Fat  
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The data are represented as median and quartiles. Women had more body fat % 
in all the groups.  
FFMI: Fat free mass index, HC: Healthy non-smoker controls, HS: Healthy 
smokers, COPD: Chronic obstructive pulmonary disease. 
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6.3.8.  Measurement of quality of life (SGRQ) and physical activity 
(Baecke’s habitual physical activity) questionnaire 
Quality of life (QOL) was difficult to measure as it has many components. 
Physiological and psychological factors could contribute to this complex state 
of mind. One of the validated questionnaires to measure quality of life in 
smokers is the St George’s Respiratory Questionnaire. In this study, the 
measure of QOL was collected by means of completing the questionnaire by all 
subjects. There was a significant difference between healthy smokers men and 
women (p<0.01). However, there was a trend in poor QOL in COPD women. 
Reduced physical activity plays an important part in the development of obesity 
and MeS. A total of 131 (HC, M=24, F=20, HS, M=24, F=22, COPD, M=22, F=19) 
completed the SGRQ and 120 completed physical activity questionnaire (HC, 
M=20, F=24, HS, M=23, F=18, COPD, M=21, F=14). 
 
Quality of life
p<0.01
n.s
n.s.
HC Male
HC Female
HS Male
HS female
COPD Male
COPD Female
0
20
40
60
80
100
S
G
R
Q
 
t
o
t
a
l
 
s
c
o
r
e
n.s. p<0.01 n.s.
Physical activity  
HC male
HC female
HS male
HS female
COPD male
COPD female
0
5
10
15
T
o
t
a
l
 
s
c
o
r
e
A  B 
 
The data are represented as median and quartiles. 
SGRQ: St George’s Respiratory Questionnaire, HC: Healthy non-smoker 
controls, HS: Healthy smokers, COPD: Chronic obstructive pulmonary disease, 
n.s.: not significant. 
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6.3.9.  Gender differences in smokers 
In the prelimary, analysis there was no difference in prevalence of MeS in 
smokers and COPD. This finding leads to the assumption that smoking rather 
than COPD per se is associated with features of MeS. Keeping this in mind, I 
decided to group all smokers (HS + COPD smokers) together. The aim was to 
test the hypothesis that there were differences in markers of inflammation, 
body composition, QOL, physical activity between men and women smokers 
with features of MeS.  
 
6.3.10.  Measurement of FEV
1, pack years and TLco in men and women 
smokers  
The total number of smokers was 87 in the study. They were sub divided into 
men and women (Male=45, Female=42). The subjects were compared for 
differences in FEV
1 percentage, pack years (total number of pack of cigarettes 
per day number of years smoked). The results are in Fig 6.8 A, B and C. Men 
had more reduced FEV
1 percentage (p<0.04*) and men smoked more cigarettes 
than women (p<0.01**). Difference in percentage of TLco was analysed 
between men and women (TLco is a measure for emphysema in the lungs) and 
found no difference between men and women smokers. 
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Figure 6.10 FEV1 percentage (A), pack years (B) and TLco percentage (C) between 
men and women smokers. 
There was a significant difference in FEV
1 percentage (p<0.04*) and pack years 
(p<0.01**). There was no difference in TLco percentage.*t-test, ** Mann-
Whitney-U test. 
FEV
1: Forced expiratory volume in 1 second, TLco: Transfer factor for carbon 
monoxide. 
 
 
 
Neutrophils, lymphocytes, monocytes, and eosinophils were measured 
in blood. They are expressed as *10^9/L. When compared between men 
and women smokers there was no difference. Independent t-test for 
normally distributed data and Mann-Whitney-U test was used to analyse 
the data. The data are expressed as median and quartiles. 
 
 
6.3.11.  Blood inflammatory cells 
 A   B 
  C 
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Figure 6.11 C-Reactive Protein (CRP) measurement in men and women smokers.  
The data are shown as medians and quartiles. 
mg/L: Milligram per litre, n.s.: not significant. 
 
 
 
6.3.12.  Measurement of inflammatory marker in smokers 
C - reactive protein is a helpful inflammatory marker to understand the extent 
of inflammation in clinical practice. In my study, blood CRP was measured in all 
subjects. Differences in men and women smokers were analysed and the 
results showed no significant difference in CRP levels between them (Fig 6.10). 
 
6.3.13.  Inflammatory cytokines and apolipoprotein1 (apo1) in smokers 
men and women 
Inflammatory mediators play an important role in the disease process. The 
important mediators measured in my study were TNF-α, IFNg, IL-2, IL-4, IL-5, IL-
6, IL-8, IL-10, IL-13, and IL-12p70. APO-1 antigen is a transmembrane 
glycoprotein, which is involved in apoptosis within the immune system and cell 
death, was also measured in study.  
  150  
The inflammatory mediators were measured my multiplex Luminex and apo1 
by ELISA methods (Fig 6.11). A total of 67 samples were analysed (men 
were=33 and women were=34). Differences between men and women were 
analysed and found that there was no difference in TNF-￿, IFNg, IL-13, IL-8, IL-
6, IL-10, IL-4, IL-2, and IL-5 levels in plasma. There was a significant difference 
in IL-12p70 (p<0.01) and apo1 (p<0.006) between men and women smokers 
(Fig 6.11). 
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The data are represented as median and quartiles.  
TNF-α: Tumor necrosis factor alpha, IFNg: Inteferone gamma, IL: Interlukin, 
pg/L:picogram per litre, n.s :not significant. 
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Figure 6.13 Plasma inflammatory mediators measured by Luminex in male and 
female smokers, (A) IL-6, (B) IL-10, (C) IL-4, (D) IL-12p70,(E) IL-2 (F) IL-5 and (G) Apo- 
1. 
 IL: Interlukin, Apo: Apolipoprotein. g/L: grams per litre, pg/L: Picogram per 
litre. 
 
6.3.14.  Prevalence and features of metabolic syndrome in men and 
women 
The prevalence of MeS was analysed in men and women smokers. The 
classification is based on IDF criteria. Central obesity is the key for the subjects 
to have MeS and any of the other two features from the list of increased 
triglycerides, low HDL, high blood glucose, and increased blood pressure must 
be present. There was a prevalence of 44.4% in men and 23.52% in women. 
Chi-square test was applied for the analysis. There was an increased trend but 
the differences were not statistically significant (Fig 6.13) 
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Figure 6.14 Prevalence of metabolic syndrome 
Prevalence of metabolic syndrome between men and women in all smokers 
(healthy smokers and COPD smokers combined). Men (n=45) and women 
(n=42) were analysed by chi-square test and represented in bar diagram. The 
Y-axis is the percentage of MeS and diagnosis on the X-axis.  
% MeS: Percentage of metabolic syndrome, n.s.: not significant. 
 
6.3.15.  Comparison between features of MeS in men and women 
smokers 
Men and women smokers were compared for features of MeS, which were waist 
circumference, fasting glucose, triglycerides, HDL, and systolic and diastolic 
pressure. There was no difference in fasting glucose (Fig 6.14 A), triglycerides 
(Fig B) However, men tend to have less HDL levels compared to women (Fig C, 
p<0.02).  
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Figure 6.15  Fasting glucose, (B) triglyceride (C) HDL levels in men and women 
smokers. 
 The data are represented as median and quartiles. 
HDL: High-density lipoprotein, mmol/L: millimoles per litre.   
 
6.3.16.  Measure of waist circumference, W/H ratio, insulin resistance 
and mean blood pressure 
Waist circumference and waist to hip ratio are the measure to diagnose central 
obesity. Insulin resistance is associated with central obesity in people with 
MeS. Waist circumference and w/h ratio was measured in all smokers. Insulin 
resistance (M=42, F=33) was measured by HOMA-R. There was a difference in 
waist circumference (p<0.007), w/h ratio (p<0.0002), systolic BP (p<0.0003) 
and diastolic BP (p<0.0002) shown in Fig 6.15. There was no difference in 
insulin resistance between men and women smokers. 
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Figure 6.16 Features of MeS, (A) waist circumference (p<0.007), (B) waist/hip (w/h)  
ratio, (C) insulin resistance, (D) systolic blood pressure and (E) diastolic blood 
pressure in male and female smokers. 
The data are represented as median and quartiles.   
 
Anthropometric measurements or body composition includes measurement of 
total body fat, fat free mass. Fat free mass can be measured more accurately 
by calculating fat free mass index (FFMI). In this study it was measured by 
bioelectrical impedance analysis (BIA). The principal and methods are 
explained in chapter 2 (section 2.3.2). All subjects were measured in minimal 
clothing. The analysis between men and women showed that, women were 
more fat than men in the study (Fig A and B, p<0.003 and p<0.0006) and men 
had more fat free mass (Fig C and D, p<0.0001 and p<0.0003) than women.  
Figure 6.17 Anthropometric measurements in men and women smokers, (A) Fat % 
and (B) fat in kilogram, (C) lean mass in kg and (D) fat free mass index 
 
6.3.17.  Body composition measurements in men and women smokers 
Smoker male Smoker female
0
50
100
150
200
250
m
m
H
g
Systolic blood pressure 
   D    E 
Diastolic blood pressure 
p<0.0003  150
p<0.0002 
100
m
m
H
g
50
0
Smoker male Smoker female
  158  
Smoker male Smoker female
0
20
40
60
80
k
g
Fat (kg)
p<0.003**
Smoker male Smoker female
0
20
40
60
%
Fat %
p<0.0006**
Smoker male Smoker female
0
20
40
60
80
100
k
g
Lean (kg)
p<0.0001*
Smoker male Smoker female
0.000
0.001
0.002
0.003
F
F
M
I
FFMI
p<0.0003*
 
 A    B 
  C    D 
 
 
Figure 6.18 Anthropometric measurements in men and women smokers, 
(A) Fat % and (B) fat in kilogram, (C) lean mass in kg and (D) fat free 
mass 
FFMI: Fat free mass Index. kg:Kilogram, %:Percentage 
 
 
 
 
 
 
 
 
 
 
 
  159  
6.4. Discussion 
This study for the first time, has demonstrated gender differences in smokers 
with features of MeS. The main findings were that the prevalence of MeS was 
not significantly different; however, there was a trend towards an increase in 
men in all three groups. Men demonstrated increased central obesity measured 
by w/h ratio. HDL levels were high in women in non-smoker controls and 
smokers without COPD group, however there was no difference in triglyceride 
levels. Fasting blood glucose was increased in men in non-smoker controls and 
healthy smokers group, however there was no such difference in COPD 
subjects. The  body composition was different in men and women, Total 
percentage body fat was increased in women in all the groups and there was a 
difference in fat free mass index. The quality of life as measured by SGRQ and 
physical activity as measured by Baecke’s physical activity questionnaire were 
found to be different in only in healthy smokers. I found that men smoked 
more than women and their FEV
1 was significantly reduced, however, there was 
no difference in TLco. Men demonstrated increase in blood pressure compared 
to women smokers. Blood inflammatory  markers, measured from peripheral 
blood, neutrophils, lymphocytes, monocytes and eosinophils and inflammatory 
cytokines (except IL-12p70) showed no difference between men and women. 
Interestingly there was a difference in apolipoprotein-1 and this finding 
suggests that there is an autoimmune response in smokers. These differences 
in men and women smokers are discussed in detailed below. 
When features of metabolic syndrome were analysed there was an 
increasing trend in men. There were many important differences in the 
individual features of MeS. Men had larger waist circumference than women. 
W/h ratio increased in men in all groups, suggesting that men smokers have 
more central obesity than women. This could be one of the reasons for men to 
have reduced FEV
1. It was shown before that w/h ratio is a better predictor of 
FEV
1 in men
169. This also supports the idea that the gender difference in the 
form of central obesity is one mechanism of impairment in lung function due 
to weight gain
403, 404. This has an impact on the decline in lung function
169. The 
second observation was that men had a higher glucose concentration than 
women and may suggest a higher prevalence of pre diabetes in the cohort of 
men smokers. Women tend to have higher HDL cholesterol concentration than 
men, which may be due to consequences of lesser smoking habits. Women in 
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my study who smoke had higher fat mass in smokers and COPD groups, which 
probably confirm that smoking does not reduce fat mass in everyone and there 
are susceptible smokers who gain weight through increased fat mass. 
Interestingly I found that women had a decreased measurement for quality of 
life compared to men. However, there was no difference in physical activity to 
explain the reasons behind such a reduced quality of life. Again, this could be 
due to the many reasons, one of which could be due to excess weight and 
excess fat mass which affects their behaviour like depression.  
Women in my study smoked less than men, which may offer the reason 
for the more diametric reduction in FEV
1 in men. Smoking varies by social class 
and is highly interrelated to behaviour, gender, age and ethnicity
405. Historically 
smoking in men was associated with a strong sense of social acceptance and 
identity. However, in the present environment there are more women smokers 
than men. One arguable explanation for this is that women think that it 
reduces appetite and stops them putting on weight. When smoking pack years 
was measured in my study there were men who smoked more than women in 
the COPD group. However, in the smokers without COPD group there was no 
difference in the amount of cigarettes smoked between men and women. 
There is an increasing appreciation of gender differences in smokers with 
COPD; however, there is less data concerning low lung function as a risk factor 
might better contribute to the development of MeS in men and women. In the 
current study women had more preserved FEV
1 compared to men. The general 
view is that the prevalence of COPD is higher in men historically because of 
heavy smoking. However, there are more deleterious effect of smoking in 
women which has partly contributed to the recent increase in the prevalence 
rate of COPD in women
391, 394, 406, 407. Burrows et al suggested that a low initial 
reduction in lung function would predict subsequent rapid decline in FEV
1 in 
smokers and called it  ‘horse racing effect’ found only in men
408.  Other 
measure of lung function decline and a reflection of small airways disease is 
the measurement of transfer factor (TLco). TLco is clinically useful for the 
diagnosis of pulmonary vascular and interstitial lung disease and also 
importantly to diagnose emphysema in smokers with airway disease
409-411. Age 
and change in weight predicts the rate of decline of TLco
412, however, there is 
no significant change in young adults male and female until age of 40 years 
and suggests that TLco may be constant until this period and begins to decline 
later
412 and is independent of smoking status. In my study the measure of TLco 
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showed no difference in men and women. In a study undertaken by Anthonisen 
et al, they concluded that the lung function loss is similar in both sexes if they 
continue to smoke
413. However, in an another study it was shown that an 
increase in the number of cigarettes smoked resulted in a steeper FEV
1 decline 
in men but not in women
414.  
  Inflammatory cells play a crucial role in the development of airway 
disease. . However, in the present study there was no difference in CRP 
measurements between men and women smokers with and without MeS. There 
is enough evidence to show that there are raised neutrophils in smokers with 
COPD
79 and increased eosinophils in asthmatic airways
415. Increased neutrophil 
count is related to risk of death in cardiovascular disease
416. There is also 
ongoing subclinical inflammation which is associated with features of MeS
417 
and atherosclerosis. Most of the studies in the literature measured CRP as a 
marker of inflammation. In my study many other inflammatory cells were 
measured including blood neutrophils, monocytes, lymphocytes and 
eosinophils and found that in smokers and COPD there was no difference in 
blood neutrophils, monocytes, lymphocytes and eosinophils between men and 
women. However, there was a decreasing trend in female smokers with COPD 
subjects for neutrophils, monocytes and eosinophils. C-reactive protein is an 
acute phase protein released in the body during an inflammatory state and it is 
used as a clinical marker of inflammation
418. Mild chronic elevations in CRP 
concentrations even within the clinically normal range independently predicts 
future cardiovascular events
419, 420. Smoking is associated with elevated CRP
421 
and it may be due to the tissue damaging effect of smoking. The inflammation 
persists even after quitting smoking after many years
422, 423. CRP is also elevated 
in smokers with COPD
355 and in the cohort I studied there was a linear increase 
in CRP levels in smokers with and without COPD. However,  when this was 
analysed independently in men and women there was no significant difference. 
CRP predicts the development of features of MeS independently of the levels of 
adiposity and insulin resistance in women
418 
  There was a significant difference in IL-12p70 measurement between men 
and women. Inflammatory mediators are released in the airway epithelium in 
smokers due to the influx of inflammatory cells. These are also represented in 
the systemic circulation and could be measured in the peripheral blood. Some 
of the inflammatory markers are TNF-α, interferon gamma (IFNg) and 
interleukins. TNF-α is a pro inflammatory mediator and also a neutrophilic 
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chemoattractant
424 which is raised in smokers with and without COPD. Plasma 
TNF-α was measured by Luminex method in the study and found that it was no 
different in men and women and no difference in smokers with and without 
features of MeS. IL-2 is a key inducer of Th1 associated inflammatory response 
which protects against intracellular infections and cancer but its involvement in 
autoimmune tissue destruction is important
425. Human Th2 cells interact with 
dendritic cells which effectively induce bioactive IL-12p70 and cause T cells to 
revert to Th0/Th1 phenotype
425. The measurement of IL-2 was no different in 
men and women smokers in previous studies.  
In summary, I found that men smoke more than women I speculate that 
the body fat distribution would explain the link between low FEV
1  and 
development of features of MeS. High waist hip ratio is associated with 
impaired glucose metabolism and hyperlipidemia. In addition it has been well 
established in the general population that FEV
1 and FVC are predictors of 
overall mortality
426-428. There were no major differences in inflammatory 
markers. The prevalence of MeS was no significantly different, however, men 
were shown to have obesity that is more central, and women had more total 
body fat. Women had reduced QOL in general, however, there was no 
difference in QOL and physical activity between men and women with MeS. 
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7.0 Chapter-Predictors of lung function decline in a 
follow up study in smokers and COPD 
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7.1.  Introduction 
Understanding lung function is essential, as the physiology of the lungs is 
more complex. This complexity of the mechanism involved is still more 
difficult to understand in the lung, which has a disease. The rate of decline as a 
marker of disease progression in COPD was developed many years ago by 
Fletcher and Peto
53. However, this decline is not uniform across all smokers. 
Decline is seen more rapidly in susceptible smokers who develop chronic 
obstructive pulmonary disease (COPD) which is a preventable and treatable 
disease of the airways. In this disease, there is a progressive decline in forced 
expiratory volume in 1 second (FEV
1) which is partially reversible in the early 
stages of the disease. Lung function decline is important not only to measure 
disease process but also an indicator of premature mortality in smokers
429. 
Smoking cessation is seen so far only means of reducing or stopping the rapid 
decline in FEV
1
430. 
There could be more than one reason for the decline in lung function. 
The main contributor is the duration and quantity of cigarette smoked. There 
is a  correlation between duration of smoking and FEV
1 decline
431. Other factors 
which could contribute to decline include genetic predisposition, air pollution, 
occupational exposure
432 and susceptibility with gender. Women suffer from 
early COPD changes than men. There are few physiological reasons for the 
susceptibility in women for the disease. Firstly it is said that the women have 
smaller lung than men and require less exposure to nicotine to produce 
negative effect
433 and the other was that the manner in which women smoke 
and it is understood that women tend to inhale deeper and hold the breath for 
a longer time
398. There are relatively few measures one could take to reduce the 
decline in lung function. The only proven one so far is to encourage smoking 
cessation. The other possible measure according to Judith Garcia-Aymerich et 
al is moderate to high level of regular exercise could reduce lung function 
decline and risk of developing COPD in smokers
432.  
FEV
1 is associated with the diagnosing the airway disease there are other 
important indices, which could contribute to the disease process. Anthonisen 
et al and Burrows et al suggested that other prognostic factors which 
contributes to the disease for e.g. age, active smoking, symptoms, poor 
bronchodilator response, functional reserve capacity,  exercise tolerance
54, 55. 
Smoking also contributes to airway inflammation, which could be measured in 
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sputum. Airway obstruction and chronic expectoration are associated with 
increased number of sputum neutrophils
147, 359 which  is associated with 
accelerated decline in lung function. 
The purpose of this study was to understand the FEV
1 decline in this 
cohort of smokers and COPD. The subjects in my study underwent baseline 
spirometry and a repeat spirometry between 5-6 years. Data was compared to 
the base line to calculate the annual decline. The other aim of the study was to 
evaluate the association with age, pack years, sputum neutrophils, HRCT that 
predicts FEV
1 decline in subjects who were followed annually for the study. 
  
7.2. Methodology  
7.3. Subject characterisation   
In total 102 were followed up once and 70 were followed up once more after a 
further year. Out of 70 subjects, there were 15 healthy controls, 21 healthy 
smokers, 10 COPD GOLD stages 0&I, 14 COPD GOLD II & III and 10 subjects 
with diagnosis of emphysema on HRCT but no obstruction on lung function 
testing. The study design is explained in chapter 2 (section study design 6). 
The final analysis was done on 64 well-characterised subjects (table 7.1). 
All participants underwent medical examination, skin prick testing, 
pulmonary function testing, and induce sputum. All subjects had their lung 
functions done in the morning to avoid any inconsistency in the measurement. 
They had bronchodilator reversibility with 400μg of inhaled salbutamol and 
subjects with ≥ 12% reversibility were excluded from the study. Bloods were 
taken, centrifuged and stored for future analysis. All subjects who were 
followed previously had HRCT and densitometry measurements done and 
analysed by then research fellow for his study titled’ Differential gene 
expression study in health smokers and COPD. Bronchial brushings and 
biopsies were taken as a part of the study. As with my previous predecessor, 
pre-bronchodilator FEV
1 was used for his analysis .Henceforth in the follow-up 
study I used the same to compare with the base line measurement.  
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Subject characteristics 
 Non-
smoker 
controls 
Healthy 
smoker 
GOLD 
stage 0 
and 1 
GOLD 
stage II 
and III 
Ex-
smokers 
 
No of 
Subjects 
 
15 
 
 
 
21 
 
10 
 
14 
 
4 
 
M/F 
 
6/9 
 
 
 
8/13 
 
7/3 
 
10/4 
 
2/2 
 
Age 
 
60.2 ± 7.5 
 
52.7 ± 10 
 
 
 
56.8 ± 6.2 
 
61.1 ± 6 
 
59.3 ± 7.5 
 
Pack years 
 
N/A 
 
36.6± 14.4 
 
43.6± 18.4 
 
55.4± 18.4 
 
56.7± 25.2 
 
Baseline 
FEV
1 (%) 
 
105.3 ± 13 
 
102.1±11.6 
 
97.6± 12.4 
 
63.1± 14.6 
 
87.5± 37.2 
Annual 
FEV
1 
change (%) 
 
-0.75 ± 1.3 
 
-0.15 ± 1.3 
 
-1.73 ± 1.3 
 
-2.5 ± 2.6 
 
1.64 ± 1.8 
 
Table 7.1 Subject characterisation. 
The data are represented as mean and standard deviation. FEV
1: Forced 
expiratory volume in 1 second, M/F: Male/Female, N/A: Not applicable, %: 
Percentage. 
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7.4. Statistical analysis 
The outcome variable used was annual percentage change in pre 
bronchodilator FEV
1 from baseline for each subject. This was calculated from 
the baseline visit to the final visit for each subject. The variables investigated 
univariately for their ability to predict annual percentage change from baseline 
were, 1) the percentage volume of lung tissue < -950HU in density on 
inspiratory CT. 2) baseline FEV
1, 3) Pack years, the baseline pack years was 
used as this appeared to be more reliable. 4) Age at final visit. 5) gender 6) 
baseline percentage neutrophils in sputum. 7) baseline absolute count of 
neutrophils per gram. 8) baseline count of CD8+ve cells per square mm of 
submucosa from the bronchial biopsy. 
The results were obtained from the univariate analysis data for 70 
subjects. As there were only two variables that reached the 5% level of 
significance, and these were both neutrophil variables, multivariate analysis 
was not performed. Baseline percentage neutrophils in sputum was the best 
predictor of decline in FEV
1, and this variable explained around 10% of the 
variability in the model. This is a reasonably high amount of variability for a 
single predictor to explain. The rest of the variables showed no significance 
with the FEV
1 decline.  
 
7.5. Results 
7.5.1.  Association of FEV1 decline with clinical and pathological 
correlates of the rate of decline variables in all smokers with and without 
COPD. 
A number of clinical variables for e.g. age, pack years, HRCT, sputum 
neutrophils, CD8+ cells were examined to understand which of these 
independently predicts the FEV
1 decline in the subjects. The following section 
will discuss individually the above variables. 
 
7.5.2.  Correlation of FEV1 with the HRCT densitometry measurement 
A total of 64 subjects underwent high resolution CT scan and an experienced 
radiologist reported the scans. An expert in the field did  the densitometry 
measurement by using a programme, which quantified HRCT density 
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parameters. Three parameters were measured, percentage (%) area of low 
attenuation, mean lung density and ratio of expiration to inspiration. For the 
analysis, the percentage of volume of lung tissues was used to correlate with 
decline in FEV
1 (Fig 7.1). There was a weak correlation and only 3 % of the 
variation was explained and the correlation was not significant. 
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Figure 7.1 Annual percentage change in FEV1 decline (X-axis) to inspiratory lung 
volumes (Y-axis) 
FEV
1: Forced expiratory volume in 1 second. 
 
 
 
7.5.3.  Association of FEV
1 decline with age 
Age is an important factor for normal lung function decline. In this study, the 
association with age was measured against FEV
1 decline. The decline was 
calculated annually and the age at the final visit was considered for the 
analysis. A total of 64 subjects were analysed and the linear regression 
analysis showed (Adjusted r
2=0.010 & p<0.1) that age does not independently 
predicts the decline in FEV
1 (Fig 7.2) when controlled for gender and smoking. 
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linear regression analysis was not significant (R
2  adjusted was 0.010 and 
p<0.1). 
Figure 7.2 Annual percentage change in forced expiratory volume in 1 second (FEV1
) decline in the X-axis and age in the Y-axis. 
 
 
 
7.5.4.  Association of FEV
1 decline and pack years 
Pack years was calculated by using the formula, number of cigarette (20 
cigarette = I packs) smoked per day times number of years of smoked. A total 
of 64 subjects were then analysed for the FEV
1 decline. Linear regression 
analysis was done and found that pack years was not independently associated 
with decline (Adjusted r
2 was 0.001 and p<0.3, Fig 7.3). 
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Adjusted r2 =0.001
p<0.3
 
Figure 7.3 Smoking pack years and annual percentage change in FEV1 decline. 
There was no statistical difference in the linear regression analysis (Adjusted r
2 
was 0.001 and p<0.3). FEV
1: Forced expiratory volume in 1 second. 
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A) Neutrophil % B) Absolute neutrophil/gram
R2 adj=0.07
p<0.03
R2 adj=0.10
p<0.013
C) Sputum CD8+ R2 adj=002
p<0.1
7.5.5.  Association between neutrophils in sputum and FEV
1 decline 
 
Figure 7.4 A) Percentage of neutrophils in sputum and annual percentage 
                     change in FEV1 decline. B) absolute neutrophils/gram in sputum and annual percentage  
                change in FEV1 decline. C) sputum CD8+ cells and annual percentage change in FEV1 
decline. 
 
Sputum was processed (chapter 2 section 2.4.7) in 51 subjects who could 
produce sufficient sputum and analysed for inflammatory cell neutrophils. 
There was an increase in sputum neutrophils in smokers and COPD. In the 
linear regression analysis there was a significant difference in neutrophil 
percentage in sputum (Fig 7.4A, adjustedr
2 was 0.10 and p<0.013) when 
controlled for smoking, age and gender. There was a difference in absolute 
neutrophil count in the sputum (Fig B, R
2 adjusted was 0.07 and p<0.03). This 
suggests that sputum neutrophils predicts FEV
1 decline in smokers and COPD. 
However, there was no difference in CD8+ cells in the bronchial biopsies of the 
subjects (Fig C, adjusted r
2 was 0.02 and p<0.1 
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7.6. Discussion 
The aim of this study was to understand and explore the determinants of FEV
1 
decline in our study population. This was a longitudinal study of cohort 
diagnosed as either healthy non-smoker controls or smokers with or without 
COPD. The main findings in this study was an increase in sputum neutrophils 
both absolute and percentage in smokers and COPD. In the linear regression 
analysis there was a significant difference in neutrophil percentage in sputum 
when controlled for smoking, age and gender. There was also a difference in 
absolute neutrophil count in the sputum, which suggests that sputum 
neutrophils predicts FEV
1 decline in smokers and COPD. The other important 
variables like smoking, age and HRCT densitometry measurements did not 
independently predict FEV
1 decline in this cohort. The findings are discussed in 
detail below. 
  COPD is a chronic disease of the airways, which is caused by smoking. 
There is no single criterion by which the severity of the disease could be 
adequately described. The most commonly used determinant to diagnose 
disease severity is FEV
1. This is considered the most important predictor of 
mortality besides age in COPD patients
434, 435. There are determinants that are 
associated with predicted FEV
1 which are smoking, age, gender, respiratory 
symptoms, exercise capacity. However, the results are not the same in every 
study. Weaver et al found FEV
1 was associated with exercise capacity and not 
with dyspnea
436. In our study, the annual rate of decline was not determined by 
age and there was a poor correlation between age and annual rate of FEV
1 
decline. This may be because of the relatively younger population in the study.  
Long-term smokers develop COPD. Airway inflammation is the important 
in pathogenesis of COPD which leads to alveolar destruction and airway 
remodelling
338.  The toxic substances in the cigarette smoke promote an 
inflammatory response in the lung which is characterised by increase in the 
number and activity of inflammatory cells e.g. neutrophils and macrophages
437. 
There are inflammatory cells e.g. neutrophils, monocytes and lymphocytes 
which play a major role in COPD. There is enough evidence to prove that 
neutrophils are raised in the sputum in patients with
79 COPD. Sputum 
neutrophils were measured in my follow up study, which showed that both 
percentage neutrophils and absolute  neutrophil count were  independent 
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determinants of annual FEV
1 decline. However, there was no correlation with 
CD8+ cells in the bronchial biopsies. 
Cigarette smoking is the major cause of reduced lung function which is 
an important characteristic of COPD
438, 439. Other factors, which are associated 
with accelerated lung function decline in general population, are gender, body 
weight, and respiratory symptoms
168, 393, 440, 441.  
  In 1976, Fletcher et al. published a monograph summarizing the
 results 
of an 8-year observational study of the relationship
 between cigarette smoking, 
chronic expectoration, and the development
  of irreversible airflow 
obstruction
53. According to this study, COPD consisted of two components, 
chronic bronchitis, and emphysema. However, there was no mention of airway 
obstruction at that time. The clinical features were described as either ‘pink 
puffer’ who were patients with COPD and reduced BMI (cachexia) or blue 
blotters who were obese or overweight and clinically suffered from respiratory 
failure. The study also showed that a subgroup of smokers had an accelerated 
rate of decline in FEV
1. This finding of accelerated decline in FEV
1 led to 
subsequent investigations into apparent susceptibility factors for cigarette 
smoke and therapies that could slow down the decline in FEV
1
442.  
  In my study, smoking pack years was analysed in the linear regression 
model and found that degree of smoking was not independently contributing 
to FEV
1 decline in our subjects. Smoking is the major cause of COPD in both 
men and women
443, 444. In the Six Cities Study, a cross-sectional analysis showed 
that current smokers had a lower FEV
1 compared to ex-smoker
393. Interestingly 
both ex and current smokers had identical pack years history and the decline 
of FEV
1 was proportional to the number of cigarette smoked each day which 
imply that heavy smokers will regain more lung function than light smokers 
after smoking cessation
445. There is a also evidence to show that increase in the 
number of cigarettes smoked results in steeper FEV
1 decline in men, however, 
it is not same in women
414.  The gender differences is controversial as Xu et al 
concluded from his 24yrs longitudinal follow up study that the female smokers 
overall tend to have faster decline in FEV
1 than male smokers. The observations 
were consistent among ex-smokers and continued smokers
393   
In the linear regression analysis, I found that percentage of volume of 
lung tissue showed a weak correlation with FEV
1 decline when controlled for 
age, gender. COPD is a chronic disease, which consists of chronic bronchitis 
and emphysema. Chronic bronchitis is a measure of productive cough and 
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duration of the cough with preserved lung function test. This was previously 
categorised as GOLD stage 0 COPD, however, this has been withdrawn from 
the current guidelines. Emphysema is the disease of the small airways and is 
diagnosed by High Resolution Computed Tomography scan (HRCT). HRCT is 
the most sensitive method of diagnosing different subtypes of emphysema in 
the lung both visual and quantitatively. These HRCT findings are well 
correlated with the pathological extend of the disease
446. The results were 
further compared and classified by densitometric measurement. In my study 
three parameters were measured by densitometry, percentage (%) area of low 
attenuation, mean lung density, and ratio of expiration to inspiration. For the 
analysis for this study, the percentage of volume of lung tissues was used to 
correlate with decline in FEV
1 
  There are longitudinal studies, which have tried to explore the treatment 
options to reduce or stop the accelerated decline in FEV
1 in patients with COPD. 
The recent UPLIFT (Understanding Potential Long-Term Impacts on Function 
with Tiotropium) study had a primary objective to determine whether 
tiotropium reduces the rate of lung function decline as measured by FEV
1. The 
results of this study showed no difference at the end of 4 years in rate of 
decline compared to the placebo arm of the study
447. There are many other 
studies which have shown similar results
448, 449. However, only intervention that 
has disease modifying therapy is smoking cessation as shown in the Lung 
Health Study
450 . The Lung Health Study assessed effects of changes in the 
smoking habits on FEV
1 decline in COPD patients and found that women who 
quit smoking had an average improvement in FEV
1 which was two and half 
times as great as that in men
451.  
  The limitation of this study was the number of subjects who were 
followed up was half of the actual number recruited for the main study. There 
were various reasons for the poor follow up, a) some patients had moved 
houses, b) two of them were deceased due to lung cancer and c) some were 
unable take time off their work. d) The data analysed was pre bronchodilator, 
as I had no post bronchodilator data from the original cohort, e) the lung 
function machine used for the follow up study was different from the machine 
used for the original study which could induce variations. 
In summary, I conclude that age, smoking pack years, densitometric 
measurement for assessing percentage lung volume,  CD8+ cells do not 
independently determine FEV
1 decline in smokers and COPD. However, sputum 
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neutrophils was found to independently determine FEV
1 decline in stable 
smokers and COPD subjects. Future work should include a longitudinal study 
with a larger cohort to identify other clinical biomarkers for the decline in FEV
1. 
. 
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8.0 Chapter-Main conclusions and general 
discussion 
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The main conclusions of my study were: 
 
1. Prevalence of MeS was higher in smokers with and without COPD compared 
to non-smoker controls, however, there was no difference between smokers 
with and without COPD, suggesting the effect is due to smoking rather than 
the disease. Subjects with features of MeS demonstrated increased reduction in 
FEV
1 compared to subjects without MeS in smokers. However, TLco was 
reduced in smokers with MeS when compared with non-smokers with MeS. 
 
2. Inflammatory marker CRP and inflammatory cell neutrophils, monocytes, 
lymphocytes and eosinophils were raised in smokers. However, CRP, 
neutrophils, monocytes, lymphocytes, and inflammatory cytokines for e.g. TNF-
￿, IFNg did not show any difference between smokers with and without MeS 
suggesting that inflammation play no role in the development of MeS in 
smokers. 
 
3. Insulin resistance was shown to be the main cause for the development of 
MeS in smokers and non-smokers in the study. Physical activity and QOL did 
play a role in this process. 
 
4. There were many gender differences in smokers. Men smoked more and 
showed increased reduction in FEV
1 compared to women. There was an 
increase in central obesity in men and total body fat in women. Men showed a 
trend towards an increase in prevalence of MeS than women. QOL was reduced 
in women smokers and were physically less active compared to their 
counterpart. The inflammatory cytokine IL-12 was reduced and apolipoprotein 
1 was increased in women. 
 
5. The determinants of the annual FEV
1 decline were sputum neutrophils in the 
study, however, age, pack years, HRCT densitometry measurement, CD8+ cells 
in the biopsies did not show the same affect on FEV
1 decline. 
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My first hypothesis was that smokers have an increased prevalence of MeS and 
this was found to be correct in my study. My other hypothesis was that there is 
an association between MeS and COPD. One explanation would be that COPD is 
a systemic inflammatory disease and, as such, contributes to the development 
of features of MeS. The other explanation would be that MeS precedes the 
development of and is a risk factor for COPD. However, I found that COPD was 
not associated with a clear increase in MeS, although there was a trend towards 
a higher prevalence of MeS in patients with COPD. As my final major 
hypothesis, in a prospective study I wanted to identify factors which could 
predict progression of lung function decline. Of all the factors that I assessed 
only sputum neutrophilia was found to be a predictive factor for the change in 
FEV
1. 
  The recruitment for the study done by word of mouth and subjects came 
from all occupations. No particular group was targeted for recruitment to avoid 
any potential bias. I therefore believe that the findings of the study are 
representative of the general population. All subjects were Caucasians as 
ethnicity plays an important role in the development of features of MeS. 
My first step was to explore the prevalence of MeS in my cohort. Subjects 
were carefully classified as non-smoker controls who were life long non-
smokers, smokers without COPD who had well preserved lung function without 
any symptoms of bronchitis and the third group was smokers with COPD. 
COPD subjects were diagnosed according to GOLD criteria and the subjects in 
the study were from COPD stage0 (currently referred to as chronic bronchitis) 
to COPD stage III. In order to diagnose the features of MeS, the IDF and NCEP 
ATP III criteria were used. These classifications were well recognised and 
commonly used in clinical practice across the globe. The recruitment was done 
across Wessex, mainly from Southampton city. 
The prevalence of features of MeS is on the rise around the world. The 
current estimated prevalence of MeS is around 16%
363. The prevalence varies 
with ethnicity and with various chronic diseases. The first analysis in my study 
showed that there was an increase in prevalence of features of MeS in smokers 
with and without COPD when compared with non-smoker controls. There was a 
trend towards an increase in MeS from healthy smokers to COPD. However, the 
prevalence of MeS in smokers with and without COPD was no different. This 
was in contrast to a paper which suggested that the prevalence of features of 
MeS is high in COPD patients
236 . There were many limitations to that study. 
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Firstly, the study had no healthy smokers and the subjects were recruited from 
the cardio-pulmonary rehabilitation programme. Secondly, there was no 
information about the smoking status. 
The important message from this first observation in my study was that 
there was an increase in the prevalence of MeS, which is due to something, in 
common for both smokers with and without COPD, i.e. cigarette smoke. The 
conclusion at that stage was that smoking causes features of MeS and that it 
was not due to the systemic effect of COPD. It was then important to 
understand various pathways which may be responsible for causing the 
development of MeS in my subjects. All smokers (healthy smokers and COPD 
smokers) were then grouped together to understand different determinants 
triggered by smoking causing lung damage and to understand the relationship 
with features of MeS. The analysis showed that smokers with MeS and smokers 
without MeS differed only in respect of the prevalence of individual features of 
MeS (as would be expected) but were no different in respect of a series of pro-
inflammatory markers except for IL-12. However, insulin resistance was seen 
as being a driving force in MeS and correlated with smoking history. 
Furthermore, FEV
1 was reduced in smokers with MeS which was an interesting 
observation. 
Smoking is the major contributor for up to 87% of emphysema, chronic 
bronchitis
452 and lung cancers,  it is estimated that there are over 430,000 
annual deaths from cancer. Smoking affects the fetus, children, and 
adolescents who are vulnerable early in life by maternal smoking either during 
pregnancy or because of environmental tobacco smoke (passive smoke). Some 
studies indicate that an increased susceptibility to the effects of smoking and 
exposure to environmental tobacco smoke may exist among those with 
specific genetic polymorphisms
453. Several smoking behaviours may account for 
increased dependence and higher measures of smoke-related toxins 
experienced among smokers especially African Americans. Although African 
American smokers generally smoke fewer cigarettes per day, and take less puff 
per cigarette than white smokers, they tend to inhale deeper
454. They like to 
smoke mentholated cigarettes, which have higher cotinine and tar levels. By 
doing this they also inhale 30% more nicotine which will result in 2 hour longer 
clearance rate in the blood
455-457. 
Cigarette smoke has immediate or acute effects and long-term chronic 
changes on the pulmonary and extrapulmonary tissues in the body. In 
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comparison with the chronic effects there are fewer studies which have looked 
at the immediate effect like inflammation and lung function
458. In chronic 
smoking the inflammatory cells like neutrophils increased in peripheral blood 
and broncho alveolar fluid
459-461, however, in acute smoke exposure they are 
both increased
462 and unchanged in neutrophil numbers in the bronchoalveolar 
fluid
463. In my study, there was an increase in peripheral blood neutrophils, 
monocytes, lymphocytes in smokers. Interestingly there was an increase in 
eosinophils counts in smokers regardless of whether smokers were non-atopic 
and had no symptoms or infection in 6 weeks prior to recruitment. One could 
think that these subjects may be steroid sensitive smokers and if they develop, 
COPD in later stages may benefit from anti-inflammatory drugs. However, 
some studies show that peripheral blood eosinophils are reduced in acute 
smoke exposure
464. These inflammatory cells were also analysed between men 
and women smokers in my study to understand the phenotypic nature, but 
found that there were no differences between them. Other inflammatory 
markers for e.g. CD19 positive B cells and the total number lymphocytes were 
also decreased during acute exposure to cigarette smoke
464, 465. However, in the 
chronic smoke exposure like that in my study showed increased lymphocytes 
in the peripheral blood in smokers. 
   The role of inflammatory mediators is important in smokers with airway 
disease and most of the studies show an increase release in IL-8 from various 
cell types after exposure to smoke
466, 467. There are inconsistent results showing 
increase in TNF-￿, IL-1â and ICAM being increased when exposed to cigarette 
smoke
468, 469. It is worthy of note that some of the studies have shown that 
cigarette smoke exposure depresses the release of LTB
4, interferon gamma and 
IL-2
470, 471. I measured the inflammatory cytokines for e.g. TNF-￿, IFNg and 
interleukins (IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, and IL-13) in smokers 
and non-smokers. Surprisingly there was no difference between the groups. 
One could speculate that these inflammatory cytokines may not be raised in 
stable state and that looking in the airways would show more differences. 
Smoking also inhibits fibroblast function, which is one of important cells in the 
repair process in the airway epithelium. The ongoing inflammation and chronic 
injury and repair process caused by smoking contribute to the development  of 
COPD
472 in susceptible smokers.  
C-reactive protein is an important inflammatory marker in many diseases. 
Smoking is associated with long term elevation of CRP
473. One of the markers of 
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systemic inflammation which is constantly raised in COPD is also CRP
139 when 
compared with healthy controls. The levels of CRP in my study showed an 
increase across the groups, and COPD subjects in particular showed maximum 
raise. This emphasises that COPD subjects even in stable state show ongoing 
systemic inflammation. CRP was also analysed in men and women smokers in 
my study and found that there was no difference in their levels between them. 
Regression analysis was done and when adjusted for smoking, age, and 
gender, CRP was shown to be a significant and independent predictor of FEV
1 
reduction.  
Smoking causes systemic effects and is a risk factor for many diseases for 
e.g. cardiovascular disease, several forms of cancers, COPD and others
474. While 
smoking habits have declined among adult men in the western world, it is still 
increasing among young adolescent men and women
475. Most women know 
that smoking could cause chronic bronchitis and emphysema, cancers and 
heart disease. Smoking can also cause early wrinkling of the skin, and 
contributing to infertility and menopause and osteoporosis
476, 477. In my study 
smokers, men and women were analysed for various clinical determinants to 
understand the gender differences. As discussed earlier there were no 
differences in blood inflammatory cells for e.g. neutrophils, monocytes, 
lymphocytes, and eosinophils. There were also no differences in blood CRP 
levels. The inflammatory mediators in my study were not markedly raised 
except for IL-12p70 which is a bioactive cytokine produced by IL-4 which is  
Th2 specific, which revert to a IFNg producing Th0/Th1 phenotype when they 
interact with dendritic cells. IL-12p70, which helps in cell mediated immunity, 
was raised in men compared to women in my study. Men smoked more than 
women in my study and the most important finding was that FEV
1 was reduced 
more in men than in women. This could be because men smoked more than 
women. However, there was no difference in transfer factor between the two 
genders. 
  Body composition and physical activity are two important determinants 
which could also potentially affect the quality of life in smokers. Waist 
circumference and w/h ratio have been used to estimate the abdominal fat 
accumulation as a part of MeS 
478-480. W/h ratio was reported to be associated 
with cardiovascular risk factors
481, 482. Differences in body composition in men 
and women are quite common. In my study, there was an increase in waist 
circumference in men compared to women. There was also a difference in w/h 
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ratio between men and women. However, the percentage body fat and fat 
weight were raised in women. This is an indication that men have obesity that 
is more central and women have generalised body fat accumulation. This is an 
important finding for the reason that men with increased central obesity also 
had reduced FEV
1. However, these findings did not change their physical 
activity score, as measured by Baecke’s physical activity questionnaire. 
Similarly, one would expect a reduction in quality of life because of increased 
central obesity in men and total body fat in women, however there was no 
difference in QOL as measured by SGRQ between them.    
Metabolic syndrome has evolved into an increasingly recognised and 
important clinical entity. There are many differences in the measurements of 
features of MeS as many factors determine the prevalence. Some of them are 
more important than the others because of variation, for e.g. age, ethnicity, 
and gender. Over the past decade, progress has been made in the 
understanding of the pathways, which link obesity to insulin resistance, and 
other aspects of metabolic syndrome. It was important in my study to use a 
common definition, which was accepted, hence, the classification of the 
features of MeS was done according to IDF recommendation. According to IDF, 
MeS was defined by ≥ 3 criteria of the IDF definition and central obesity being 
the key features for the diagnosis. In my study, the prevalence of features of 
MeS was high in smokers when compared with non-smoker controls. Both 
smoking and MeS are independent risk factors for cardiovascular disease and 
type II diabetes and previous studies have reported increased rates of MeS in 
adult smokers
483, 484. However, this study is unique in exploring the relationship 
between smoking and MeS with respect to lung function changes, 
inflammation, body composition, insulin resistance, gender, physical activity, 
and QOL. 
  Impaired lung function as indicated by reduced FVC or reduced FEV
1 is a 
risk factor for cardiovascular events and death independent of smoking
485. The 
association of FEV
1 and features of MeS was measured in my study and found 
that smokers with features of MeS had reduced FEV
1 and interestingly there was 
a difference in FEV
1/FVC ratio between smokers and non-smokers with MeS. 
The transfer factor showed similar results.  These results suggest that in 
smokers, the development of features of MeS is caused in relation to reduction 
in FEV
1 and FEV
1/FVC ratio. However, the fact that COPD patients who have MeS 
have no greater reduction in lung function when compared to COPD patients 
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without MeS suggest that, once COPD is established, the reduction in FEV
1 play 
little or no role. 
Smoking causes inflammation and it is the key feature in the development 
of airway disease and features of MeS. In my study inflammatory cells for e.g. 
neutrophils, monocytes and lymphocytes were raised in smokers. However, 
when analysing smokers with and without MeS there was no association 
between inflammatory cells except for lymphocytes, which showed a strong 
positive correlation with triglyceride levels. The possible cause of the 
development of MeS is not inflammation alone but it may play a minor role in 
the disease progression.  
Anthropometric measurements are important in many chronic diseases, 
which are responsible for the mortality and morbidity of that particular 
disease. Smoking is well known to cause an increase in abdominal fat or 
central obesity
486. In my study, I have confirmed this. In addition, I found that 
the fat mass was increased in smokers with MeS and it was more pronounced 
in women then in men. The conclusion from these results is that smoking 
increases central obesity in men more so than in women and this could be one 
of the explanations for the reduced FEV
1 in men. The tendency in women is to 
accumulate generalised body fat, which could be a smoking-related effect on 
the endocrine hormones in the body.  
Increased fat mass provides a focal point for the immunological and 
metabolic events leading to MeS
487. It is proposed that increased enzyme 
aromatase activity results in reduced testosterone and increased estradiol 
concentration resulting in decrease in muscle mass and increase in total fat 
mass in elderly men and this increase in fat mass contributes to oxidative 
stress, inflammation and increase in aromatise levels which will be responsible 
for the development of MeS
488. Another hypothesis is that increased visceral fat 
releases higher  amounts of non-esterified fatty acids which promote the 
development of dyslipidemia and in turn MeS
489.   
Insulin resistance is one of the key features, which drives features of MeS. 
Smoking is associated with a continuous inflammatory response and Bolton et 
al found that insulin resistance was linked to circulating  IL-6
490 in COPD 
patients. Fasting insulin was measured in my study and found that it was 
significantly elevated in smokers with MeS. It was also noted that there was an 
increase in insulin resistance in smokers with MeS. Surprisingly similar results 
were found in non-smoker controls with MeS. It is not clear from my study that 
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insulin resistance in smokers was due to smoking alone or with other 
associated factors for e.g. diet and physical activity. Hypoxemia induces 
glucose intolerance in healthy individuals, however, the results are conflicting 
in COPD and other severe diseases
491-493. Since physical inactivity and excess 
weight are the main underlying contributors to the development of metabolic 
syndrome, getting more exercise and losing weight can help reduce or prevent 
the complications associated with this condition. Increased activity alone can 
improve insulin levels. A brisk 30-minute walk a day can result in weight loss, 
improved blood pressure, improved cholesterol levels, and a reduced risk of 
developing diabetes. Physical activity and dietary management are the first line 
therapies in overweight and obese patients with MeS. The major benefits of 
these life style changes are improvement in dyslipidemia, insulin sensitivity, 
glucose tolerance, and blood pressure
494. These life change modification is very 
important as I discovered that smokers have poor quality of life. It was shown 
in my study that women who smoke have a worse quality of life score. It was 
also shown that it does not matter whether they have MeS or not. Women in my 
study were shown to be less physically active compared to men. 
There is no specific drug so far indicated for the treatment of the 
metabolic syndrome. This is due, in part, to lack of understanding of 
pathogenesis, the heterogeneity of diagnostic criteria and uncertainty of which 
one to treat first. Therefore, the current approach is to correct the individual 
risk factors for e.g. smoking cessation. In the XENDOS trial, the use of orlistat 
(an intestinal lipase inhibitor indicated for the treatment of obesity) plus 
lifestyle modification reduced the incidence of type 2 diabetes in obese 
patients by 37% more than lifestyle alone
495. In addition to antihypertensive 
agents, established therapies include those directed towards individual aspects 
of metabolic syndrome like the statins to reduce the cardio vascular morbidity 
and mortality in patients with type 2 diabetes or other components of 
metabolic syndrome
496. The use of fibrates which are peroxisome proliferators 
activated receptor gamma agonists, reduce major coronary events in patients 
with low HDL  cholesterol levels
497, these fibrates also improve insulin 
sensitivity, thereby improving glucose utilization. 
In the second part of my study, I measured the annual rate of decline in 
smokers and COPD. The aim of the study was to understand and determine the 
independent predictors of FEV
1 decline. FEV
1 is a widely used outcome measure 
of disease severity. The natural history of COPD is characterised by an 
  185  
accelerated decline in FEV
1
53. The classification of severity of COPD is based on 
FEV
1 .The one and only proven intervention to reduce the rate of decline is by 
smoking cessation
498. There is a normal decline of 30ml//year in a healthy 
individual, however in susceptible smokers it is 60ml/year
499. A number of 
p r e d i c t o r s  o f  l u n g  f u n c t i o n   h a v e  b e en studied including lower respiratory 
illness
500 and low starting Kco
501. The rate of decline is also associated with 
airway reactivity, exacerbations, and inflammation
499. In my study sputum 
neutrophils (both percentage and absolute neutrophil) counts independently 
predicted FEV
1 decline but not any change in TLco. I examined various clinical 
and pathological variables, which could predict the decline. The first variable 
was age and the linear regression analysis showed that age did not 
independently predict the rate of decline. Smoking pack years was shown in 
the past to be associated with decline, however, in my study it did not 
independently predict the decline. HRCT and densitometry tools were used to 
analyse the extent of lung damage. The percentage of lung volume measured 
by HRCT also did not predict the decline. 
Cross sectional and longitudinal studies have also been performed to 
evaluate the effects of smoking and smoking cessation on age related FEV
1 
decline
502 and smokers have been shown to decline more rapidly than non-
smokers. Men who quit smoking had reduced rate of decline than continued 
smokers. 
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Study limitations  
 
1. The subjects were mostly recruited in and around city of Southampton. The 
study took place at the Southampton General Hospital, which is located in an 
impoverished area of the city. The socioeconomic status was not documented, 
however I believe they represented the general population. It is possible that a 
large proportion of the subjects came from the local community. This could 
introduce a potential bias to the findings of the study. 
 
2. All COPD smokers were mild to moderate in severity and they were stable at 
the time of the recruitment. The reason for recruiting mild to moderate COPD 
subjects  was because of the reason that co morbidities is associated with 
severe and very severe disease which could be clinically difficult to interpret 
whether diagnose of features of MeS is due to smoking/COPD or due to the 
influence of other co-morbid conditions like cardiovascular abnormalities. This 
will not enable us to understand what exact happens in an uncontrolled 
environment. It was difficult to recruite subjects with severe disease as most of 
them were on inhaled corticosteroids or oral prednisolone and other 
medications which could influence the outcome of the study. 
 
3. The other limitation was that the study was slightly underpowered. With 
more numbers in the study group could shed more light on to the prevalence 
of MeS in COPD and the role of inflammatory markers in MeS. The Physical 
activity questionnaire measured was subjective and I feel that better 
measurement should be used to explore the activity levels and energy 
expenditure as this plays an important role on lung function and on the 
features of MeS. The future study should include socio-economic status, 
dietary factors, and intake of alcohol which are known to contribute to obesity 
in health and disease which I have not documented in my study.  
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8.1. Future work 
 
My study demonstrated that smoking is a major factor for the development of 
MeS, however MeS does not per se cause or occur has a consequence of COPD. 
The prevalence of MeS was high in COPD subjects, however it was not 
statistically significant compared to healthy smokers. It may be worth visiting 
this issue in a larger cohort of subjects with COPD. I was unable to identify a 
set of inflammatory mediators which could explain the pathogenesis of MeS in 
smokers. Future studies should explore this in sputum and in biopsies of 
smokers with MeS. I have also shown that gender differences are important as 
they showed many differences in the disease process. Hence, future work 
should try to seek an explanation in a larger cohort for this at a 
pathophysiological level and understand the interactions between arterial 
disease, insulin resistance, blood pressure, lipids, and glucose at the molecular 
level to identify different pathways which could be a target for future drug 
discovery. My findings have potential clinical implications. No studies have 
been conducted to see whether smoking cessation results in an improvement 
in MeS; such studies are, therefore, needed and to understand whether reversal 
of MeS might exists and it may contribute to this improvement in COPD. 
However, even in the absence of such data, patients should be strongly 
encouraged to stop smoking, as this is the only known intervention so far to 
reduce the progression of COPD. There is also a need to understand other 
pathways for e.g. oxidative stress in smokers to explore any association 
between smoking and MeS.  
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